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ABSTRACT 
 
DISSOLUTION AND ANTIVIRAL ACTIVITY OF A  
NOVEL NEVIRAPINE FORMULATION 
 
The author’s objective was to follow the product life-cycle process of a novel antiretroviral, 
nevirapine formulation in South Africa, to generate and compile data to pursue market 
registration. Five supramolecular co-crystals, viz. nevirapine-saccharin (NVSC), nevirapine-DL-
tartaric acid (NVTTA), nevirapine-maleic acid (NVMLE), nevirapine-glutaric acid (NVGLT) 
and nevirapine-salicylic acid (NVSLI) were reproduced1 and confirmed by powder X-ray 
diffraction (PXRD). A pre-formulation study ensued to identify the most appropriate co-former 
candidate to formulate a tablet dosage form comparative to the proprietor brand, Viramune. 
The co-crystals were synthesized by the co-precipitation and solvent-drop grinding techniques 
and identified by hot stage microscopy (HSM), differential scanning calorimetry (DSC), 
thermogravimetric analysis (TGA), fourier transform infra-red spectrophotometry (FTIR), PXRD 
and single X-ray diffraction (SXRD).1 
The solubility, dissolution and antiviral activity profiles of these co-crystals were assessed and 
compared to pure NV and NV:co-former mixtures in a 1:1 ratio. The preliminary dissolution 
analysis applied the BP 20052 rotating-basket method with water as dissolution medium. 
Initially, the dissolution samples were assayed with UV/VIS spectrophotometry which led to a 
more convincing quantitative approach where dissolution samples were assayed by HPLC. 
Solubility data revealed a fivefold increase in solubility of NV co-crystallized with maleic acid. 
Dissolution data, however revealed NVGLT as the best performing co-crystal with a 59 % NV 
drug release in water (dissolution media) with the remaining 4 co-crystals all indicating an 
enhanced aqueous solubility of NV. The antiviral activity of all 5 co-crystals performed by the 
National Institute of Communicable Diseases of South Africa determined whether the co-crystals 
had an improved antiviral activity against HIV-1 compared to pure NV. The results indicated that 
NVSC and NVSLI had the greatest antiviral activity compared to pure NV and the remaining co-
crystals. 
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The pre-formulation results formed the basis for the selection of the best co-former candidate for 
a NV co-crystal tablet formulation by direct compression.3 All solid dosage form quality control 
tests according to the USP 364 was performed on the prototype co-crystal tablet and the 
Viramune tablet. Comparative dissolution analysis to evaluate bioequivalence was conducted 
and assayed by HPLC. The dissolution analysis utilized 3 media, viz. HCl buffer (pH 1.2), 
acetate buffer (pH 4.5) and a phosphate buffer (pH 6.8) which displayed no similarity in the 
dissolution profile of the prototype and the proprietor brand. Solution stability of NV in these 
buffered media was assessed after 4 weeks exposure of the dissolution samples to cold chain (2 - 
8 °C, 0 % RH) and accelerated environmental conditions (40 °C, 75 % RH). The results 
indicated no significant degradation of NV in the prototype co-crystal tablet and the proprietor 
brand during the accelerated stability tests. Cytotoxicity against a host cell 293T and antiviral 
activity against the pseudo-HIV-1 virus of the prototype and proprietor brand was further 
determined. The antiviral activity results were favourable for both the prototype co-crystal and 
the proprietor brand tablet. 
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DISSOLUTION AND ANTIVIRAL ACTIVITY OF A NOVEL NEVIRAPINE FORMULATION 
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1 Introduction 
Chapter 1 explains the life-cycle of a new product from discovery to commercialisation. Pre-
formulation aspects such as the active ingredient’s physical forms and techniques used to 
manipulate physical characteristics of the active ingredient, is discussed. This is an important 
aspect in drug discovery and development of intellectual property protection. In addition, 
formulation factors for the development of a tablet as a pharmaceutical dosage form and key 
aspects relating to the determination of quality attributes of the tablet such as dissolution, 
stability testing and antiviral activity is reviewed. Furthermore, co-crystallisation as a technique 
to overcome the challenges of HIV drug resistance is considered theorectically. Finally, the 
introduction concludes with the overall aims and objectives of this study.  
 
1.1 Pre-formulation 
The development of a new medicinal product from a novel synthesized chemical compound, a 
chemical extracted from a natural source or a compound produced by biotechnological processes 
is a long and complex procedure. The process involves many different disciplines operating 
jointly to achieve the final formulated dosage form. There are six distinct stages in the discovery 
and development process of a medicinal product namely; (i) strategic research, (ii) exploratory 
research, (iii) candidate drug selection, (iv) exploratory development, (v) full development and 
(vi) marketing and commercialisation (figure 1.1).1 
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Figure 1.1: Product life-cycle1 
 
 
 
 
 
 
 
 
 
 
 
 
 
The product life-cycle process starts by conducting strategic research based on the company’s 
strategy. At this stage, stage (i) of the process, feasibility studies are conducted to investigate 
whether a drug interferes in a particular biological mechanism that has an effect which might be 
of therapeutic value. At certain times the company already has a database of drug compounds 
that were previously discovered but never pursued to a final pharmaceutical product. Once a 
particular biological mechanism has been targeted, an investigation into the identification of a 
chemical or biological drug “lead” that disrupts the biological mechanism is conducted. This 
exercise is stage (ii) of the process, exploratory research. 
 
At stage (ii), many compounds are screened for the desired biological activity. The recent 
advances in technologies now allow the scientist to conduct a larger volume of screening tests in 
a shorter time; these technologies are known as combinatorial chemistry.1 
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In the early 1960’s a paradigm shift in the industrial pharmaceutical product development arena 
evolved. The move in product development was from an emphasis on formulating elegant dosage 
forms to formulating stable and pharmaceutically viable dosage forms through a thorough pre-
formulation study.1 Pre-formulation studies are conducted at stage (iii) of the product life-cycle 
process as it is essential that physical, chemical and other derived properties of a drug is known 
prior to the development of a dosage form. There are many advantages of conducting a pre-
formulation study. A pre-formulation study outlines a logical and scientific approach in order to 
characterize drug substances and excipients. It allows the formulation scientist to collect 
sufficient information on a proposed chemical entity and rationally select compatible excipients.1 
Pre-formulation studies is a time and labour saving mechanism as potential problems in the 
exploratory development phase, stage (iv), can be identified and mitigated during this process. 
The aim of a pre-formulation study is also to provide an insight into the strengths and 
weaknesses of the drug and supports the formulation of a dosage form into the final marketable 
pharmaceutical product in the shortest possible time and at the lowest cost.1 
 
The physical characteristics of the solid state of the drug are also assessed at the pre-formulation 
phase. A solid material consists of molecules, atoms or ions that are statically positioned. The 
physical and chemical properties of solid materials are largely dependent on the structural 
interactions between the subunit atoms, ions and molecules. Any alteration in the interactions 
between these entities will affect the properties of the solid.2 There are various chemical 
processes that are successfully used to synthesize active pharmaceutical ingredients (APIs). 
These chemical processes are designed to produce salts, polymorphs, solvates, hydrates or co-
crystal derivatives of the drug i.e. using the crude “lead” drug and chemically processing it to 
create an API with the intention of formulating it into a stable pharmaceutical dosage form. 
Figure 1.2 illustrates some of the hypothetical physical forms that APIs can be synthesised into.3  
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Figure 1.2: Schematic illustration of physical state properties of APIs3 
 
 
 
 
 
 
 
The most common chemical process employed to synthesize APIs is the process yielding a salt 
derivative of the API. On the South African medicine’s market, most of the registered 
pharmaceutical products are the salt API derivative. This chemical process is preferred due to its 
easy approach to alter the physical properties of the API. The limitation to the formation of a salt 
is that the API must have a suitable (basic or acidic) ionisable site.3 
 
It is well known and proven that an API can be successfully synthesized into a salt, polymorph, 
solvate or hydrate. In figure 1.2, a pharmaceutical drug in the salt form is an ionisable drug that 
has been combined with a counter-ion to form a complex.4 A polymorph of a drug is a drug that 
shows an alternative packing arrangement in the crystal lattice than that of the same molecule.5 
Furthermore, a solvated drug is formed when a material is crystallised and in the process of 
crystallisation, solvent becomes trapped in the crystal lattice. If the solvent used is water then the 
resulting drug is called a hydrate.6  
 
API  
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There are many examples of commercial medicines containing APIs in these different drug 
forms on the South African medicines market, for example diclofenac sodium (Voltaren®) a 
sodium salt, nevirapine hemihydrate (Viramune® paediatric suspension) a solvate/hydrate and 
chlorampenicol palmitate (Chloromycetin®) a polymorphic form.7 A commercial medicine 
containing a co-crystal form of an API may have reached the medicines market by now given the 
intense research that has been ongoing since its inception. 
 
A pharmaceutical co-crystal is crystalline material that is composed of two or more entities in a 
definite stoichiometric ratio. The co-crystal is formed by a reversible non-covalent bond between 
the molecular or ionic API and the co-crystal former (co-former). The API and co-former are 
solid materials at room temperature. When the two entities are combined to form a co-crystal, the 
resulting product (co-crystal) of the two or more entities (API and co-former) have unique 
characteristics in terms of the structure, physical form/reactivity, particle size, melting point and 
solubility. Co-crystals can be prepared using several techniques such as slow evaporation, neat 
grinding and solvent drop grinding methods.8, 9 
 
Pharmaceutical co-crystal synthesis is a specific aspect of supramolecular chemistry. 
Supramolecular chemistry is a solid state phenomenon and is defined as the chemistry of the 
non-covalent bond. The molecular components in a supramolecular compound are held together 
and organised by means of non‐covalent binding interactions in the form of hydrogen bonding, 
ionic bonding, van der Waals and hydrophobic interactions.10  
 
Table 1.1 provides a summary of supramolecular interactions, including its strength and table 1.2 
expands on hydrogen bond interactions and their properties. 
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Table 1.1  Summary of supramolecular interactions10 
Interaction Strength (kJ mol -1) Example 
Ion-ion 200-300 Tetrabutylammonium chloride 
Ion-dipole 50-200 Sodium [15] crown-5 
Dipole-dipole 5-50 Acetone 
Hydrogen bonding 4-120 (See Table 1.2) 
Cation-π 5-80 K+ in benzene and graphite 
π-π 0-50 
Interactions involving 
π‐systems can be found in 
nature, for example, the weak 
face‐to‐face interactions 
between base‐pairs along the 
length of the double helix are 
responsible for the shape of 
DNA. 
Van der Waals < 5 but variable depending on 
surface area 
Argon; packing in molecular 
crystals 
Hydrophobic Related to solvent-solvent 
interaction energy 
Cyclodextrin inclusion 
compounds 
 
Table 1.2  Hydrogen bond interactions and their properties (A-acceptor; D-donor)10 
Interaction/property Strong Moderate Weak 
D-H···A Mainly covalent Mainly electrostatic Electrostatic 
Bond energy (kJ mol -1) 60-120 16-60 < 12 
Bond length (Å)    
H···A 1.2-1.5 1.5-2.2 2.2-3.2 
D···A 2.2-2.5 2.5-3.2 3.2-4.0 
Bond angle (degrees) 175-180º 130-180º 90-150º 
Example HF complexes Acids C-H···A 
 H5O2
+ Alcohols D-H··· π 
 - DNA/RNA - 
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The technique of co-crystallisation has many benefits as it affords the pharmaceutical formulator 
the opportunity to modify existing APIs with limitations in its physicochemical properties and 
thus producing a better or improved API giving new “life” to the drug.11 APIs that are rigid, 
highly symmetrical having strong non-bonded interactions and have a low molecular weight are 
more likely to co-crystallise with additional components (co-formers or counter-molecules). 
 
Nevirapine (NV) is a molecule with a rigid amide group which suggests that co-crystallisation 
with soluble carboxylic acid or amide co-formers are possible.12 NV by nature has a high lipid 
permeability and low aqueous solubility hence being classified as a class II drug by the 
biopharmaceutical classification of drugs. The advantage of co-crystallisation over salt and 
solvate formation is that the amount of co-formers available to produce co-crystals is immense 
and in the South African context, the disease state that NV is used as treatment bear a significant 
burden on the economy and health care system. Therefore, opportunities to simplify, improve or 
modify current regimens or drugs are always welcomed.12 
 
In the year 2011 Caira et al. successfully produced five co-crystal forms of NV that could have 
the potential to be developed into stable pharmaceutical preparations. Due to the benefits of 
pharmaceutical co-crystals, it seems obvious to continue exploring the possibility of formulating 
new dosage forms for the co-crystals produced by Caira et al. (2011).12 The five NV co-crystals 
prove to have an enhanced aqueous solubility (compared to the parent NV) but the lipid 
membrane permeability remained the same. Thus it presents an opportunity to investigate the 
possibility of NV as a twice daily dose at half the concentration of the API currently being used, 
yet maintaining the efficacy at the lower concentration. This possibility would allow for better 
control over side effects of NV or significantly reduce it. 
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One of the key considerations in drug development and formulation is the aspect of intellectual 
property and patenting. The question of whether co-crystals can afford pharmaceutical 
companies additional intellectual property protection on APIs due to the end product (drug) 
meeting the criterion of novelty, utility, and non-obviousness is up for debate. The items that 
would essentially be considered for the patent in this study are the co-crystal synthesis process, 
the prototype formula and the manufacturing method.3 
 
The Department of Trade and Industry of the South African government published a draft policy 
in September of 2013 to amend legislation dealing with intellectual property and patenting law. 
The intent of the amendment to the law was said to improve access to intellectual property-based 
essential goods and services. The main focus of the amendment was around education, health 
and food.13 Furthermore, the Treatment Action Campaign, an HIV social activist group in South 
Africa, has been lobbying for two years to inspire the government to prevent multinational 
pharmaceutical companies to “evergreen” patents. “Evergreen” is a controversial strategy in 
which companies take out new patents on minor changes or new uses for a product with a patent 
that is about to expire.13 
 
South Africa has a depository system for patents. In South Africa, patents are granted without 
substantive scrutiny for novelty or inventiveness. Therefore, should anyone want to oppose a 
patent, they need to wait until the patent is awarded, and then turn to the courts to challenge it. 
Thus, the current system is time consuming and costly. The proposed amendment to the policy is 
to introduce a patents examination office that will scrutinise applications, and also makes 
provisions for pre-and post-grant opposition. 
 
The proposed amendment to the law is a strong message from the South African government that 
profits of multinational pharmaceuticals shall not be placed above health needs of the public. 
This proposed amendment to the legislation may pose a challenge for future quests of patenting 
pharmaceutical co-crystals as the proposed change to the law will seek to prevent pharmaceutical 
companies from reformulating and repatenting an existing API.13  
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The potential impact this law would have on patenting of this novel formulation may be 
significant should the government of South Africa be of the opinion that the co-crystal form of 
NV is evergreen. However, it can be strongly argued that due to the novelty of the synthesis, 
prototype formulation and manufacturing method that the product is legible to be granted a 
patent to protect the intellectual property of the inventors. 
 
Drugs are seldom administered to a patient as a pure chemical substance. A drug is almost 
always given as a formulated medicine. The medicine can vary from being a simple solution to a 
complex drug delivery system incorporating compatible additives called excipients. The 
excipients are inactive components that provide varied and specialised pharmaceutical functions 
in the medicine such as solubilising, suspending, thickening, preserving, emulsifying, flavouring 
and improving compressibility of the API. Even though excipients are regarded as inert 
additives, each excipient must have a clear justification for its inclusion into the final formulation 
and it must perform its specific function in the presence of the API and any other excipients in 
the formulation. It is critically important to select compatible excipients. If incompatible 
excipients are selected and included into the formula it can have a serious impact on the quality 
and stability of the product. For example, an excipient with high water content can cause 
microbial contamination and hydrolysis of the API. Arguing that the scientific process may be 
patented for the development of pharmaceutical co-crystals, this “scientific process” should 
firstly be defined very clearly. Hence the “scientific process” may be defined as a process of 
selecting, manipulating and developing an API with compatible excipients and this is called 
formulation. 
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1.2 Formulation 
Pharmaceutical product formulation is an aspect of applied pharmaceutics. The intention of the 
formulation exercise is to ultimately produce a chemically stable pharmaceutical dosage form 
that can be administered to a patient in a safe, efficient, reproducible and convenient manner. 
Formulation is generally carried out at stage (iv) and (v), the exploratory development and full 
developmental stages of the product life-cycle process (figure 1.1). The key deliverables of these 
stages is to achieve a quantitative formula that defines the grades and quantities of each excipient 
and API, defined pack, define drug, excipient and component specifications and to define the 
product specification.1 
 
There are various routes of administration available to the formulation to deliver the drug to its 
intended target such as oral, rectal, topical, parenteral, respiratory, nasal, eye and ear. At the pre-
formulation stage of the design and development process the formulator decides on which route 
of administration would be best suited for the drug after an extensive evaluation of the 
biopharmaceutical aspects of the drug, physical and chemical factors of the drug and patient and 
therapeutic factors. During the formulation of the product the formulator pays particular attention 
to quality by design principles such as good laboratory practices to ensure that quality is built 
into the product.1, 6 
 
Drug administration via the oral route has been and still is the most popular, convenient and 
preferred route of administration. For this reason, the NV co-crystals that were developed by 
Caira et al. (2011)12 and formulated by Haas et al. (2013)14 into a tablet dosage form were 
assessed against an original proprietor branded tablet registered on the South African medicines 
market. A typical flow diagram to devise a conceptual formula of a tablet dosage form is 
illustrated in figure 1.3. 
 
 
 
 
 
 
 
 
 
 
12 
 
Figure 1.3: Flow diagram of the tablet formulation1 
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1.3 The tablet dosage form 
Tablets are solid pharmaceutical dosage forms containing an API with or without suitable 
excipients and are prepared either by compression or moulding methods. William Brockedon 
obtained in the year 1843 the world’s first patent for a hand operated compression device. The 
device, as seen in figure 1.4, was simple in design, consisting of an upper and lower punch with a 
die (hole) between the punches.6 
 
Figure 1.4: Tablet compression device14 
 
Tablets are generally intended for oral administration and are available in a variety of shapes and 
sizes. Tablets usually consists of the API and excipients such as diluents (lactose, sucrose, 
mannitol, cellulose), disintegrants (starch, cellulose, sodium starch glycolate), solution binders 
(gelatine, polyethylene glycol, starch), dry binder (cellulose, polyvinyl pyrrolidone), glidants 
(silica, magnesium stearate, talc), lubricants (stearic acid, sodium lauryl sulphate, liquid paraffin, 
magnesium stearate) and anti-adherents (talc, starch, magnesium stearate, cellulose). Tablets are 
produced by passing a mixture of the API and excipients (granulate) or the API alone, in a 
defined weight, into a die and compressing the punches together using a hammer roller of 
physical force.  
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The granulate can be produced by various methods of granulation i.e. wet granulation and dry 
granulation (roller compaction or slugging). Alternatively, the API alone or the API and selective 
excipients are blended and compressed into tablets. The latter process of tablet production is 
known as direct compression. In the wet granulation method, a binding solution is firstly 
produced by mixing a binder with a solvent such as water or alcohol. The binder mixture is then 
added to the API and excipients (excluding the lubricant) in an ordered manner. The wet 
granulate is then dried either in an oven or fluid bed drier. The dried granules are mixed with the 
lubricant and after that compressed into tablets. It is clear that this method of tablet production is 
very complex and complicated. It involves many different unit operations that introduce a myriad 
of opportunities where errors could occur. The dry granulation method makes use of compaction 
and milling to form a granulate. The API and excipients are blended, compacted and then milled 
into granules. The granulate is then placed on the tablet compression machine to produce tablets. 
The dry granulation method and direct compression method of tablet production is preferred over 
the wet granulation method due to it being less cumbersome to manage, however these methods 
also have their disadvantages.6 
 
Some tablets are swallowed whole, some are chewed, some dissolved or dispersed in water 
before consumption and some are placed in the mouth under the tongue (sublingually). 
Conventional tablets are usually, circular solid cylinders, the end surfaces of which may be 
bevelled. Tablets may also have line (scores) or break marks and may bear a symbol or other 
marking (embossing). Certain tablets may also be coated. There are various tablet processing 
problems that may occur during routine tablet production. In some cases the fault lies with the 
formula, in some cases with the compression equipment, sometimes with the raw material 
(subsequent to a raw material source change), sometimes as a result of the symbol or marking on 
the tablet (embossing) and sometimes there is a combination of reasons. The most common 
tablet processing problems are capping, lamination and chipping. Other problems such as 
mottling, mass variation and hardness variation can also occur.6 
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The term “capping” is an expression that describes the partial or complete separation of the top 
or bottom of the tablet from the main body whilst “laminating” is the separation of a tablet into 
two or more distinct layers. “Chipping” is the situation where chips or pieces of the tablet come 
off the body of the tablet. These tablet defects are usually visible immediately; however in some 
cases it only becomes apparent after a few days.6 
 
Compressed tablets have many advantages over other dosage forms administered orally. To 
name a few, a precise dose of API is administered, convenience of administration as the oral 
route is natural, easy to handle and identify and easy to scale up for mass production. Compared 
to liquid dosage forms, tablets generally have better chemical and physical stability and 
unpleasant drug tastes can be masked by the application of coating techniques. There is, however 
limitations to the tablet dosage form. The main drawback of tablets is the concerns around the 
bioavailability of poorly water-soluble or poorly absorbable drugs. Furthermore, some drugs may 
cause local irritation or harm to the gastrointestinal tract.6 
 
Tablets are primarily used for systemic delivery of the API. In the oral route of administration, 
the drug must be released from the tablet, in other words, the drug must dissolve in the fluids of 
the mouth, stomach or intestine, and thereafter be absorbed into the systemic circulation, by 
which it reaches its pharmacological site of action. It is important to note that the pattern of drug 
release, the rate of release and the ability of the body to absorb the API from the tablet are of 
utmost importance. The very act of producing a tablet may have profound effects on the 
biological availability of the tablet. Therefore, it is important that a pharmaceutical product 
formulator achieves the balance between the factors that affects the utilisation of the drug by the 
body and other factors required to produce an elegant tablet. 
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1.4 Dissolution 
Aesthetic appeal, elegance and patient acceptance are important tablet attributes; however, a 
tablet designed for its systemic effect would be futile if the API is not absorbed from the 
gastrointestinal tract. APIs are physiologically absorbed by various mechanisms such as active 
transport, facilitated transport, passive diffusion and pinocytosis. All these methods, with the 
exception of pinocytosis, require the drug to be in solution. Dissolution of a drug is defined as 
the measure of the concentration of the drug that passes into solution over a period of time and 
provides a description of the overall rate of all processes involved in the release of a drug into its 
bioavailable form. The concentration of API in the dissolution test is expressed as a cumulative 
amount of drug that passes into solution.1 
 
There are a number of official and unofficial dissolution testing methods. These methods are 
used on both crude drug substances and formulated preparations. There are two categories of 
widely used test methods for formulated pharmaceutical preparations i.e. stirred-vessel and 
continuous-flow methods. These methods are based on forced convection of the dissolution 
medium. The stirred-vessel method comprises of the paddle method and the rotating-basket 
method as seen in figure 1.5. Both of these methods were employed in this study. These methods 
are also listed as official methods in well recognised pharmacopoeias such as the European 
pharmacopoeia, the British pharmacopoeia and the United States pharmacopoeia to name a few.6 
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Figure 1.5: Example of the paddle method (A) and rotating-basket method (B)15, 16 
 
 
 
 
 
 
 
 
 
 
 
There are many similarities between the two methods as seen in figure 1.5. Both methods use the 
same type of vessel that would be filled with a dissolution medium of controlled volume and 
temperature. A distinct difference in the two methods is that the paddle method, as its name 
implies, agitates the dissolution medium using a paddle in a rotating manner while the tablet is 
placed in the vessel. In the rotating-basket method the tablet is placed in a small basket formed 
from a mesh screen. The basket is immersed into the dissolution medium and is rotated at a 
defined speed. The sampling point in each method is also different, with the paddle the sampling 
probe is being immersed deeper into the dissolution medium to compensate for the level of 
agitation. In the rotating-basket method the sampling probe is higher up in the vessel in order to 
maintain the correct distance from the basket where the drug is being released.6 
 
 
 
 
A. Paddle method16 B. Rotating-basket method15 
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In category two, the continuous-flow method, the product is held within a flow cell. The 
dissolution medium is pumped through the flow cell at a controlled rate from a large reservoir. 
The liquid that passes through the flow cell is collected and analysis of drug content is 
performed.6 
 
The dissolution test is a very dynamic test. As mentioned before, there are many ways by which 
a drug can be absorbed in the human or animal body. However, for a tablet, the drug must first 
be dissolved in the fluid at the site of absorption. Therefore, the drug in a tablet administered 
orally is not absorbed until drug particles are dissolved or solubilised by the fluids in the 
gastrointestinal tract. The dissolution of the drug is dependent on pH and the solubility profile of 
the drug. During the dissolution of the drug, the drug molecules in the surface layer of the tablet 
dissolve. This situation creates a saturated solution around the particles. This layer is known as 
the diffusion layer. The dissolved drug molecules then moves through the dissolving fluid to the 
mucosa where it is absorbed. The replenishment of diffusing drug molecules in the diffusion 
layer is achieved by further drug dissolution and the absorption process continues. If dissolution 
is rapid, the rate of absorption is primarily dependent on the ability of the drug to cross over the 
semi-permeable lipid membrane. However, if the drug dissolution is slow due to its 
physicochemical properties or formulation factors then the dissolution may be the rate-limiting 
step in the absorption of the drug and will influence the bioavailability of the drug.6 
 
The dissolution of a drug compound is described in a simplified way by the Noyes-Whitney 
equation: 
dm 
dt 
Where dm / dt denotes the dissolution rate, k is the dissolution rate constant, A is the surface area 
of the dissolving solid, Cs is the concentration of drug in the dissolution medium at time t and C 
is the concentration of the drug. Based on this equation the dissolution rate can be increased by 
increasing the surface area of the drug or by increasing the solubility of the drug in the diffusing 
layer or by increasing k which incorporates the drug diffusion layer thickness and diffusion 
coefficient.6 
= kA(Cs – C) 
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The dissolution test is one of the most important tests in drug development as it allows the 
scientist to perform an in vitro study on the drug released from a solid dosage form in various 
dissolution media. In drug development, the dissolution test is used as a tool for several reasons 
such as; to assess factors affecting bioavailability of a drug, to evaluate the potential effect of 
formulation and process variables on the bioavailability of a drug, to ensure that the product 
complies with the regulatory registered specification as a quality control test and to predict the 
performance of the product under in vivo conditions. During the early stages of the drug master 
formula and manufacturing method development of oral solid dosage forms, in particular the 
tablet, the composition and manufacturing process are defined. At this stage of the development 
process dissolution testing is used as a means of quality control of the scale-up process and 
production batches to ensure both batch-to-batch consistency and that the dissolution profiles 
remain similar to those of pivotal clinical trial batches. In routine tablet production after 
registration of the product with the regulators, dissolution testing is used as a quality control test 
method to verify the process and product consistency i.e. a quality control tool.6 
 
Furthermore, dissolution testing can be used to support the bioavailability of a new 
pharmaceutical product, the bioequivalence of an essentially similar product or variations. 
Bioequivalence surrogate inferences are also made where there is a demonstrated similarity in 
the dissolution profiles between different product formulations of an active substance (variations 
and new, essentially similar products included) and the reference medicinal product.17 
 
The fact that a solid dosage form passes the dissolution test is no guarantee of the bioavailability 
of the API. Physico-chemical factors such as drug solubility under physiologic conditions, 
pKa/pH ratio, Koctanol/water and its permeability through the membranes of the gastrointestinal 
tract, play pivotal roles in bioavailability. Due to the critical nature of these factors, dissolution 
of a pharmaceutical product in vitro can, in certain instances, be relevant to anticipate the in vivo 
characteristics. When modifications are made to pharmaceutical products, manufacturing 
procedures, and other associated processes including change of site, their impact on safety, 
efficacy and quality should be demonstrated where required.  
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In this study a novel antiretroviral prototype tablet that was aimed to be a therapeutic equivalent 
of the registered proprietor brand of nevirapine was evaluated in pursuit of registration with the 
Medicines Control Council (MCC) of South Africa. The MCC describes various circumstances 
where dissolution can be used in support of a biowaiver. A biowaiver in simple terms is an 
exemption to prove clinical bioequivalence (human clinical trials) of a generic drug via an in 
vitro dissolution. These circumstances are commonly referred to as a case viz.17 
Case A 
Dissolution testing should be conducted as a release test according to the original submission, or 
in accordance with compendial requirements, for the proposed and currently registered 
formulations, for that product. 
Case B 
Dissolution testing should be conducted as a multipoint test in the application or compendial 
medium, for the proposed and currently registered formulations, at intervals such as 10, 15, 20, 
30, 45, 60 and 120 minutes, or until an asymptote (a straight line that continually approaches a 
given curve but does not meet it at any finite distance) is reached for the proposed and currently 
registered formulation. For rapidly dissolving products (profiles reaching 85 % at 30 minutes) 
the minimum time points are 10, 15, 20 and 30 minutes. 
Case C 
Dissolution testing should be conducted as a multipoint test in the three dissolution media as 
specified in case B for the proposed, and currently registered formulations, at intervals such as 
10, 15, 20, 30, 45, 60 and 120 minutes, or until either 85 % dissolution is obtained, or an 
asymptote is reached. 
 
An evaluation of the Biopharmaceutical Classification Index indicates that NV, the API in the 
proprietor brand, is classified as a class II drug having a high lipid permeability and low aqueous 
solubility. 
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The Biopharmaceutics Classification System (BCS) is based on aqueous solubility and intestinal 
permeability of the active pharmaceutical ingredient (API). It classifies the API into one of four 
classes viz.17 
Class I: high aqueous solubility with high lipid permeability 
Class II: low aqueous solubility with high lipid permeability 
Class III: high aqueous solubility with low lipid permeability 
Class IV: low aqueous solubility with low lipid permeability 
NV, a class II drug, is poorly soluble in water having a solubility of 0.1 mg / mL at a pH of 7 and 
temperature of 25 °C.9 The poor water solubility of NV has a significant impact on the 
dissolution of the drug. It was proven that the poor water solubility resulted in a low dissolution 
profile of NV and is assumed to be the rate-limiting step for absorption of the drug.18 After a 
careful assessment of the three MCC cases in the dissolution guideline, the case C dissolution 
category was considered for this study. 
 
If an active substance is considered highly soluble, it is reasonable to expect that it will not cause 
any bioavailability problems if, in addition, the dosage system is rapidly dissolved in the 
physiological pH-interval expected after product administration. A clinical in vivo 
bioequivalence study may in those situations be waived based on the similarity of the dissolution 
profiles in vitro. It is a known fact that NV is poorly soluble in water. This fact poses a challenge 
to bioavailability and in 2011 Caira et al.12 conducted a study in which five co-crystals of NV 
were identified and produced. The five co-formers that were used to produce the NV co-crystals 
were saccharin (SC), rac-tartaric acid (TTA), maleic acid (MLE), salicylic acid (SLI) and 
glutaric acid (GLT). The investigators performed dissolution studies on nevirapine-saccharin 
(NVSC) and nevirapine-rac-tartaric acid (NVTTA) co-crystals using the British Pharmacopoeia 
(2005)15 rotating-basket method (figure 1.5, B). 
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It was determined that the co-crystals increased the drug release of NV during the dissolution 
experiment. The NVSC co-crystal obtained 75 % dissolution of NV within 45 minutes and 
NVTTA only obtained 75 % NV dissolution after 120 minutes. Therefore, the NVSC co-crystal 
passed the acceptance criteria as per British Pharmacopoeia requirement of 70 % dissolution in 
45 minutes whilst the NVTTA co-crystal failed to meet the acceptance criteria as only 61.7 % 
NV dissolution was achieved after 45 minutes. The study also concluded that both co-crystals 
achieved a better dissolution profile than the NV alone. The analytical technique used to quantify 
the amounts of NV in the dissolution samples was UV/VIS spectrophotometry.12  
 
The study thus concluded that NV could possibly be transformed from a class II drug to a class I 
drug as the physicochemical property of aqueous solubility was enhanced with the high lipid 
permeability maintained. Hence, the outcome of the problem statement for this study presented 
below: 
 
This study aimed at reproducing the five co-crystals12, identifying them, performing dissolution 
tests (BP 2005 method as before) on the co-crystals and physical mixtures (1:1 molar ratio) 
thereof and analysing the dissolution samples using high performance liquid chromatography 
(HPLC). One of the challenges envisaged in reproducing the co-crystals by the co-precipitation 
method was the variability in the yield which foresaw the synthesis of multiple batches to 
achieve the required amount of co-crystals to perform the dissolution analysis. When the 
dissolution profiles of the five co-crystals and physical mixes were established, the best co-
crystal former (co-former) was selected together with a specific set of criteria for further 
analysis. Subsequent to the selection of the most appropriate co-former, a prototype co-crystal 
tablet was produced in a study conducted parallel to this study and comparative dissolution 
studies was performed on the prototype co-crystal tablet and the proprietor brand (Viramune®) 
in three different dissolution media viz. acidic, neutral and alkaline.  
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The dissolution specification for the comparative dissolution study was set using the United 
States Pharmacopoeia (USP 36)16 standard and the Medicines Control Council (MCC) of South 
Africa dissolution guideline.17 The project design was intended to align the methodology to USP 
standards and MCC guidelines in order to support the vision of progressing the most suitable NV 
co-crystal to a stage where it could be registered on the South African medicines market for 
human use. 
 
1.5 Stability testing 
The rationale of conducting stability studies on pharmaceutical products is to provide evidence 
of how the quality of a drug substance or formulated product varies with time under the influence 
of a variety of environmental factors such as temperature, light and humidity. The stability of 
finished pharmaceutical products depends, on the one hand, on environmental factors such as 
ambient temperature, humidity, light, and on the other hand, on product-related factors, e.g. the 
chemical and physical properties of the active substance and of pharmaceutical excipients, the 
dosage form and its composition, the manufacturing process, the nature of the container-closure 
system and the properties of the packaging materials.1 
 
The objective of stability testing is to apply appropriate test methodologies to allow for the 
establishment of recommended storage conditions, retest periods and shelf-lives. It is important 
for pharmaceutical companies to have confidence that their product will be ‘fit for purpose’ 
throughout the proposed shelf-life of the product. A proper stability study will provide such 
assurance, however it can also indicate unacceptable changes that can occur during the period of 
storage up to the proposed expiry date. A well designed stability test protocol will include test 
methods that take into account factors affecting drug potency, formation of degradation products 
and the microbial and physical integrity of the product. Stability studies are conducted at all 
stages of product development of a new drug substance, formulated product and where 
appropriate, novel formulation excipients. However, the stability design and type of test 
methodologies employed will depend on the stage of the development process and the nature of 
the drug and product under test.1 
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There are various types of stability studies that are conducted during the development of a 
pharmaceutical. These stability studies include: accelerated stress stability testing, stability to 
support safety and clinical studies and stability to support product license applications. The 
accelerated stress stability test is aimed at exposing samples of the product to conditions that are 
designed to stress the drug. This type of test usually involves exposure to extreme temperature 
and/or humidity, intense light, metal ions and oxygen. The purpose of this type of study is to 
obtain information on the possible routes of drug degradation and the physical and chemical 
factors that affect the process of degradation.1, 6 
 
During phase I and II clinical trials, usually performed at stage (v), full development, of the 
product life-cycle, pharmaceutical companies are required to submit stability testing results to 
regulators. This requirement is set out to support safety in clinical studies. The type of stability is 
designed to evaluate the stability of formulations used in clinical trials. The duration of the 
stability study will typically depend on the length of the clinical trial. The information generated 
in the execution of the stability study is sometimes used to provide supporting data for product 
license application. These stability studies usually monitor changes in the product performance 
characteristics and identifying formulation degradants produced under actual storage conditions.1 
 
Stability testing to support a product license application is usually conducted during phase III 
clinical trials. The stability study is designed to test the proposed commercial formulation stored 
in the proposed market packaging and using the final manufacturing process at the proposed 
commercial production site. To ensure both patient safety and the rational management of drug 
supplies, it is important that the expiry date and, when necessary, the storage conditions are 
indicated on the label. These storage conditions need to be complied to throughout the supply 
chain to the end user of the pharmaceutical in order for the patient to receive a quality product 
and receive the appropriate pharmaceutical care.1 
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1.6 Antiviral activity 
Microorganisms are important elements in the cycle of life. They are omnipresent in nature and 
are divided into two categories of similar characteristics in terms of taxonomic units namely; 
prokaryotic and eukaryotic cells. These entities are primarily different in their arrangement of 
their nuclear material. In eukaryotic cells, a true nucleus is present with chromosomes that are 
separate from the cell cytoplasm. The chromosomes are enclosed in the nuclear membrane. In 
contrast, the prokaryotic cell does not possess a true nucleus. The prokaryotic cell nuclear 
material is free within the cytoplasm and may be aggregated into discrete areas called nuclear 
bodies. Viral species typically form part of the prokaryotic organisms which comprises of the 
lower forms of life. Eukaryotic cell types comprises of the higher forms of life of which fungi is 
an example.6 
 
Viruses are obligate intracellular parasites with no intrinsic metabolic activity, being devoid of 
ribosomes and energy-producing enzyme systems. Therefore, viruses do not have the capability 
of reproducing independently and cannot be cultivated on growth media unless there is a host 
cell present. Structurally viruses consist of a core of nucleic acid, either as deoxyribonucleic acid 
(DNA) or ribonucleic acid (RNA) enclosed in a protein shell also known as the capsid. The 
protein capsid makes up to between 50-90 % of the weight of the virus. There are many viruses 
that are pathogenic and cause disease in both humans and animals. The virus that was targeted in 
this study is the human immuno-deficient virus (HIV).6 
 
The first case of HIV infection in a human was identified in 1959. The transfer of the HIV 
disease from animal to human likely occurred several decades earlier, however the infected 
individual lived in the Democratic Republic of the Congo. He did not know (and research could 
not identify) how he was infected.19 
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HIV, as illustrated in figure 1.6, is a retrovirus that causes AIDS (acquired immunodeficiency 
syndrome) by infecting helper T cells of the immune system. HIV uses the enzyme reverse 
transcriptase to reverse transcribe its RNA and incorporate it into the host cell’s reproduction 
machinery, which then allows it to reproduce freely. 
 
Figure 1.6: Example of the structure of the HIV viral particle20 
 
The HIV cycle of replication as displayed in figure 1.7 provides a depiction of how HIV would 
typically infect its human host helper T cells and destroy it after its replication. The virus 
attaches and binds itself to the surface receptors of the host cell, fuses the viral envelope with the 
host cell membrane and releases the HIV nucleocapsid directly into the cytoplasm. This process 
is referred to as attachment and insertion. 
 
The HIV RNA and various enzymes, including reverse transcriptase, integrase, ribonuclease, 
and protease, are injected into the host cell. The enzyme reverse transcriptase liberates the 
single-stranded RNA genome from the attached viral proteins and copies it into a complementary 
DNA (cDNA) molecule. The DNA is integrated into the nucleus of the host by integrase. The 
host genetic machinery produces viral mRNA. The protease enzymes support the assembly and 
budding process by manipulating the viral copies into the appropriate sizes. The viral copies 
mature and are released into the host to further infect other healthy host cells. Subsequent to the 
release of the viral particles, the host cell dies.6 
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Figure 1.7: Replication cycle of HIV21 
 
There are many means of testing antiviral activity. In particular, HIV like any other virus requires 
a host cell in order for the virus to successfully replicate. Therefore many of the established 
techniques applied some form of a cell line to conduct antiviral activity experiments. In anti-HIV 
assays a wide range of established human cell lines are used. These cell lines include those of T-
cell lineage (CEM-SS, MT-2, MT-4, H9, Jurkat, Molt-4, SupT1, and others); B-cell lineage 
(AA5, AA2, and others); monocyte-macrophage lineage (U937, THP1, HL60, and others); and 
other human cell lines (HeLa-CD4-LTR-βgal, MAGI-CCR5, 174xCEM, and others).22 
 
Anti-HIV assays are routinely performed using a variety of endpoints including: 
I. Cytoprotection - inhibition of viral cytopathic effects is measured using the tetrazollium 
dye MTS (Promega) to evaluate cell viability following virus infection, 
II. Reporter gene induction - cell lines engineered to express reporter genes (e.g., β-
galactosidase or luciferase) following HIV infection are used to evaluate antiviral activity, 
III. Reverse transcriptase (RT) - inhibition of virus replication determined as a reduction in 
supernatant RT activity, 
IV. ELISA - supernatant or cell-associated HIV-1 p24 antigen content assessed using 
commercially available ELISA kits, and 
V. Virus infectivity - supernatants from infected cultures are titrated to quantify the relative 
titer of infectious virus released from the cells.22 
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In vitro antiviral testing of the co-crystals is important in order to establish whether the NV co-
crystal had improved its antiviral activity against HIV compared to pure NV. The antiviral test 
should preferably be performed before a batch size scale-up is considered as the antiviral tests 
results will be a leading indicator of whether the advancement of the project to an up scaling 
stage is feasible i.e. stage (v) of the product life-cycle, full development.  
 
The antiviral tests were performed by the National Institute of Communicable Diseases of South 
Africa (NICD). The assay employed by NICD was the HIV-1 single-cycle non replication assay. 
Toxicity screening of the co-crystal and co-former were assessed using formazan dye (MTS) to 
establish the maximum non-toxic concentration to the NICD 293T host cells. It is an important 
requirement to complete the cytotoxicity test prior to the antiviral activity test to ensure the 
antiviral agent does not destroy the host cell at the given concentration. Serial dilutions of the co-
crystals, formulated prototype co-crystal tablet and comparator proprietor brand tablet were 
tested against pseudo-HIV-1 virus. 
 
These antiviral tests provided a description on the toxicity (cytotoxic concentration 50, 
specificity in 293T cells) and activity (minimum inhibitory concentration-50, specificity against 
the HIV-1 MJ4 reference strain) of the co-crystals, prototype co-crystal tablet and comparative 
proprietor brand tablet. 
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1.7 Molecular modelling and HIV resistance 
Molecular modelling, commonly known as computational chemistry, is a discipline that deals 
with the development of molecular system models, chemical reactions and other phenomena of 
interest to chemistry. The type of methods used in molecular modelling are; automatic structure 
generation, analysis of three-dimensional databases, and construction of protein models by 
techniques based on sequence homology, diversity analysis and docking of ligands or continuum 
methods.23 Therefore, it is evident that molecular modelling utilises various strategies to model 
and deduce information of a system at the atomic level. The core aspect of molecular modelling 
utilises methodologies like computation of the energy of a molecular system, energy 
minimization, Monte Carlo23 methods or molecular dynamics. The computational molecular 
modelling methodologies provide a platform to study new biomolecular moieties or derivatives 
of existing moieties. The methodology allows the scientist to predict accurately the type of 
interaction a new biomolecular moiety or a derivative of it would have with a specific receptor or 
biological target. Therefore, allowing full understanding of the molecular mechanism responsible 
for its specific biological activity without having to perform time-consuming wet chemistry 
work. In turn, this knowledge is aimed at designing new active molecules that can be 
successfully used as drug compounds.23 
 
In the South African context, molecular modelling plays a pivotal role in the development of 
strategies to overcome the escalating problem of HIV resistance to antiretroviral therapy (ART). 
HIV resistance to ART is primarily attributed to poor patient adherence, transmitted drug 
resistant virus and monotherapy i.e. single drug treatment with a non-nucleotide reverse 
transcriptase inhibitor in particular nevirapine, in prevention therapy of vertical mother-to-child 
transmission.24 
 
The first line treatment for HIV infection in South Africa’s public health sector is a combination 
therapy of two nucleotide/nucleoside reverse transcriptase inhibitors (NRTI) and one non-
nucleotide reverse transcriptase inhibitor (NNRTI).25 Therefore, it is evident that currently the 
key biological target to block HIV replication is the inhibition of the reverse transcriptase 
enzyme (RTE).  
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The HIV replication cycle is repeated every second day. The rapid production of new HIV viral 
copies combined with a high mutation after every replication cycle, results in a large pool of 
viral variants referred to as quasispecies. These subtype variants of HIV adds to the challenge of 
managing the disease state with ART. The HIV mutation is a result of the inability of both the 
host RNA-dependent DNA polymerase and the RTE to proofread and correct errors that occur 
during viral replication. The error rate per nucleotide introduced in a single cycle of retroviral 
replication is between 1 0 - 4  and 1 0 - 5 .26 The subtype variants of HIV have the full capability to 
perform normal HIV functions, however mutations affect the efficiency of the replication cycle 
to varying degrees.26 
 
As previously mentioned, the mechanism of action of both NRTIs and NNRTIs are similar. 
These drugs bind to the hydrophobic pocket of the RTE and inhibit replication of HIV. The 
NNRTI-binding site of the RTE is dynamic; upon binding of the NNRTI to the RTE, the RTE 
alters its conformation to accommodate the NNRTI, forming a non-nucleoside inhibitor-binding 
pocket (NNIBP).27 However, research indicated that despite major chemical differences among 
the first-generation NNRTIs they all bind to the very flexible, hydrophobic NNIBP, mainly by 
means of energetically favorable positions. Therefore, indicating that binding to the RTE is 
dependent on a conformational fit, rather than a slight structural change.28 
 
Even though HIV inherently mutate during each replication cycle, resistance to antiretroviral 
drugs is conferred when the virus replicates in the presence of the drug at therapeutic or sub-
therapeutic levels. Research has shown that NNRTI resistance has been linked to over 40 
possible amino acid substitutions occurring mainly at the NNIBP. These mutations affect NNRTI 
binding indirectly by hampering access to the NNIBP or by directly altering the size, shape and 
polarity on different areas of the NNIBP.28, 29 However, mutations are primarily noted at either 
the Tyr181 or Tyr188 amino acids within the NNIBP and it is these alterations that confer a high 
level of resistance to NNRTIs. These specific amino acid changes avert affinity of a specific 
NNRTI for the binding site, ultimately resulting in drug resistance.30 
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In order to overcome HIV-1 reverse transcriptase mutant strains, major structural changes are 
required that will incur increased flexibility for the already flexible NNIBP. Figure 1.8 depicts 
the type of structural changes required for the RTE. Therefore, slight structural modifications 
(e.g. angle changes or isomeric forms) will not meet the required flexibility of the RTE.28, 29 
 
Figure 1.8: Structural changes required for the RTE 
 
 
The current strategy in South Africa used to overcome resistance is with combination therapy of 
highly active antiretrovirals (HAART). This treatment regimen consists of two NRTI’s and one 
NNRTI, usually efavirenz.25 This strategy has been effective however; multi-drug resistant 
strains of HIV may still emerge in combination therapy with HAART in naïve patients.24, 26 
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The recent advances in pharmaceutical technology have seen the emergence of antiretroviral 
drugs formulated into fixed dose combinations (FDC) in an attempt to simplify the dosage 
regimen and improve patient adherence. The total daily amount of tablets administered per day is 
now reduced to only one tablet daily. The FDC antiretroviral drug (ARV) consists of three drugs 
viz. tenofovir, emtricitabine and efavirenz. The FDC ARV dosage form brings along great 
advantages. However, there are also many disadvantages. In particular, the costs of this type of 
treatment is very expensive, multiple excipients are required to produce a FDC dosage from, the 
manufacturing process is complex and specialised equipment is required and an undesirable large 
dosage form is produced which may pose a problem with oral administration.31, 32 
 
The limitations observed in FDC antiretroviral drug therapy and the HIV resistance can easily be 
overcome by molecularly modelling the antiretroviral drugs i.e. supramolecular manipulation of 
two or more APIs to non-covalently bind it by the co-crystallization technique (figure 1.9). The 
limitation here, however is the fact that once in solution, the co-crystal separates into its separate 
entities since non-covalent bonds are relatively weak. 
 
Figure 1.9: Representation of drug-drug co-crystal and combination drugs. 
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Drug-drug co-crystallisation offers an alternative API combination approach with fewer 
excipients needed compared to FDC tablet dosage forms. The co-crystallisation of two or more 
APIs are now combined in stoichiometric amounts of each API. These APIs interact by non-
covalent interactions and as a result form a single solid component (instead of two or more 
entities) at ambient conditions.33 
 
The selection of APIs for drug-drug co-crystallisation is often based on APIs commonly 
prescribed together.34 However, drugs with related structures and similar 3-D assembly are more 
likely to form a co-crystal with drug-drug physiochemical synergism.35 Antiretroviral drug-drug 
co-crystallisation has been demonstrated with the successful synthesis of a lamivudine and 
zidovudine co-crystal at therapeutic amounts of each API.36 An additional advantage over FDC 
tablet dosage forms is the fact that the physicochemical properties of the parent APIs are 
modified upon co-crystallization. This modification in the chemical structure often leads to a 
superior API with enhanced aqueous solubility which lends itself to better dissolution and 
bioavailability. The change in aqueous solubility of the API usually has an impact on its 
biopharmaceutical classification (BPC). Studies involving NV showed a complete BPC class 
change from class II to class I. The change in class brings definite benefits as a combination 
ARV at a lower concentration, however maintaining therapeutic efficacy may be a possibility. 
Furthermore, minimal excipients and quantities thereof would be required to formulate a tablet 
with acceptable quality. This will allow for a smaller tablet size compared to the FDC tablet. 
Molecular modelling by co-crystallization of clinically relevant ARVs with histone deacetylase 
inhibitors such as vorinostat and valproic acid to disrupt HIV latency and completely eradicate 
the infection may also be a possibility.37 However, for this study, only the discussion of 
molecular modelling by co-crystallization in this literature review of clinically relevant ARV 
combinations as stipulated in the standard treatment guideline of South Africa for HIV infection 
was achieved above. 
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1.8 Nevirapine (Viramune®) 
Viramune®, the registered proprietor brand of nevirapine (NV) was discovered by Boehringer 
Ingelheim. NV, a non-nucleoside reverse transcriptase inhibitor, is effectively used in 
combination with other antiretroviral drugs to treat the human immuno deficiency virus (HIV) 
type 1 infection. The pharmacological mechanism of action of NV is to directly inhibit the 
reverse transcriptase enzyme in order to suppress deoxyribonucleic acid (DNA) replication of 
HIV. The product was approved by the Federal Drug Administration of the United States of 
America in 1996 for adult use and in 1998 for paediatrics.38 
 
Viramune® tablets are for oral administration and each tablet contains 200 mg of NV. The tablet 
consists of other inactive ingredients viz. microcrystalline cellulose (binder/disintegrant), lactose 
monohydrate (diluent), povidone (binder), sodium starch glycolate (disintegrant), colloidal 
silicon dioxide (glidant) and magnesium stearate (lubricant). These excipients are found in 
specific quantities in the tablet formula. The excipients are used in specific quantity for various 
reasons such as, binding all solid to form a tablet, preventing the tablet from sticking while 
compressing and supporting disintegration when the tablet comes into contact with stomach 
fluids. It is vitally important that the excipients are of the exact grade, quality, integrity and 
quantity, as mentioned before, in order for the tablet to meet the desired quality and maintain its 
stability. Should there be any compromise in these attributes it will adversely impact the tablet. 
Therefore it is important to mention that these excipients were purposely selected as all of them 
are chemically compatible with the API i.e. nevirapine. Viramune® is also formulated in a 
suspension for oral administration in paediatrics. The suspension contains 50 mg of nevirapine 
(as nevirapine hemihydrate) per 5 mL. The suspension contains the following excipients: 
carbomer 934P (suspending/gelling agent), methylparaben (preservative), propylparaben 
(preservative), sorbitol (sweetener), sucrose (sweetener), polysorbate 80 (emulsifier/surfactant), 
sodium hydroxide (pH modifier) and purified water (vehicle) in specific quantities. The NV used 
in the suspension is in the hemihydrate form. The reason for this is that the hemihydrate form of 
NV has a better aqueous solubility compared to the other forms of NV.7, 39 
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The generic name for nevirapine (figure 1.10) is chemically written as 11-cyclopropyl-5,11-
dihydro-4-methyl-6H-dipyrido [3,2-b:2',3'-e][1,4] diazepin-6-one and forms part of the 
dipyridodiazepinone chemical class of compounds. NV is a white to off-white crystalline powder 
with a molecular weight of 266.30 g/mol and with the following molecular formula C15H14N4O. 
The chemical structure of NV resembles that of a butterfly as illustrated by figure 1.10. 
 
Figure 1.10: Nevirapine chemical structure 
 
 
It has been determined that the butterfly-like shape in the NV chemical structure is essential for 
the engagement of the molecule at the reverse transcriptase inhibition site. It is of concern that 
co-crystallization of NV could alter the conformational flexibility of the molecule and potentially 
impact the binding of NV to the reverse transcriptase enzyme of the HIV. However, in 2010 
Samsodien9 determined that no significant conformational changes occurs upon co-
crystallisation with selected co-formers and thus the impact on the binding ability to the reverse 
transcriptase enzyme is not affected with saccharin and tartaric acid as co-formers.9 There were 
three more NV co-crystals viz. NVMLE, NVGLT and NVSLI that were analysed with respect to 
conformational changes. No significant conformational changes occurred upon co-
crystallisation.9 
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Overall Aims and Objectives 
The generation and compilation of data to pursue registration of a novel nevirapine formulation, 
the product life-cycle of an enhanced water soluble nevirapine prototype formulation took the 
following approach according to the product life-cycle explained previously: 
To achieve (i) strategic research and (ii) exploratory research, a pre-formulation study was 
performed. Co-crystals of the anti-retroviral, nevirapine, was synthesised, identified and analysed 
by dissolution studies. The co-crystals were synthesized by co-precipitation and solvent-drop 
grinding. Identification of five co-crystals was done by HSM, FTIR, DSC, TGA, PXRD and 
SXRD. The dissolution experiments applied the BP 200515 dissolution method, with UV/VIS 
spectrophotometry for quantitative analysis. Repeated pre-formulation dissolution experiments 
applied the BP 200515 dissolution method with HPLC for quantitative analysis. Cytotoxicity was 
determined against a host cell 293T and antiviral activity was determined against a pseudo-HIV-
1 virus.40,41 
To achieve (iii) ‘(candidate selection)’ the selection of the most appropriate NV co-crystal for 
development into the prototype formulation, the best co-former candidate was reviewed. Each 
co-former was investigated according to a set of variables and scored accordingly. The co-former 
that satisfied the selection criteria most appropriately was chosen for stage (iv), exploratory 
development. 
 
To achieve (iv), exploratory development, a co-crystal prototype tablet was formulated. The 
formulation of the co-crystal tablet was achieved by direct compression after the careful 
selection of compatible excipients and application of tablet compression technology. Quality 
control tests were performed on the prototype co-crystal tablet and the proprietor brand. 
Dissolution experiments applied the USP 3616 method and HPLC for quantitative analysis and 
solution stability was evaluated after 4 weeks exposure of the dissolution samples to cold chain 
and accelerated environmental conditions. Cytotoxicity against a host cell 293T and antiviral 
activity against the pseudo-HIV-1 virus was once again determined.40, 41 Finally, limitations and 
recommendations for optimisation of the co-crystal tablet were investigated and discussed. 
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Stage (v), full development can only be achieved once stage (iv), exploratory development, of 
the prototype formulation is concluded. At stage (v) of the product life-cycle, the quality, safety 
and efficacy of the pharmaceutical product is demonstrated. This entails producing ideally a 
tenth of a full batch size to complete activities such as process validation, human clinical trials, 
stability studies which is then followed by regulatory submission and stage (vi) marketing and 
commercialisation. Stages (v) and (vi) are not included in this study. 
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DISSOLUTION AND ANTIVIRAL ACTIVITY OF A NOVEL NEVIRAPINE FORMULATION 
              
CHAPTER 2 
EXPERIMENTAL 
MATERIALS AND METHODS 
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2 Introduction 
As discussed in chapter 1, there are six distinct stages in the product life-cycle process of a 
pharmaceutical product, viz. (i) strategic research, (ii) exploratory research, (iii) candidate drug 
selection, (iv) exploratory development, (v) full development and (vi) marketing and 
commercialisation. Chapter 2 describes the materials, preparation methods and analytical 
techniques that were required for the life-cycle process of the novel nevirapine formulation. The 
experimental materials and method section broadly describes the methodologies and analytical 
techniques utilized at each stage of the product life-cycle. 
 
(i) Strategic research and (ii) exploratory research 
A pre-formulation study was performed. Co-crystals of the anti-retroviral, nevirapine, was 
synthesised, identified and analysed by dissolution studies. The co-crystals were synthesized by 
co-precipitation and solvent-drop grinding. Identification of the co-crystals was achieved by 
HSM, FTIR, DSC, TGA, PXRD and SXRD. The dissolution experiments applied the BP 20051 
dissolution method, with UV/VIS spectrophotometry for quantitative analysis. Repeated pre-
formulation dissolution experiments applied the BP 20051 dissolution method with HPLC for 
quantitative analysis. Cytotoxicity was determined against a host cell 293T and antiviral activity 
was determined against a pseudo-HIV-1 virus.2, 3 
(iii) Candidate drug selection 
To select the most appropriate NV co-crystal for development into the prototype formulation, the 
best co-former candidate had been reviewed. Each co-former was investigated according to a set 
of variables and scored accordingly. The co-former that satisfied the selection criteria most 
appropriately was chosen for exploratory development. 
 
(iv) Exploratory development  
Exploratory development led to the formulation of the co-crystal tablet. The formulation of the 
prototype co-crystal tablet was achieved by direct compression after the careful selection and 
inclusion of compatible excipients and application of tablet compression technology. Quality 
control tests were performed on the prototype co-crystal tablet and the proprietor brand.  
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Dissolution experiments applied the USP 364 method and HPLC for quantitative analysis and 
evaluated solution stability after 4 weeks exposure to cold chain and accelerated environmental 
conditions. Cytotoxicity against a host cell 293T and antiviral activity against the pseudo-HIV-1 
virus was once again determined.2, 3 Finally, limitations and recommendations for optimisation 
of the co-crystal tablet were investigated and discussed. 
 
(v) Full development and (vi) marketing and commercialisation 
Full development can only be achieved once the exploratory development of the prototype 
formulation is concluded. This entails producing ideally a tenth of a full batch size to complete 
activities such as process validation, human clinical trials, stability studies which is then 
followed by marketing and commercialisation. Stages (v) and (iv) is not included in this study as 
it is not in the scope of this study. 
 
2.1 Materials 
The following materials were required for stages (i), (ii), (iii) and (iv) of the life-cycle 
development of a novel NV formulation. 
 
Material for (i) strategic research and (ii) exploratory research 
All chemicals used were of an analytical grade. The pure NV (lot number IF-NE-080702) was 
purchased from Cipla (Mumbai, India, batch number 1001003). The co-formers SC, TTA, SLI, 
GLT and MLE were purchased from Sigma-Aldrich (China). Material for the cytotoxicity and 
antiviral testing was supplied by the NICD, viz. thiazolyl blue tetrazolium bromide, dimethyl 
sulfoxide (DMSO), Dulbecco’s modified eagle medium (DMEM), sodium dodecyl sulphate, 
dimethylformamide, Fetal bovine serum (FSB) 
 
Material for (iii) candidate selection and (iv) exploratory development 
Pure NV (lot number B024277; item number 141980; expiry date: June 2016) was supplied by 
Aspen Pharmacare to produce the prototype tablets containing glutaric acid (NVGLT). The GLT 
(lot number STBC3486V) and MCC (AVICEL®) (lot number BCBJ8498V) were supplied by 
Sigma-Aldrich (China).  
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Material for buffer solutions for final comparative dissolution studies were potassium chloride, 
hydrochloric acid, sodium acetate, acetic acid, monobasic potassium phosphate and sodium 
hydroxide which were all analytical grade was supplied by Sigma-Aldrich (China). 
 
Buffer solutions for dissolution media 
A HCl buffer (pH 1.2) 
Placed 50 mL of 0.2 M potassium chloride solution in a 200 mL volumetric flask. Added 
85 mL 0.2 M hydrochloric acid. Added MilliQ® water to volume. 
 
Preparation of 0.2 M potassium chloride solution: 
Dissolved 14.91 g of potassium chloride in water. Diluted with water to 1000 mL. 
 
Preparation of 0.2 M hydrochloric acid solution: 
Diluted 19.6 mL hydrochloric acid to 1000 mL of water in a volumetric flask. 
 
B Acetate buffer (pH 4.5) 
Placed 2.99 g of sodium acetate NaC2H3O2 • 3H2O in a 1000 mL volumetric flask. Added 
14 mL of 2 N acetic acid solution. Added water to volume and mixed. 
 
Preparation of 2 N acetic acid solution: 
Diluted 116 mL glacial acetic acid to 1000 mL water in a volumetric flask. 
 
C Phosphate buffer (pH 6.8) 
Placed 50 mL of 0.2 M monobasic potassium phosphate solution in a 200 mL volumetric 
flask. Added 22.4 mL of 0.2 M sodium hydroxide solution. Added water to volume. 
 
Preparation of 0.2 M monobasic potassium phosphate solution: 
Dissolved 27.22 g of monobasic potassium phosphate in water in a 1000 mL 
volumetric flask. Made solution up to volume of 1000 mL with water. 
 
Preparation of 0.2 M sodium hydroxide solution: 
Dissolved 8 g of sodium hydroxide to 1000 mL water in a volumetric flask. 
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Arrhythmic mathematical calculations were conducted to make up the appropriate quantities of 
buffer for the dissolution tests. 
 
Material for (iv) exploratory development 
The proprietor brand tablet from Boehringer Ingelheim, Viramune® 200 mg (lot number 
145057) with the expiry date 12/2014, was used to perform the comparative dissolution studies.  
 
All solvents used and other consumable chemicals used for this study were of analytical grade 
and purchased from Sigma-Aldrich (China). 
 
2.2 Preparation methods 
(i) Strategic research and (ii) exploratory research 
There were two techniques used to prepare the five co-crystals of NV viz. co-precipitation and 
the solvent-drop grinding procedure: 
 
Co-precipitation technique 
Stoichiometric amounts of the components (co-former and NV) were dissolved in a known 
volume of solvent. Samples were dissolved separately in the solvent system, and stirred with a 
magnetic stirrer while on a hot plate at 10 °C below the boiling point of the solvent until the 
powders were completely dissolved. The two solutions were then mixed together in the vial with 
the lesser amount of solvent. The mixture was then stirred, extracted via a syringe and filtered 
through a 0.45 μm filter into a clean vial. The vial was closed with Parafilm® and perforated to 
allow the solvent to evaporate. This procedure was followed for the production of all co-crystals 
prepared by the co-precipitation technique. 
 
Solvent-drop grinding technique 
A mortar and pestle was used to grind stoichiometric amounts of the API and co-former. A 
solvent was added slowly to the powders in a drop-wise manner. Only a few drops of solvent 
were used in order to maintain a moist consistency. The powder was ground for a period of time 
at room temperature and allowed to stand at room temperature to allow for the solvent to 
evaporate. 
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The amount of powders used included a 10 % excess of each material. The material was closed 
with Parafilm® and the Parafilm® was perforated to prevent any environmental contamination 
and to allow for any excess solvent to evaporate even further. 
 
(iii) Candidate selection 
Each co-former was investigated according to a set of variables placed in a table and scored 
accordingly. The variables investigated were as follows: co-former’s toxicity, flowability, angle 
of repose, Hausner’s ratio and Carr’s Index, compressibility, aqueous solubility, disintegration 
time, moisture content, cost of the material, antiviral activity and dissolution of the co-former. 
Then the co-former was further investigated as a NV co-crystal with respect to the following 
variables; flowability, compressibility, aqueous solubility, dissolution and the antiviral activity 
and QC tests such as the disintegration time, moisture content, particle size, bulk density and 
tapped density. The co-former that satisfied the selection criteria most appropriately ‘as is’ and 
as a ‘co-crystal’ was chosen for exploratory development. 
 
(iv) Exploratory development 
Preparation of the co-crystal prototype tablet 
The prototype co-crystal tablet was prepared by direct compression of a mixture of the co-crystal 
with selected excipients from the branded formulation. A single punch and die apparatus was 
used to perform compression of the tablet. 
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2.3 Analytical methods 
Hot stage microscopy (HSM) 
The identity, integrity and purity of all co-crystals for the pre-formulation dissolution test were 
verified using hot stage microscopy (HSM). A Linkam® TH MS600 temperature control stage 
connected to a T95 Linkpad® System Controller was used to heat the crystals at a controlled rate 
of 20 °C per minute. Visual characterisation was captured by an Olympus UC30 colour video 
camera fitted to an Olympus SZX7 stereoscopic microscope. The recorded images were analysed 
by Stream Essentials software®.  
 
The HSM analysis was performed at the University of the Western Cape, School of Pharmacy, 
Discipline of Pharmaceutics. 
 
Differential scanning calorimetry (DSC) 
Thermal identification of the co-crystals was achieved using a Perkin Elmer DSC-7 analyzer 
utilizing the Pyris® software program. The sample was heated from 40 °C to 260 °C at 10 K/min. 
 
The DSC analysis was performed at the University of the Western Cape, School of Pharmacy, 
Discipline of Pharmaceutics. 
 
Powder X-ray diffraction (PXRD) 
PXRD was utilized to identify the co-crystals and the parent compounds. Ground samples were 
recorded on a Philips PW1050/25 vertical goniometer with Ni-filtered CuKα radiation (λ = 
1.5418 A) produced at 40 kV and 25 mA. PXRD patterns were recorded using a Huber Imaging 
Plate Guinier Camera 670. 
 
The PXRD analysis was performed at the University of Cape Town, Supramolecular Chemistry 
unit. 
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Thermogravimetry analysis (TGA) 
TGA measures the mass loss of a sample as a function of time or temperature. It is used to 
establish the stoichiometry of inclusion compounds and to study the decomposition of desolvated 
materials. TGA for all compounds were performed on a Mettler Toledo TGA/SDTA851e 
instrument under N2 gas purging at a flow rate of 30 mL/min. The Mettler TG instrument was 
calibrated using indium (mp = 156.6 ºC) and aluminium (mp = 660.3 ºC) in an automated 
process in which temperature calibration, tau lag calibration and sensor calibration were 
performed simultaneously. The crystals were rapidly dried on a filter paper to remove surface 
solvent. The weighed samples were placed in an open porcelain pan. The programmed TG 
analyses were carried out over a temperature range 30 ºC to 400 ºC at the predetermined linear 
heating rate of 10 K/min. This technique was primarily used to determine the stoichiometry of 
the compounds from the percentage weight loss. The samples were continuously purged by a 
stream of dry N2 gas at a flow rate of 30 mL/min. 
 
The TGA was performed at the University of Cape Town, Supramolecular Chemistry unit. 
 
Fourier transform infrared analysis (FTIR) 
IR spectra were obtained using a Perkin-Elmer 100 FTIR instrument fitted with UATR and 
controlled with Spectrum® software for sample analysis. Samples were run and percentage 
transmittance was recorded against frequency. All starting material was analysed for purity. 
FTIR and the melting point analysis confirmed the identification of all starting material (see 
appendix A). The analyses were compared to theoretical data and for the FTIR analysis there had 
to be a match in the fingerprint whereas for the melting point analysis, a 0.3 °C variance was 
considered acceptable for identification purposes. 
 
The FTIR analysis was performed at the University of the Western Cape, School of Pharmacy, 
Discipline of Pharmaceutics. 
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Single X-ray diffraction (SXRD) 
Two single crystal X-ray diffractometers were employed: a Nonius Kappa CCD (Charge 
Coupled Device) Single Crystal X-ray Diffractometer and a Bruker KAPPA APEX II DUO 
diffractometer. Crystal intensity data were collected on a Nonius Kappa CCD (Charge Coupled 
Device) Single Crystal X-ray Diffractometer, using graphite-monochromated MoKα radiation (λ 
= 0.71069 A) generated by a Nonius FR590 generator operated at 50 kV and 30 mA. Unit cell 
determinations were carried out both at ambient temperature (294 ± 2 K) as well as low 
temperature (113 ± 2 K). This check was performed to ensure there were no significant changes 
in the unit cell dimensions that might indicate phase transformations induced by cooling. All full 
intensity data-sets were measured at 113 ±2 K. The low temperatures were maintained by 
cooling the crystals with a constant stream of N2 gas at a flow rate of 20 mL/min with the aid of 
a Cryostream cooler (Oxford Cryosystems, UK). Data were corrected for Lorentz-polarisation 
effects; unit cell refinement and data-reduction were performed using the programs DENZO and 
SCALEPACK.5 All data were subjected to absorption correction using the multi-scan method 
(program SADABS6). The Bruker KAPPA APEX II DUO diffractometer used graphite-
monochromated Mo-Kα radiation (λ = 0.71069 Å). The unit cells of the crystals were determined 
at low temperature (100 ± 2 K) after their removal from mother liquor. The data collections were 
carried out in the above temperature range using Cryostream coolers (Oxford Cryosystems, UK). 
Data reduction was performed using the program SAINT.7  
 
The SXRD was performed at the University of Cape Town, Supramolecular Chemistry unit. 
 
Dissolution: British Pharmacopoeia (BP 2005) method1 – (i) strategic research 
Two types of dissolution instruments were used to conduct the pre-formulation dissolution 
analysis. The initial pre-formulation dissolution studies were conducted using the rotating-basket 
method BP 20051. The analysis was performed on a Vankel VK 700 (220 V) dissolution 
apparatus and with the Vankel VK 650 A Heater/Circulator Benchsaver® series to regulate 
temperature at 37 °C. 900 mL flasks filled with distilled water were used and a stirring speed of 
100 rpm was applied.  
 
 
 
 
 
52 
 
The capsules containing the co-crystals or co-crystal physical mix were enclosed in stainless 
steel baskets to prevent floating. A 3 hour run was conducted with sampling intervals set to 15 
minute. 5 mL samples were withdrawn and filtered for analysis, with 5 mL of the distilled water 
being replaced to maintain a constant volume.  
 
The assay was by UV/VIS spectrophotometry at an appropriate wavelength for the active 
ingredient. 
 
The powders placed in the capsules were kneaded prior to encapsulation for ~5 minutes to obtain 
uniform and predictable dissolution of the drug. The particle size range of the powders was 
between 65 and 200 μm. Powders were not sieved prior to encapsulation. 
 
The initial pre-formulation dissolution analysis was performed at the University of the Western 
Cape, School of Pharmacy, Discipline of Pharmaceutics. 
 
Dissolution: British Pharmacopoeia (BP 2005) method1 - (ii) exploratory research  
The repeated pre-formulation dissolution analysis was conducted to evaluate reproducibility of 
the initial dissolution results obtained. Dissolution profiles of pure NV and NV co-crystals 
NVSC, NVTTA, NVSLI, NVGLT and NVMLE, as well as separate physical mixes of NV with 
SC, TTA, SLI, GLT and MLE in a 1:1 molar ratio were established. To ensure reproducibility, 
the rotating-basket method used in previous studies was applied.1, 8, 9 
 
The Distek® evolution 6100 automated dissolution system was used for the dissolution analysis. 
The dissolution media temperature was maintained at 37 °C with heating coils. Flasks (900 mL) 
filled with MilliQ® water was used as dissolution media and a stirring speed of 100 rpm was 
applied. The dissolution media was degassed with a DissoPrep® x 8 media degasser. The 
capsules were placed in stainless steel baskets to prevent floating.  
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A 3 hour run as per the British Pharmacopoeia (BP 2005)1 standard was conducted and 7.5 mL 
samples were drawn from the six individual flasks at defined sampling intervals. The samples 
were extracted at 15 minute intervals and filtered inline using a 0.45 µm Cronus® nylon filter. 
The sample volume extracted from the media was not replaced since the validated Microsoft 
Excel® spreadsheet was used to calculate percentage drug release and the spreadsheet calculation 
had the capability to include a compensation factor.  
 
The samples were assayed with high performance liquid chromatography (HPLC). 
 
The powder mixtures and co-crystals were ground for 5 minutes before encapsulation to ensure a 
particle size range of 65 – 200 µm. Gelatine capsules were used to encapsulate six 10 mg of NV, 
six 10 mg of each of the five co-crystals, and six 10 mg of each mixture at a 1:1 molar ratio. 
Powders were not sieved prior to encapsulation. 
 
The repeated pre-formulation dissolution analysis was performed at the laboratory of 
GlaxoSmithKline Pharmaceuticals (Pty, Ltd.) in Cape Town. 
 
The data generated in the pre-formulation dissolution studies along with other sets of criterion 
such as toxicity, flowability, compressibility, aqueous solubility, disintegration time, moisture 
content, cost and antiviral activity were used to select one co-former to formulate and produce a 
prototype co-crystal tablet. The prototype co-crystal tablet was produced by Haas et al. (2013) in 
a study conducted in parallel to this study.10 
 
Dissolution: United States Pharmacopoeia (USP 36) method4 - (iii) candidate drug selection 
The dissolution performance of the formulated prototype co-crystal tablet NVGLT (lot number 
2013/08) was compared to the dissolution performance of the proprietor brand Viramune® 200 
mg (lot number 145057). The dissolution tests were conducted in three dissolution media i.e. a 
hydrochloric acid buffer (pH 1.2), an acetate buffer (pH 4.5) and a phosphate buffer (pH 6.8). 
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The Distek® evolution 6100 automated dissolution system was used for the comparative 
dissolution studies between the formulated prototype co-crystal tablet (n=6) and the Viramune® 
(n=6) tablet. The dissolution media temperature was maintained at 37 °C with heating coils. 
Flasks (900 mL) filled with dissolution media (pH 1.2, 4.5 and 6.8) and a stirring speed of 50 
rpm was applied. The paddle dissolution method (USP Apparatus 2) was used. The dissolution 
media was degassed with a DissoPrep® x 8 media degasser. A 60 minute run was conducted. 7.5 
mL samples were extracted from each flask at 10, 15, 20, 30, 45, 60 minutes, respectively. The 
sample volume extracted from the media was not replaced as a validated Microsoft Excel® 
spreadsheet was used to calculate the percentage drug release and the spreadsheet calculation had 
the capability to include a compensation factor. The method used an inline 0.45 µm Cronus® 
nylon filter. The filtrate was filtered and placed in a 1.5 mL HPLC vial. The dissolution samples 
were assayed with HPLC. 
 
The USP 364 was used as a reference standard to perform comparative dissolution studies of the 
prototype co-crystal tablets (NVGLT) versus the proprietor brand (Viramune®) in the buffered 
dissolution media. The reference standard was changed from BP (2005) to USP (36) to align the 
study with the requirements of the South African Medicines Control Council (MCC) to support 
the compilation of data to pursue registration of the prototype co-crystal tablet on the South 
African medicines market.  
 
The MCC guideline11 states that the dissolution specification in the case of multisource 
pharmaceutical products is generally the same as the reference product. There are two possible 
scenarios to be satisfied when comparing the dissolution profiles obtained from multipoint 
dissolution testing i.e.: 
 
I. The test and reference product show more than 85 % dissolution within 15 minutes, the 
profiles are considered similar (no calculations required). If not, the f2 value needs to be 
considered. 
II. Calculate the f2 value. If f2 ≥ 50, the profiles are normally regarded similar such that 
further in vivo studies are not necessary. Only one measurement should be considered 
after 85 % dissolution of both test and reference product and excluding point zero. 
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The similarity factor (f2) is a logarithmic reciprocal square root transformation of the sum of 
squared errors, and is a measurement of the similarity in the percentage (%) dissolution between 
the two curves. It can be calculated using the following formula: 
f2 = 50. log{[1+ (1/n)t=1 n (Rt - Tt)2]-0.5.100} 
Where n is the number of time points, Rt is the dissolution value of the reference batch at time t, 
and Tt is the dissolution value of the test batch at time t. For f2 calculations a minimum of three 
time points (excluding point zero) must be used, and only one measurement included after 85 % 
dissolution of both products has occurred.  
 
For the curves to be considered similar, f2 values should be close to 100. Generally, f2 values 
greater than 50 (50 to 100) ensure sameness or equivalence of the two curves and, thus of the 
performance of the test and reference products.11 
 
The NVGLT tablet was produced at the University of the Western Cape, School of Pharmacy, 
Discipline of Pharmaceutics. 
 
The comparative dissolution studies between the formulated prototype co-crystal tablet NVGLT 
and the proprietor brand Viramune® were performed at the laboratory of GlaxoSmithKline 
Pharmaceuticals (Pty, Ltd.) in Cape Town. 
 
All the analytical instrumentation was calibrated and validated prior to the execution of the 
experiments. 
 
A validated Microsoft® Excel spreadsheet calculation was used to perform the percentage active 
drug dissolution calculation. 
 
An additional 1.5 mL filtered sample was extracted from the flask that displayed the greatest 
release of active NV.  
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The sample was placed in an amber 1.5 mL HPLC vial and labelled accordingly. The samples 
were stored between 2 - 8 °C for one week before being couriered to the National Institute of 
Communicable Diseases (NICD) for antiviral activity testing. 
 
Solution stability 
A duplicate sample of the one couriered to NICD for both the test (NVGLT) and reference 
(Viramune®) product was placed on stability to evaluate the solution stability of NV in the 
buffered dissolution media. The stability tests involved the exposure of the sample to 2 – 8 °C 
and 40 °C, 75 % RH environmental conditions. The sample was exposed to these conditions for 
4 weeks and was subsequently assayed with HPLC.  
 
The rationale behind the solution stability test was to indicate whether or not the NV degraded 
during storage prior to antiviral testing and also should degradation occur, what the significance 
of it was. 
 
Assay methods 
UV/VIS Spectrophotometry - (i) strategic research 
Assays for the solubility tests and pre-formulation dissolution tests were performed using UV 
spectrophotometry at an appropriate wavelength. UV spectra were recorded on a BECKMAN 
DU® 640 series UV/VIS spectrophotometer. All samples were dissolved in distilled water. The 
samples were placed in 2 mm quartz cuvettes and the concentrations were suitably adjusted such 
that all absorbance readings were measurable between zero and one absorbance unit. Calibration 
curves were constructed using readings taken at the λ max value. 
 
The UV/VIS Spectrophotometry was performed at the University of the Western Cape, School of 
Pharmacy, Discipline of Pharmaceutics. 
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High Performance Liquid Chromatography 
 
HPLC assay: Pre-formulation dissolution samples - (ii) exploratory research 
A standard curve of NV was constructed before the assays were performed. 10 mL 3 M HCl was 
dissolved in 1 L MilliQ® water to prepare the diluent. The stock solution was prepared by adding 
55.5 mg of NV dissolved to 100 mL of diluent in a 100 mL volumetric flask. The flask was 
placed in a sonicator to aid the dissolution of NV with 3 drops of 3 M HCl to increase NV 
solubility. 4 mL of the stock solution was diluted to 200 mL using MilliQ® water. The standard 
was performed in duplicate to ensure accuracy or reproducibility.  
 
A linearity test was performed using a serial dilution of the stock solution to ensure accuracy, 
reliability and reproducibility of the results. A regression line with r2=0.9969 was obtained. 
The HPLC assay for the pure NV was performed using an all-in-one system, the Shimadzu LC 
2010 AHT system with Class VP software®. The system consisted of a SIL-20AC auto sampler 
fitted with a sample cooler, a UV/VIS photodiode array detector (SPD-M20A) and a LC-20AD 
solvent delivery module. A Phenomenex Luna 5 u C18 (2) 100 A column was used and the flow 
rate was set to 1 mL per minute with the column temperature being maintained at 35 °C. The 
injection volume was set at 10 µL and the wavelength was set to 220 nm. 
 
The HPLC assays of the co-crystals and the physical mixes were performed on an Agilent 1200 
system with Waters Empower software®. The system consisted of an auto injector with heater 
(G1316A), a diode array detector VL (G1329A) and a quaternary pump (G1315D) as the solvent 
delivery module. A Phenomenex Luna 5 u C18 (2) 100 A column was used and the flow rate was 
set to 1 mL per minute with the column temperature being maintained at 35 °C. The injection 
volume was set at 10 µL and the wavelength was set to 220 nm.  
 
The mobile phase was prepared by dissolving 14.38 g of ammonium phosphate with 4 L of 
MilliQ® water. The mixture was stirred with a magnetic stirrer until the ammonium phosphate 
dissolved. 
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The mixture was placed into a 5 L volumetric flask and the pH was adjusted to pH 5 using 1 M 
sodium hydroxide and then made up to 5 L using MilliQ® water. The mobile phase was filtered 
through a 0.45 µm membrane filter using compressed air. 
 
System suitability and reproducibility test 
A system suitability test was performed on the HPLC machine to ensure accurate and reliable 
analysis and results. The standards of the NV and the blank (water) were injected five times and 
the retention time of NV was established. The chromatograms obtained were assessed for their 
peak consistency and retention times. All five injections had identical peak sizes, shapes and 
retention times. 
 
HPLC assay: Co-former qualification 
To eliminate potential interferences of the co-formers in the analysis of the concentrations of 
NV, a standard (in duplicate) of each co-former was prepared and injected to evaluate if it would 
elute at a different time or at the same time as NV. Only SLI eluted at 3 minutes. None of the 
other co-formers eluted. The failure of the other co-formers to elute on the chromatograms is 
attributed to a combination of the mobile phase, column and the wavelength detector variables. 
Furthermore, SLI is classified as an active pharmaceutical ingredient whilst the other co-formers 
are inactives. 
 
Preparation of co-former standards for HPLC 
Diluted 10 mL of 3 M hydrochloric acid and made it up to 1000 mL with MilliQ® water in a 
volumetric flask to produce the diluent. Dissolved 0.027 g of each individual co-former (SC, 
TTA, SLI, GLT and MLE) and made up to 50 mL with diluent to produce separate stock 
solutions. Diluted 4 mL of each stock solution to 200 mL with MilliQ® water in a 200 mL 
volumetric flask. 
 
HPLC assay: Comparative dissolution samples - (iii) candidate selection 
In a 1000 mL volumetric flask, a 500 mL of dehydrated alcohol was diluted with 500 mL of 
MilliQ® water to prepare the diluent. The stock solution was prepared by adding 55.5 mg of NV 
dissolved to 100 mL of diluent in a 100 mL volumetric flask.  
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The flask was placed in a sonicator to aid the dissolution of NV. 4 mL of the stock solution was 
diluted to 200 mL in a volumetric flask using the buffered dissolution media (hydrochloric acid 
buffer, acetate buffer and phosphate buffer). The standard was performed in duplicate to ensure 
accuracy and reproducibility. 
 
The HPLC assays of the prototype tablets (NVGLT) and the (Viramune®) tablets were 
performed on an all-in-one system, the Shimadzu® LC 2010 AHT system with Waters Empower 
software®. The system consisted of a SIL-20AC auto sampler fitted with a sample cooler, a 
UV/VIS photodiode array detector (SPD-M20A) and a LC-20AD solvent delivery module. A 
Phenomenex Luna 5 u C18 (2) 100 A column was used and the flow rate was set to 1 mL per 
minute with the column temperature being maintained at 35 °C. The injection volume was set at 
10 µL and the wavelength was set to 214 nm. 
 
The mobile phase was prepared by mixing 1150 mL of acetonitrile with 3850 mL MilliQ® water 
in a 5000 mL volumetric flask. The mixture was stirred with a magnetic stirrer. The mobile 
phase was filtered through a 0.45 µm membrane filter using compressed air. 
 
HPLC assay: Glutaric acid content in NVGLT prototype tablet 
In a 1000 mL volumetric flask, a 500 mL of dehydrated alcohol was diluted with 500 mL of 
MilliQ® water to prepare the diluent. 0.027 g of GLT was dissolved and made up to 50 mL with 
the diluent to produce the stock solutions. Diluted 4 mL of each stock solution to 200 mL with 
buffer solutions (hydrochloric acid buffer, acetate buffer and phosphate buffer) in a 200 mL 
volumetric flask. 
 
The HPLC assay to quantify the glutaric acid content in the dissolution samples was not possible. 
A suitable method could not be developed due to analytical instrumentation constraints. 
 
All the HPLC assays were performed at the laboratory of GlaxoSmithKline Pharmaceuticals 
(Pty, Ltd.) in Cape Town. 
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2.4 Antiviral testing 
All the cytotoxicity and antiviral activity testing on the five co-crystals, the prototype tablet 
NVGLT and Viramune® were performed at the National Institute of Communicable Diseases 
(NICD). 
 
Cytotoxicity screen: Pre-formulation (co-crystals) 
Toxicity screening was conducted to determine if the co-crystals are cytotoxic towards the 
NICD’s specific 293T cells. Toxicity is reflected by cell viability. The toxicity was measured by 
the bioreduction of a tetrazolium compound, Thiazolyl blue tetrazolium bromide (MTT) (Sigma 
Aldrich, China), to a coloured formazan product in the culture medium. Dead cells do not cause 
this colour change. The formazan product was spectrophotometrically quantified and the degree 
of toxicity was related to the MTT-to-formazan conversion by the cells. The CellTiter 96 
Aqueous One Solution Cell Proliferation Assay System (Promega®) was used for this purpose. 
 
Stock solutions of each co-crystal and pure NV were prepared using dimethyl sulfoxide (DMSO) 
in order to obtain an effective NV concentration of 10 mM. This stock solution was diluted to 
working concentrations in complete Dulbecco's modified Eagle medium (DMEM with FBS, 
HEPES and antibiotics). A DMSO control solution was prepared and run in parallel. The 
working solution was titrated into complete DMEM medium by serial dilution in a 96-well 
culture plate, providing a range of concentrations for toxicity testing. A control cell was 
included. The culture plate was incubated for 2 days at 37 °C under 5 % CO2 in a humidified 
atmosphere. MTT reagent was added and the plates incubated for approximately 1 hour. A 
solution of sodium dodecyl sulphate (10 %) and dimethylformamide (50 %) was added to lyse 
the cells and dissolve the formazan crystals. The spectrophotometrical absorbance of each well 
was determined and the percentage viability was calculated. A viability of 0 % indicates total cell 
death while a viability of 100 % indicates full cell viability. 
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Antiviral activity test: Pre-formulation (co-crystals versus pure NV) 
The antiviral activity against HIV-1 pseudovirus in relation to pure NV was tested. The assay 
investigated the inhibition of viral replication in a single-cycle of infection. The pseudovirus 
contained HIV-1 subtype C reverse transcriptase, integrase and protease as well as an RNA 
transcript of the firefly luciferase protein. During infection, reverse transcription of the RNA by 
the HIV-1 reverse transcriptase to the complementary DNA occurs, which is then integrated into 
the host cell DNA by HIV-1 integrase. The firefly luciferase gene is then expressed to produce 
active firefly luciferase which was assayed through a bioluminescence reaction. The reaction was 
quantified. The signal is directly proportional to the number of infectious viruses in the 
inoculums. In the presence of an inhibitor (in this study NV) the number of firefly luciferase 
gene copies that are integrated into the genome will be reduced, thereby decreasing the amount 
of bioluminescence observed. 
 
The non-toxic concentration of each co-crystal, as determined by the toxicity screen, was used to 
determine the activity. The co-crystal solution was diluted in complete DMEM medium in order 
to contain a final effective NV concentration of 18 µM, the highest non-toxic concentration. 
Eleven three-fold serial dilutions of each sample stock was prepared, starting at 18 µM, these 
dilutions were then titrated into a 96-well culture plate. Cells and virus were added and the plates 
were incubated for 48 hours at 37 °C under 5 % CO2 in a humidified atmosphere. The co-formers 
were diluted and prepared to concentrations which were similar to the co-crystal solutions. A 
virus control was included in the test, which contained only cells, virus and medium. A DMSO 
solvent control was also included. The antiviral activity of the co-crystals was screened using a 
standard HIV-1 subtype C isolate. Following incubation, Bright Glo™ Reagent was used to 
assay for the firefly luciferase in the wells. A luminometer was used to quantify the 
bioluminescence emitted. The percentage of viral activity was calculated. A viral activity of 0 % 
indicates complete viral inhibition, while that of 100 % indicates no inhibition.  
 
The inhibitory concentration-50 (IC50) value indicates the concentration of co-crystal where 50 
% of the virus is inhibited. A dose-response curve was used to obtain these values. The activity 
screen was performed in duplicate. The average and standard deviation of the IC50 of the two 
runs was calculated using Microsoft Excel®.  
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An unpaired two-tailed t-test with 95 % confidence intervals was performed using GraphPad 
Prism 4, in order to determine if a significant difference occurs between the viral activity of the 
co-crystals and pure NV. 
 
Antiviral activity test: Comparative dissolution samples (NVGLT and Viramune® tablet) 
The sample extracted from the dissolution runs were used ‘as is’ to make a correlation between 
the dissolution profile and the antiviral activity. 
 
Working solutions of the samples were prepared by dilution (20 times) in complete Dulbecco's 
modified Eagle medium (DMEM) that contained fetal bovine serum, HEPES and gentamycin. A 
10 mM NV stock solution was prepared by dissolving NV powder in dimethyl sulfoxide 
(DMSO). Dilution in complete DMEM provided a 12 mM working solution. A DMSO solvent 
control (0.12 % DMSO in DMEM) was included.  
 
All working solutions were prepared fresh on the day of each assay. 
 
Cytotoxicity screen: NVGLT tablet and Viramune® tablet 
Toxicity screening was conducted to determine if NVGLT and Viramune® are cytotoxic towards 
the NICD’s specific 293T cells. Sample toxicity, as reflected by cell viability, is measured by the 
bioreduction of a MTS tetrazolium compound (MTS) to a coloured formazan product in the 
culture medium. Dead 293T cells do not cause this change in colour. The formazan product was 
spectrophotometrically quantified. The degree of sample toxicity is related to the MTS-to-
fomazan conversion by the cells. The CellTiter 96 Aqueous One Solution Cell Proliferation 
Assay System (Promega®) was used for this purpose. 
 
 
 
 
 
 
 
 
 
 
 
63 
 
Approach: 
Sample titration into complete DMEM medium by serial dilution in a 96-well culture–plate 
provided a range of concentrations for toxicity testing. 293T cells were seeded in the wells of the 
96-well culture plate. A cell control (cells plus medium) was included. Incubation commenced 
for 2 days at 37 °C under 5 % CO2 in a humidified atmosphere. After the addition of the MTS 
reagent, plates were incubated for 1.5 hours after which spectrophotometrical absorbances were 
read at 490 nm, with 690 nm as the reference wavelength. 
 
The percent (%) viability was calculated as follows: 
 
Viability (%) = A490nm – A690nm (test sample)   x 100 
A490nm – A690nm (medium control) 
 
A viability of 0 % indicates total cells death while a viability of 100 % indicates full cell 
viability. Cytotoxic concentration-50 (CC50) values were calculated and indicate the sample 
concentration at which 50 % of the cells are viable. 
 
Antiviral activity assay: NVGLT tablet and Viramune® tablet 
This assay investigated the inhibition of viral replication in a single-cycle of infection. Virus-like 
particles contain HIV-1 subtype C reverse transcriptase, integrase and protease. It also contains 
the RNA transcript of the firefly luciferase protein. During successful infection, the viral RNA is 
reverse transcribed by the HIV-1 reverse transcriptase to a complementary DNA (cDNA) and 
ingrated into the host cell’s chromosomal DNA by HIV-1 integrase. 
 
Once integrated, the firefly luciferase gene is expressed to produce active firefly luciferase that 
can then be assayed via a bioluminescence reaction and quantified. In the absence of inhibitors, 
this signal is directly proportional to the number of infectious virus particles present in the initial 
inoculum. Since inhibitors decrease the number of firefly luciferase gene copies that are 
integrated into the host’s genome, a decrease in the amount of bioluminescense will also be 
observed. 
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Approach: 
Activity is determined over non-toxic sample concentrations. Different dilutions of sample stock 
were titrated in 96-well culture plates as described previously. After the addition of cells and 
virus, the plates were incubated for 48 hours at 37 °C under 5 % CO2 in a humidified 
atmosphere. A standard HIV-1 subtype C isolate, MJ4, was used to screen for antiviral activity of 
the samples. A virus control (cells, virus and medium) was included. After incubation the Bright 
GloTM Reagent was used to assay for the expression of firefly luciferase in the plate wells. 
Bioluminescence was quantified on a luminometer. The virus control was used as the uninhibited 
control. 
 
The percent (%) viral activity was calculated as follows: 
 
Viral activity (%) = Bioluminescence (test sample) x 100 
   Bioluminescense (virus control) 
 
A viral activity of 0 % indicates complete viral inhibition while a viral activity of 100 % 
indicates no inhibition (full viral activity). The inhibitory concentration-50 (IC50) values were 
calculated. The IC50 indicates the sample concentration at which 50 % of the virus is inhibited. 
 
2.5 Quality control (QC) 
The following quality control tests were performed on the prototype co-crystal tablet and the 
proprietor brand tablet. The QC tests applied the USP4 specification. The tests were conducted 
by Haas et al. (2013).10 
 
The QC tests were performed at the University of the Western Cape, School of Pharmacy, 
Discipline of Pharmaceutics. 
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Evaluation of the powder 
The physical properties of the co-crystal were determined by several methods namely: angle of 
repose, moisture content, bulk density and tapped density. These tests are crucial in determining 
the flowability of the powder, which indicates whether the powder can be compressed directly 
with none or few complications with respect to tablet defects such as capping and lamination. 
 
Flowability – Angle of repose  
The angle of repose was determined using a stand with a glass cylinder attached to it. The 
cylinder was placed under a sheet of graph paper with the pointer placed at point zero. The 
sample was then added into the cylinder from the top and the cylinder was slowly raised 
allowing the powder to fall under the effects of gravity. Without disturbing the sample pile, the 
base was marked with a pencil and its diameter was measured. The height from the base to the 
apex was also recorded. The values obtained were used to calculate the angle of repose, using the 
following equation:  
Tan (Ø) = height / 0.5 base. 
 
Bulk density 
A sufficient quantity of powder was passed through a 1 mm pore size (No.18) sieve to break up 
agglomerates that might have formed during storage. 10 g of the test powder was introduced into 
a 10 mL cylinder. The powder was smoothed carefully preventing compaction and the bulk 
density was calculated using the following equation: 
 
Bulk density = M (Mass of sample) / Vo (Volume of cylinder). 
 
Moisture content  
A Mettler Toledo HR 73 Halogen moisture analyser was used to determine the moisture content. 
The heating element was set at 105 °C and the moisture balance was switched on. 1 g of the 
sample was placed on a piece of aluminium foil and was removed after the heating element had 
stopped the heat flow. The weight was recorded and expressed as a percentage of the moisture 
content.  
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Particle size analysis  
Particle size analysis was done by scanning electron microscopy (SEM) LEO 1450 model. The 
SEM was equipped with a tungsten filament operated at 20.00 KV in a secondary electron model 
using the Smart SEM program®. 
 
Evaluation of the tablets  
 
Uniformity of Mass  
The weighing balance used was a Mettler DE series AJ 100. Twenty tablets were selected 
randomly and each tablet was weighed individually on a scale to 2 decimals. The average was 
determined and the tablets were placed into one of 3 categories according to the mass obtained 
per tablet. 
 
Resistance to Crush  
The apparatus used to measure the hardness of the tablet was a Pharma test PTB 301. It consisted 
of a pair of jaws facing each other. One jaw remained motionless and the other jaw moved 
toward the tablet (i.e. force was applied to the tablet). Ten tablets were used in the measurement. 
The maximum, minimum and the mean forces were expressed in Newtons.  
 
Friability  
A Eureka TAD Gmbh was used to determine the friability of the tablets. 20 tablets were 
weighed; their mass was recorded as W1X. The tablets were placed in the friabilator and rotated 
at 100 revolutions (25/rpm for 4 min). The intact tablets were weighed from the 20 tablets and 
their mass was recorded as W2X. In addition, the percentage mass lost was calculated. A mass of 
1 % loss is acceptable. 
 
Durability  
The Erueka TAD Gmbh was used to determine the percentage mass loss in durability. This is 
similar to the friability test however, the plexidrum is rotated for 15 minutes and a loss is 
calculated in terms of percentage. A mass of 2 % loss is acceptable. 
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Disintegration 
The Veego tablet disintegration test apparatus was used for disintegration. The disintegration 
medium was water set to 37 °C (body temperature). 6 tablets were used for this test. If one or 
two tablets from the 6 tablets failed to disintegrate completely within 30 minutes then the test 
should be repeated with another 12 tablets. If less than 16 tablets did not disintegrate then the 
batch had failed the test. The disintegration time specification was set for an uncoated tablet 
(core). 
 
The results for this study will now be presented in the subsequent chapters again in the format 
for a product life-cycle: (i) strategic research, (ii) exploratory research, (iii) candidate drug 
selection until (iv) exploratory development, which is where this study concludes. 
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3 Introduction 
Chapter 3 is divided into seven sections. Firstly, a synopsis of the five supramolecularly 
synthesized co-crystals its identification and preliminary dissolution analysis is presented. The 
dissolution experiments applied the BP 20051 dissolution method and UV/VIS spectrophotometry 
for quantitative analysis. Secondly, the comparative pre-formulation dissolution experiments 
were performed on the five NV co-crystals using the BP 20051 dissolution method, however here 
HPLC was used for its quantitative analysis. In the third section, the rationale of the selection of 
one co-former and the formulation of the co-crystal into a tablet dosage form is explained. 
Fourthly, a summary of the quality control tests performed on the co-crystal tablet and the 
proprietor branded tablet is scrutinized relative to the USP specifications and the proprietor 
branded nevirapine tablet, Viramune®. In the fifth section, the dissolution experiments were 
performed on the co-crystal prototype tablet and Viramune®. The tablet formulation dissolution 
experiments applied the USP 362 method (see chapter 2) and HPLC for quantitative analysis. 
Finally, optimisation of the co-crystal tablet is considered in section six and the solution stability 
results of the tablet formulation dissolution results is analysed in section seven. 
 
Chapter 1 reviewed the product life-cycle process of a drug from discovery to commercialisation. 
The process defines six distinct stages viz. (i) strategic research, (ii) exploratory research, (iii) 
candidate selection, (iv) exploratory development, (v) full development, (vi) marketing and 
commercialisation. 
 
Stages (i) and (ii) were completed by Samsodien (2010)3 and Caira et al. (2011).4 This thesis, 
together with the study performed by Haas et al. (2013)5, forms the basis of stage (iii), candidate 
selection, and (iv), exploratory development. The outputs of this study and the study performed 
by Haas et al. (2013)5 will form the precursor to stage (v) full development. 
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(i) Strategic research and (ii) exploratory research 
3.1 Co-crystal synthesis, identification, dissolution and solubility 
The most preferred solid state in which drug compounds are synthesized is the salt acid or base 
form of the drug molecule. The salt acid or base form is the most common standard approach to 
alter the physical properties of a drug molecule. However, there are other alternate forms that are 
utilised to alter physical properties of drug molecules, such as polymorphism, host-guest 
complexation and co-crystallization. In 2010, Samsodien3 investigated the feasibility of the co-
crystallization method as an alternative method to synthesize the antiretroviral, nevirapine. The 
investigator’s objectives were to prepare a series of nevirapine co-crystals to validate the co-
crystallisation concept and characterize each co-crystal utilising thermal gravimetric analysis 
(TGA), differential scanning calorimetry (DSC), hot stage microscopy (HSM), single X-ray 
diffraction (SXRD) and powder X-ray diffraction (PXRD).3 
 
Twelve compounds were selected as potential co-formers with nevirapine (NV) viz. saccharin 
(SC), nicotinamide, isonicotinamide, succinic acid, tartaric acid (TTA) (racemic, as well as D 
and L individually), citric acid, oxalic acid, stearic acid, L-aspartic acid and maleic acid. These 
co-formers were selected based on the presence of their carboxylic acid functional moiety and/or 
other potentially complementary functionalities, and because they appeared on the GRAS 
(‘generally regarded as safe’) list at that time. An evaluation of the NV and co-formers were also 
conducted in terms of their number and arrangement of hydrogen bond donors and acceptors, salt 
forming ability, conformational flexibility and solubility requirements. In addition, a sample of 
the NV was analysed by H1-NMR analysis to evaluate its purity. The experimental values 
obtained for NV indicated a sample of high degree of purity which matched the expected 
theoretical H1-NMR.3  
 
Several experiments were conducted utilising various techniques and a wide variety of 
recrystallization solvents to isolate co-crystals of NV. The three main techniques used to screen 
as many compounds as possible were slow evaporation, neat grinding and solvent drop grinding 
methods.3  
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According to the product life-cycle process described in chapter 1, at this stage, Samsodien3 
completed stage (i), strategic research and commenced with stage (ii), exploratory research. Only 
two co-crystals were found to be reproducible i.e. NVSC and NVTTA. These co-crystals were 
reproduced by the co-precipitation method documented.3 
 
Additionally, the thermal behaviour of the co-crystals was evaluated by HSM and DSC. The 
HSM analysis found that NVSC melted at 223 °C and decomposed at 315 °C. In contrast, 
NVTTA melted at 228 °C and decomposed at 240 °C. The results obtained by HSM analysis was 
reaffirmed by the DSC analysis with NVSC melting at 223 °C with a single endotherm (215 – 
230 °C) and NVTTA melted at 230 °C with an endotherm appearing between 221 and 236 °C 
(figure 3.1). It was also established that these melting points were significantly different from the 
parent API, NV (melting point 247 – 249 °C) and the co-formers SC (meting point 228 – 229 °C) 
and TTA (melting point 206 °C).3 TGA was conducted to evaluate the potential inclusion of 
solvent in the NVSC and NVTTA co-crystals. In neither case did the TGA trace reveal any 
significant mass loss prior to the melt and degradation, confirming the unsolvated state of the co-
crystals.3 
 
Figure 3.1: DSC traces of NVSC and NVTTA 3 
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The PXRD curves of the NVSC (figure 3.2 (a)) co-crystal was found to be significantly different 
from the PXRD curves of the starting components NV and SC. It was also established that the 
PXRD pattern of the NVSC co-crystal closely matched the patterns of other NVSC products 
obtained by the same co-crystallization procedure, except that the solvents chloroform and acetic 
acid were used instead of methanol. Even though the solvent selected appeared not to be a 
critical parameter in the preparation of the co-crystal the investigator decided to use methanol as 
a solvent in all subsequent experiments for consistency. The PXRD pattern for the NVTTA co-
crystal (figure 3.2 (b)) also differed from the individual components i.e. NV and TTA (DL). A 
number of solvents were evaluated for co-crystal formation, however, only amyl alcohol yielded 
the NVTTA co-crystal.3  
 
Figure 3.2: PXRD of co-crystals (a) NVSC and (b) NVTTA3 
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In 2011 Caira et al. continued with the work performed by Samsodien by investigating new co-
crystal forms of NV. The research group expanded stage (ii), exploratory research, by 
synthesizing NVMLE, NVGLT and NVSLI. The resultant five NV co-crystals viz. NVSC, 
NVTTA, NVMLE, NVGLT and NVSLI with the NV: co-former ratios 2:1, 1:1, 1:1, 1:1 and 2:1, 
respectively could now be studied comparatively. The same batch of NV was used for the 
synthesis and study of all five co-crystals. The same procedure as documented by Samsodien 
(2010)3 was followed to synthesize the NVSC and NVTTA co-crystals. The reproducibility of 
the procedure to synthesize the co-crystals were confirmed when each co-crystal was 
successfully synthesized. Further to the successful crystallization of these co-crystals a three 
stage co-crystal screening protocol similar to the one described by Li et al.6 i.e. solution based 
approaches, dry and liquid assisted grinding, thermal methods and sublimation was utilized to 
synthesize the three remaining co-crystals. Figure 3.3 presents the molecular structure of each of 
the five co-crystals.4 
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Figure 3.3: Molecular structures of the five 
 antiretroviral nevirapine co-crystals.4 
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The purity and identity of the co-crystals were confirmed by their unique melting points 
measured by HSM and DSC techniques whilst the TGA showed no evidence that any solvent 
was present in any of the three new co-crystals, viz. NVMLE, NVGLT and NVSLI. 
 
The researchers found very unusual and complex thermal behaviour for the NVMLE, NVGLT 
and NVSLI co-crystals. This challenge motivated a decision to use a combination of HSM, TGA, 
DSC and variable-temperature PXRD in order to evaluate the thermal behaviour of these co-
crystals. It was established that the co-crystal melts with a simultaneous loss of mass of the co-
former, followed by recrystallization of the free drug, which subsequently melts. The melting 
points determined by DSC for the NVMLE, NVGLT and NVSLI co-crystals were reported in the 
ranges of 120 – 200 °C, 110 – 195 °C and 120 – 175 °C respectively (figure 3.4).4 
 
Figure 3.4: DSC trace of (a) NVMLE, (b) NVGLT and (c) NVSLI4 
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The crystal structures of the three new co-crystals were characterized by PXRD. The PXRD 
results validated the co-crystals unique structure as the patterns identified each one of the three 
co-crystals as different to that of the NV and individual co-former (figure 3.5).3,4 
 
Figure 3.5: PXRD of co-crystals (a) NVMLE, (b) NVGLT and (c) NVSLI compared to parent 
compounds4 
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In vitro dissolution studies were conducted by Samsodien3 on NVSC and NVTTA using the 
rotating-basket method at 37 °C (see chapter 2). The dissolution profiles for the pure drug NV, 
NV:co-former physical mixture (1:1) and co-crystal are shown in figures 3.6 and 3.7 for 
saccharin and DL-tartaric acid respectively. The assays were performed by UV 
spectrophotometry at 234 nm for NV in distilled water as the dissolution medium. The 
dissolution run was set for 3 hours. According to the BP 20051, 45 minutes is considered 
satisfactory for the majority of conventional-release (non-modified-release) products. Each of the 
capsules tested should yield dissolution of 70 % and the percentage of the drug tested should be 
in terms of the label claim.3 
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The dissolution profile of NV was found to have clearly increased in the presence of SC and 
TTA-DL as a (1:1) mixture and was further increased as a co-crystal. NVSC reached 75 % 
dissolution after 45 minutes and 100 % dissolution after 160 minutes (figure 3.6). In contrast, 
NVTTA only reached 75 % dissolution after 120 minutes (figure 3.7).3 
 
Compared to NV, at 15 minutes, the percentage drug release is 35, 55 and 39 % respectively for 
NV, NVSC and NVTTA. After 3 hours a significant increase in dissolution of both NVSC and 
NVTTA was observed, with 69 % dissolution for NV after 3 hours versus 100 % for NVSC and 
83 % for NVTTA. NVSC reached 75 % dissolution after 45 minutes and 100 % dissolution after 
160 minutes (figure 3.6), whereas NVTTA reached 75 % dissolution after120 minutes and only 
83 % dissolution after 180 minutes (figure 3.7).3 
 
Both physical mixtures NV:SC and NV:TTA demonstrate an improved dissolution profile 
compared to NV alone, yielding a ~10 % increase in dissolution after 3 hours. However, when 
comparing the physical mixtures to the co-crystals, we find that the NVSC co-crystal profile 
(figure 3.6) has a higher dissolution rate (~20 % difference compared to the physical mixture) 
and the NVTTA profile (figure 3.7) being ~10 % higher than that of the physical mixture.3 
 
The NV:TTA physical mixture initially hinders dissolution of NV (figure 3.7), but subsequently 
(time ~90 minutes) NV dissolution starts to improve in the presence of TTA. The dissolution 
rates of the co-crystals were, in both cases, higher than those for the untreated NV and NV:co-
crystal former physical mixtures (1:1). 
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Figure 3.6: Dissolution profile of NV, NV:SC and NVSC3 
 
 
 
Figure 3.7: Dissolution profile of NV, NV:TTA and NVTTA3 
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For the two co-crystals (figure 3.8), NVSC passed the BP 20051 test criteria by displaying 76 % 
dissolution after 45 minutes whereas NVTTA failed the test with 61.7 % dissolution after 45 
minutes. Initially there is a ~10 % difference in dissolution between NVSC and NVTTA, 
however by 105 minutes a dissolution difference of ~20 % was observed. 
 
Figure 3.8: Dissolution profile of NVSC and NVTTA3 
 
 
In 20114, these dissolution-time curves of NVSC and NVTTA were used to determine the 
solubility enhancement parameter of the co-crystals. The water solubility of the NVSC and 
NVTTA co-crystals were measured by the BP 20051 rotating-basket dissolution experiment. The 
dissolution test was conducted over a three hour period and the dissolution samples were assayed 
by a UV/VIS spectrophotometry at a wavelength of 234 nm. The results obtained from these 
dissolution tests were used to conduct an equilibrium solubility study on the other three 
(NVMLE, NVGLT and NVSLI) co-crystals.4 It was estimated that the NVMLE co-crystal would 
produce the highest increase in aqueous solubility of NV, i.e. a ~ five-fold increase for NVMLE 
(table 3.1). The approach the investigators took to establish the solubility enhancement by each 
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Furthermore, they weighed an excess of NVMLE, NVGLT and NVSLI into a 20 cm3 test tube 
filled with Milli-Q® water, respectively. The tube was sealed and mounted on an axis rotating at 
54 rpm in a bath maintained at 37 °C for 24 hours.  
 
The samples were then assayed using a Shimadzu® HPLC system.4 The investigators then 
estimated the solubility enhancements from the results they obtained from the assays (table 3.1). 
 
Table 3.1  Solubility enhancement and other properties of NV co-crystals using both UV/VIS 
spectrophotometry and HPLC analysis.4 
 
Co-crystal Preparation API : co-former Mp / °C Scc / Sfree 
NVSC SEa 2 : 1 223 1.4 
NVTTA SE 1 : 1 228 1.2 
NVMLE LAGb 1 : 1 185 5.3 
NVGLT LAG/SE 1 : 1 137 1.2 
NVSLI LAG/SE 2 : 1 203 1.1 
a Slow evaporation. b Liquid-assisted grinding. 
Scc – Aqueous solubility of NV from the co-crystal 
Sfree - Aqueous solubility of the pure NV at the same temperature (37 °C) 
 
(iii) Candidate selection and (iv) exploratory development 
3.2 Pre-formulation dissolution of the five co-crystals 
In 2012, stage (iii) of the product life-cycle was initiated in this study. Prior to the 
commencement of the pre-formulation dissolution test on the five co-crystals, identification tests 
were conducted on the starting raw materials and the synthesized co-crystals. The identification 
tests conducted confirmed the identity and integrity of the raw materials used by melting point 
analysis using HSM and fourier transform infrared spectrophotometry (FTIR). The analyses were 
compared to theoretical data and for the FTIR analysis there had to be a match in the fingerprint 
area whereas for the melting point analysis, a 0.3 °C variance was considered acceptable for 
identification purposes. The same identity tests were utilised to confirm the identity of each of 
the five co-crystals. The results of the identification tests are displayed in appendix A. 
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As part of stage (iv), exploratory development, described in chapter 1, a linearity test was 
conducted on the pure NV. As much as it is important to develop the drug into a pharmaceutical 
preparation, it is also of utmost importance that sound analytical techniques are applied and 
adequate quality control procedures utilized to ensure accurate and reliable results so as to build 
quality into the product by its design. The linearity of an analytical procedure is its ability 
(within a given range) to obtain test results which are directly proportional to the concentration 
(amount) of analyte in the sample. The range of an analytical procedure is defined as the interval 
between the upper and lower concentration (amounts) of analyte in the sample (including these 
concentrations) for which it has been demonstrated that the analytical procedure has a suitable 
level of precision, accuracy and linearity.7 
 
It is recommended by the International Conference on Harmonisation (ICH)7 that a linear 
relationship be evaluated across the range of the analytical procedure and evaluated by visual 
inspection of a plot of signals as a function of analyte concentration or content. The linear 
relationship may be demonstrated directly on the drug substance (by dilution of a standard stock 
solution) and/or separate weighings of synthetic mixtures of the drug product components. Prior 
to the assays being performed, a standard linear curve (figure 3.9) of pure NV was constructed 
on the Shimadzu LC 2010 AHT system. The linearity test was conducted using a serial dilution 
of the stock solution containing pure NV. For the establishment of linearity, a minimum of five 
concentrations is recommended by ICH. In this study a range from 10 % to 150 % was 
established. 
 
The rationale behind the extensive range was to confirm that the analytical procedure provides an 
acceptable degree of linearity, accuracy and precision when applied to samples containing 
amounts of NV i.e. NV co-crystal, within or at the extremes of the specified range of the 
analytical procedure. The linearity test ensured accuracy, reproducibility and robustness of the 
final analysis.7 
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Figure 3.9: Linearity of pure NV. 
In vitro dissolution tests, using the BP 20051 as a reference standard, were conducted on the pure 
NV, the co-crystals NVSC, NVTTA, NVSLI, NVGLT and NVMLE and their respective 
physical mixtures. The dissolution tests provided a comparison of the co-crystals’ dissolution 
profile, in aqueous media (water), to the respective NV-co-former physical mixtures and the 
untreated API (nevirapine). 
 
In figure 3.10, NV alone had a total dissolution of only 16 %. This was not expected, as the study 
performed by Samsodien (2010)3 and Caira et al (2011)4 showed a drug release of approximately 
60 %. It is important to note that the NV used in both studies and this study was from the same 
batch. The discrepancy in the dissolution profiles of NV was ascribed to a difference in 
analytical methods used for the assay of the dissolution samples. Samsodien3 and Caira et al.4 
used UV spectrophotometry at a wavelength of 234 nm, while HPLC at a wavelength of 220 nm 
was used in this study. UV spectra show peaks at varying wavelengths but only one is selected 
and thus does not have the same degree of specificity as HPLC.  
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In comparison, HPLC produces results for a distinct retention time only, and is thus more precise 
and accurate. No analytical method validation was performed to prove that the methods would 
produce similar results. 
 
Figure 3.10: Pre-formulation dissolution profiles of pure NV, NV co-crystals and physical 
mixtures using the HPLC analytical technique 
 
As seen in figure 3.10, the release profile of NV is enhanced by both the co-crystals and the 
physical mixtures. NVGLT was the only co-crystal that yielded better results than both NV and 
its physical mixture NV:GLT. However, even though the NVGLT co-crystal and its physical 
mixture displayed a better release profile, it failed to meet the BP 20051 acceptance criteria, in 
that 75 % of the NV failed to pass into solution within 45 minutes. 
 
Only 30 % of NVGLT and 26 % of NV:GLT passed into solution after 45 minutes. The NV:SLI, 
NV:MLE, NV:SC and NV:TTA physical mixtures displayed a better release profile compared to 
their respective co-crystals. 
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The pre-formulation dissolution results disproved the solubility enhancement theory of Caira et 
al. (2011)4, table 3.1, as only 39 % of NVMLE passed into solution after 180 minutes, thus 
corresponding only to a ~two-fold increase. In comparison, 54 % of NV:MLE went into solution 
after 180 minutes. The increase in aqueous solubility of NV produced by NV:SLI was twice as 
much the increase produced by NVSLI (table 3.2). 
 
Table 3.2  Solubility enhancement and other properties of NV co-crystals using identical 
HPLC analysis technique. 
 
Co-crystal Preparation API : co-former Mp / °C Scc / Sfree 
NVSC SEa 2 : 1 223 1,6 
NVTTA SE 1 : 1 228 2,7 
NVMLE LAGb 1 : 1 185 2,4 
NVGLT LAG/SE 1 : 1 137 3,7 
NVSLI LAG/SE 2 : 1 203 2 
a Slow evaporation. b Liquid-assisted grinding. 
Scc – Aqueous solubility of NV from the co-crystal 
Sfree - Aqueous solubility of the pure NV at the same temperature (37 °C) 
 
The NVSLI had a total drug release of only 32 % while NV:SLI had a total release of 65 % after 
180 minutes. The NV:SLI physical mixture had the best dissolution profile, producing the 
highest percentage of total drug release and having the fastest rate of dissolution compared to all 
other samples. At this point, it became evident that it was critically important that a qualification 
assay of all the co-formers were performed especially on NVSLI and NV:SLI as this was the 
only co-former that was also considered as an API. The co-former qualification, as described in 
chapter 2, proved to be critical as SLI eluted on the chromatogram at 3 minutes while NV eluted 
at 11 minutes. The co-former qualification ensured that interferences in the peak size of NV by 
other substances such as SLI or any one of the co-formers were eliminated. Therefore, 
confidence that only NV was quantified, was satisfied. 
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A possible theory for the improved dissolution of the physical mixtures was based on the fact 
that the co-formers used in the dissolution study were weak carboxylic acids and thus dissociated 
when added to water. The dissociation of a hypothetical carboxylic acid is illustrated in figure 
3.11. 
 
Figure 3.11: Dissociation of carboxylic acids.8 
 
 O           O        O - 
R  ̶  C  + H2O   R  ̶  C                   R  ̶  C           + H3O
 - 
 O          O -        O 
The dissociation constant (pKa) is the degree to which an acid dissociates in water, the larger the 
pKa the smaller the extent of dissociation. Once an acid dissociates it lowers the pH of the 
solvent. NV is a weak base with a pKa of 2.8. The low pKa value gives NV a better solubility in 
an acidic medium.9 A lowering of the pH of the dissolution media (water) by the dissociation of 
the co-formers in the NV:co-former mixes, will therefore increase the solubility of NV. 
 
Table 3.3 PKa values
10 and total percentage drug release of physical mixtures and co-crystals. 
 
Co-former pKa Mixture total % drug 
released at 180 minutes 
Co-crystal total % drug 
released at 180 minutes 
SLI 3 65 32 
GLT 4.3 and 5.4  47 59 
MLE 1.9 and 6.3 54 39 
SC 2 50 26 
TTA 2.96 and 4.24 54 41 
 
As can be seen in table 3.3, SLI, SC and TTA have very low pKa values, all below 3. SLI has the 
greatest total dissolution after 180 minutes (figure 3.10). This result is due to the extent of 
dissociation of the acid and the subsequent lowering of the pH of the dissolution medium, 
facilitating an increase in solubility of NV. 
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MLE, being a diprotic acid, has two hydrogen atoms per molecule capable of dissociating. The 
dissociation of both hydrogen atoms does not occur at the same time. The pKa of 6.3 refers to the 
dissociation of only one hydrogen atom per MLE molecule. If both hydrogen atoms were to 
dissociate to the full extent, the pKa value would be 1.9. On the assumption that the first 
hydrogen atom fully dissociates and the second hydrogen only partially dissociates, the pKa 
value would fall in between the reference values. This explains why the total dissolution of 
NV:MLE is less than NV:SLI but more than NV:GLT. 
 
GLT is also a diprotic acid with pKa values of 4.3 and 5.4. The higher pKa values of GLT 
compared to SLI means that it dissociates to a lesser extent and does not decrease the pH of the 
medium as significantly as SLI. This is proven by the total dissolution of NV:GLT being only 47 
% compared to 65 % of NV:SLI in water. 
 
From table 3.3 we can deduce that the lower the pKa of the co-former the better the solubility of 
NV when in a physical mixture. In comparison, a high pKa value of the co-former results in 
better solubility of NV when in the co-crystal form. This can be rationalised by a difference in 
the mechanism which causes the mixes and co-crystals to pass into solution. 
 
A possible explanation is that upon dissociation of the co-former and NV in co-crystal form, the 
molecules will both go into solution immediately. This is different from the mechanism which is 
displayed when the physical mixtures go into solution. Here the acidic co-formers go into 
solution first and lowers the pH of the solvent (water), creating a better (acidic) environment for 
the NV to go into solution. It was also very noticeable during the execution of the dissolution 
experiments that in each of the five individual NV:co-former physical mixes the powder mixture 
was completely liberated from the gelatine capsule and white particles floated in the flasks. In 
contrast, it was observed that for each of the five individual co-crystals, it took a significant 
amount of time for the co-crystal to fragment and fill the entire flask with white co-crystal 
particles then pass into solution. It was also observed that not all the co-crystal was liberated 
from the gelatine capsules. 
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A possible theory for the improved dissolution of the co-crystals is based on a relationship 
between the melting point of the co-former and that of its co-crystal. The melting point of a co-
crystal for a given API directly correlates with the melting points of the respective co-formers. 
This is demonstrated in figure 3.12.4 
 
Figure 3.12: Melting points of NV co-crystals and the respective co-formers4  
 
 
 
 
 
 
 
 
 
 
 
 
 
Low thermal stability implies high water solubility.11 NVGLT has the lowest melting point and 
the best total dissolution (figure 3.12 and table 3.3). NVMLE has a significantly higher melting 
point than NVGLT, and hence a significantly lower total percent dissolution. NVSLI’s melting 
point is only slightly higher than that of NVMLE, and its dissolution is also comparatively so. As 
can be seen from the results, the dissolution profile of each co-crystal correlates to its melting 
point. 
 
A further illustration of the theory of the improved dissolution of the co-crystals based on the 
melting point of the co-crystal is by viewing the packing diagrams of the co-crystals. Figure 3.13 
gives a comparative illustration of the five co-crystals packing diagrams along the b-axis. 
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Figure 3.13 : Packing diagrams of five NV co-crystals along b-axis 
(a) NVSC        (b) NVTTA 
 
 
(c) NVMLE       (d) NVGLT 
 
(e) NVSLI 
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There are two important factors that influenced the dissolution of the co-crystals i.e. (i) melting 
point and (ii) the bond strength between the NV and co-former (intermolecular forces). As 
indicated before, low thermal stability implies high water solubility. Viewing the packing 
diagram of NVSC (figure 3.13), it indicates that one SC molecules interacts with two NV 
molecules per unit cell. The NVSC co-crystal has the second highest melting point after 
NVTTA. The melting point of 223 °C correlates to the total percentage dissolution of 26 % 
achieved after three hours. This dissolution result was the lowest compared to all the other co-
crystals. Furthermore, the bond strength between the two NV molecules and one SC molecule 
requires a greater amount of energy to be broken down to allow dissolution to occur, hence the 
low total dissolution due to the strong intermolecular forces. 
 
The correlation between the melting point and bond strength theory is further strengthened by 
analysing the packing diagram, melting point and dissolution of the NVSLI co-crystal. The 
NVSLI co-crystal, of all five NV co-crystals, had the second lowest total dissolution of 32 %, 
after three hours. NVSLI also has the second highest melting point, 203 °C, of all five co-
crystals. Furthermore, viewing the packing diagram of NVSLI, one can clearly see the two NV 
molecules interacting with one SLI molecule in a unit cell (figure 3.13). Again, as for the NVSC 
co-crystal it can be accepted that a greater force is required to break the molecular bonds 
between the API and co-former resulting in a low dissolution. 
 
The NVGLT and NVMLE co-crystals also correlate to this theory. The NVGLT had a total 
dissolution of 59 % and NVMLE had a total dissolution of 39 %. This dissolution result 
correlates to the melting points of 137 and 185 °C respectively. The NVGLT had the highest 
total dissolution over all other NV co-crystals. The packing diagrams of these compounds 
indicate that one molecule NV interacts with one molecule of co-former. Therefore, possibly 
suggesting less force required to break the asymmetric unit. The only outlier to this theory is the 
NVTTA co-crystal. This co-crystal has a melting point of 228 °C which is the highest melting 
point of all the co-crystals. However, it achieved a total dissolution of 41 % after three hours 
which is the second highest after the NVGLT co-crystal. This anomaly in the trend could be 
attributed to the complex inter and intramolecular bonds present within the asymmetric unit.  
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(iii) Candidate selection 
3.3 Selection rationale of the best co-former for the formulation of the co-crystal tablet 
dosage form 
The data generated in the pre-formulation dissolution study along with carefully selected sets of 
criterion such as the co-former’s toxicity, flowability, compressibility, aqueous solubility and QC 
test results such as the co-former’s disintegration time, moisture content, including the cost of the 
material and the antiviral activity of the co-crystals (table 3.4) were used by Haas et al (2013)5 to 
select one co-former, the best performing, to formulate and produce a prototype tablet. The 
selection process considered the flowability of the co-former powder as good flowability is 
essential in the blending and the tablet compression unit operations. The flowability was 
determined by calculating the angle of repose, Hausner’s ratio and Carr’s Index of each co-
former. The moisture content was performed on each co-former to ascertain the water content in 
the material. Preference was not to use a co-former with a high moisture content as it would have 
presented challenges in the co-crystal stability, poor flowability upon gravitational tablet 
compression and also potential microbial contamination. The disintegration ability of the co-
formers was also assessed by firstly compressing each co-former into a disc and applying the 
disintegration test to investigate the time laps before the disc broke down into smaller particles. 
This gave an indication of whether the co-former had any disintegrating properties and also 
binding properties. Each of the co-formers was scored accordingly and after a lengthy scrutiny, 
the co-former that satisfied the selection criteria most appropriately was chosen (table 3.4). A 
colour coding scheme was applied to score each criterion as follows:  
 
 
 
 
 
Furthermore, clear identification is made to identify all contributors to this work as follows: 
*  Study conducted by Caira et al. (2011) 
**  Study conducted by B. Geldenhuys (2012 and 2013) 
*** Study conducted by Haas et al. (2013) 
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Good 
 
Average 
 
Fair 
 
Bad  
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Table 3.4 Selection criteria for the co-former selected for final tablet formulation.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*  Study conducted by Caira et al. (2011) 
**  Study conducted by B. Geldenhuys (2012 and 2013) 
*** Study conducted by Haas et al. (2013) 
Co-former  Saccharin  Glutaric Acid Salicylic Acid Rac-Tartaric Acid Maleic Acid 
* Ratio 2 is to 1  1 is to 1  2 is to 1 1 is to 1  1 is to 1  
* Solubility increase 1.4 times 1.2 times 1.1 times 1.2 times 5 times 
pKa 2 4.3 & 5.4 3 2.96 & 4.24 1.9 & 6.3 
** Dissolution (Co-crystal) 
24 % in 45 min                  
26 % in 180 min  
30 % in 45 min 
59 % in 180 min 
20 % in 45 min 
32 % in 180 min 
14 % in 45 min              
41 % in 180 min 
18 % in 45 
min 39 % in 
180 min 
** Dissolution 30 % in 45 min 
26 % in 45 min 
47 % in 180 min 
49 % in 45 min  
65 % in 180 min 
30 % in 45 min               
54 % in 180 min 
34 % in 45 
min 54 % in 
180 min 
(mixture) 50 % in 180 min  
Cost R 323.10/g R 4.25/g R 8.65/g R 300/g R 1,074.57/g 
Safety 
Safe since less than 77.6 
g can be used per day in 
a 70 kg  
Acute oral 
toxicity LD/50: 
420 g in a 70 kg  
Concentrations 
above 0.8 g/L 
after 6 hours 
post-exposure is 
severely toxic 
and may be 
lethal  
Safe since 500 g 
needed to kill a 
person with 70 kg 
Acute oral 
toxicity 
LD/50: 708 
mg/kg (rat)  
Use Artificial sweetener 
Surfactant, food 
supplement and 
improves protein 
synthesis 
Food 
preservative, 
bactericidal and 
antiseptic 
properties  
Anti-oxidant Make salts 
Side-effects 
Headaches, Breathing 
difficulties, Diarrhoea, 
Skin problems  
None 
Gastric 
ulceration 
Thirst, Vomiting, 
Diarrhoea, 
Abdominal pain, 
Irritation, acute 
renal failure 
Severe 
irritation to the 
skin, eyes and 
mucous 
membranes  
** Toxicity against viral HIV-1 
pseudovirus  
Non-toxic (184) 
Non-toxic to 
organism 
Non-toxic to 
organism 
Non-toxic 184 
Non-toxic 
(184) 
*** Angle of repose 38.37 Degrees 29.70 Degrees 35.9 Degrees 35.2 Degrees 33.60 Degrees 
*** Carr’s index 20.21 11.42 No results No results 19.3 
*** Moisture content 0.10 % (1.20 min) 0.2 %(1.20 min) 
0.96 % (1.20 
min) 
0.39 %(1.20 min) 
6.31 % (1.20 
min) 
*** Disintegration time 
It is too weak to be 
compressed 
21 seconds Over 30 min Over 30 min 
1 minute 43 
seconds 
*** Manufacturing process problems  Unable to be compressed None observed None observed Grinding & yield  None observed 
 
Excellent 
 
Good 
 
Average 
 
Fair 
 
Bad  
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From the information gathered in table 3.4 and the fact that glutaric acid (GLT) proved to be the 
most successful in the pre-formulation dissolution with a dissolution profile of 30 % as a 
nevirapine-glutaric acid co-crystal in 45 minutes and 59 % drug was released in 180 minutes 
(figure 3.10), Haas et al. (2013)5 selected glutaric acid as the co-former for the production of the 
prototype tablets. 
 
(iv) Exploratory development 
The NVGLT prototype tablet was prepared in three phases i.e. synthesis of the NVGLT co-
crystal with identification, scaling-up and compression of the co-crystal into a tablet with 
selected excipients. 
 
A master formula was developed to establish the input quantity of the NV and GLT for the 
synthesis of a 1:1 molar ratio NVGLT co-crystal. As Viramune® tablets contain 200 mg of NV, 
the co-crystal formulation was also aimed at incorporating 200 mg of NV. A molar calculation to 
determine the number of moles equivalent to 200 mg NV (in a 1:1 NVGLT co-crystal) was 
performed in the following manner. 
 
NV molecular mass (MM) = 266.30 g / mol  
GLT molecular mass (MM) = 132.12 g / mol  
 
NV label claim =200 mg  
Therefore, for 1 tablet:  
The number of moles of (n) NV = mass ÷ MM 
n (NV) = 200 mg ÷ 266.30 g / mol  
= 0.2 g ÷ 266.30 g / mol  
= 0.000751 mol  
 
Ratio of moles of NV: GLT = 1: 1  
 
Mass (GLT) to be used  
Mass = n X MM  
= 0.000751 mol x 132.12 g / mol  
= 0. 099 g  
=99.2 mg 
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Based on the calculated values of a 1:1 molar ratio NVGLT co-crystal, a batch size scale-up was 
investigated. In the scaling up process three theoretical batch sizes were derived i.e. a small scale 
of 329 mg, medium scale of 1645 mg and a large scale of 3290 mg (table 3.5). The amount of 
NV increased five-fold to create the medium scale while the large scale batch size increased the 
NV content by almost ten-fold to maintain the 1:1 molar ratio. The amount of GLT was also 
increased appropriately to maintain a 1:1 molar ratio (table 3.5). In each instance during the scale 
up exercise the amount of solvent and time taken to grind the co-crystal to the appropriate size 
increased.  
 
Table 3.5 Batch scaling up of the NVGLT co-crystal by solvent-drop grinding method5 
 
 Co-crystal 
 
molar ratio 
NV 
quantity (mg) 
GLT 
quantity (mg) 
Chloroform 
quantity (mL) 
Grinding time 
(min.) 
Small scale 1:1 220  
(including 10 % overage) 
109 
(including 10 % overage) 
2 25 
Medium scale 1:1 1100 
(including 10 % overage) 
545 
(including 10 % overage) 
12 62 
Large scale 1:1 2200 
(including 10 % overage) 
1090 
(including 10 % overage) 
48 235 
 
Subsequent to the successful establishment of the various theoretical batch sizes, two fresh 
batches of NVGLT co-crystal was synthesized by the solvent-drop grinding technique using two 
master formulae (table 3.6). A small mortar and pestle was used to grind the appropriate amounts 
of each ingredient. The solvent, chloroform, was added slowly to the powders in a drop-wise 
manner. Only a few drops of chloroform were used at a time in order to maintain a moist 
consistency. The powder was ground to form the co-crystal. The amount of powders used 
included a 10 % overage of each material. The processing time to manufacture batch 1 amounted 
to 5 hours and 35 minutes for the grinding and 43.95 mL of chloroform was required. This batch 
produced 40 tablets which included a 10 % overage of NV and GLT. The second batch required 
3 hours 55 minutes to grind the powder and 48 mL of chloroform. The second batch produced 48 
tablets inclusive of a 10 % overage as well (table 3.6). The material was closed with Parafilm® 
and the Parafilm® was perforated to allow the solvent to evaporate.5 
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Table 3.6 NVGLT prototype tablet master formulae5 
 
Batch 1  Quantity (mg) Total  (mg) 10% overage (mg) Total (g) 
NV 200 X 40 (tablets) =8000 8800 8.8 
GLT 99.22 X 40 (tablets) = 3968.8 4365.68 4.4 
Batch size    13.2 
Batch 2     
NV 200 X 48 (tablets)  = 9600 10560 10.6 
GLT 99.22 X 48 (tablets) = 4762.6 5238.8 5.23 
Batch size    15.83 
 
Prior to the compounding of the tablet, the identity and integrity of the co-crystal was confirmed 
by DSC and PXRD analysis (figures 3.14 and 3.15). Glutaric acid (GLT) has a melting point 
range between 96 - 101 °C and nevirapine has a melting point range between 185 - 220 °C. The 
unique NVGLT co-crystal was formed with an onset of 127.53 °C and peaked at 123.26 °C. This 
melt differed from the original melt (140 °C) however; the PXRD patterns were a match which 
confirmed that it was indeed the same species. These analytical tests guaranteed the quality of 
the input material (co-crystal) for the tablet production as it confirmed the identity and integrity 
of each component and the final co-crystal form.  
 
Figure 3.14: DSC traces of (a) GLT, (b) NV and (c) NVGLT5 
 
 
 
(a) DSC trace GLT 
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(Continued) Figure 3.14: DSC traces of (a) GLT, (b) NV and (c) NVGLT5 
 
   
 
 
 
 
 
 
 
 
 
 
 
(b) DSC trace NV 
(c) DSC trace NVGLT after 3 hours and 55 minutes grinding 
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l 
Figure 3.15: PXRD of NVGLT, GLT and NV5 
 
 
 
 
 
 
 
 
 
 5     25 
2θ° 
 
Quality control (QC) tests performed on the co-crystal included particle size analysis, 
flowability, moisture content, angle of repose, bulk density and tapped density. These QC tests 
utilized the United States Pharmacopoeia (USP)2 as a reference standard. QC tests were also 
performed on the final NVGLT prototype tablet and the proprietor brand Viramune®. These tests 
included uniformity of mass, resistance to crush (hardness), friability and durability as per the 
USP standard. The rationale for the QC tests on the final compressed NVGLT prototype tablet 
was to assess the tablet’s ability to withstand pressure and frictional forces which occurred 
during manufacture, storage, handling and transportation. The uniformity of mass test was also 
performed in order to ascertain the variation in the tablet mass. Additionally, disintegration 
analysis on the final compressed NVGLT prototype tablet was performed to quantify the time 
taken for the tablet to disintegrate over a set period of time. The same QC tests were applied to 
the Viramune® proprietor brand in order to draw comparisons.5 
 
The key objective was to formulate the NVGLT prototype tablet using only the co-crystal as a 
single ingredient directly compressed into a tablet dosage form. The rationale for this was to 
design an efficient formulation with minimal costs. The preliminary QC tests performed on the 
NVGLT co-crystal and GLT were all favourable and suggested that direct compression of the 
NVGLT co-crystal into a tablet dosage form would be possible without addition of other 
excipients. 
 NVGLT 
 GLT 
 NV 
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The angle of repose for the co-crystal was calculated to be 29.70.° This value indicated excellent 
flow properties. A powder with a low angle of repose exhibits good flow properties.2 The angle 
of repose for GLT was also calculated. This was performed on the original, coarse form and the 
ground form of the material. The angle of repose test was performed on the ground form of GLT 
to account for the fact that the powder was ground during the co-crystal formation process. The 
flowability of the coarse and ground particles were different. A correlation between the size of 
the particle and angle of repose was observed; as the particle size decreased, the angle of repose 
increased and this reduced the flowability of the powder. 
 
The tapped density and bulk density tests were also performed on the coarse GLT and used to 
calculate the Carr’s index and Hausner ratio. Carr’s index describes the relationship between the 
packed and loose densities of powders. A Carr’s index of 11.42 % was achieved for the GLT. 
The USP has a specification of between 5 – 15 % for a Carr’s index value. A Carr’s index value 
that lies within this range would be deemed as having good flow properties, hence GLT 
complied to the USP specification.2 It is important to note that particle size of the GLT bears a 
significant impact on the aforementioned QC tests.  
 
The moisture content analysis for the NVGLT co-crystal revealed 2.10 % water content and for 
GLT a 0.20 % was obtained. The moisture content of a powder is the quantity of water or water 
vapour contained within a substance. It is expressed as the percentage by mass of water in a 
sample of a mixture or form of matter. The lower the moisture content of a granulate the lesser 
the likelihood tablet processing challenges would arise during tablet compression. Any slight 
change in particle size and moisture content could cause tablet processing problems. In 
particular, high moisture content could lead to tablet capping during tablet compression.2 
 
Particle size of a material can be determined by methods such as the sieving method, Andreasen 
pipette method and scanning electron microscope (SEM). Due to the co-crystal powder being 
very fine, the sieve method was not deemed appropriate and the Andreasen pipette test method 
required a 50 g sample of the co-crystal. Therefore, SEM was used to determine the particle size 
of the co-crystal.  
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The microscope used was a LEO 1450 model, the SEM was equipped with a tungsten filament 
operated at 20.00 KV in the secondary electron model using Smart SEM program.® The particle 
size ranged from 1,389 to 2,425 µm.5 
 
The particle size is an important aspect to determine as it provides an indication of the 
flowability and other important properties of the powdered material. A reduced particle size 
causes an increase in the overall surface area of the powder, which increases the surface tension 
and results in greater apparent cohesion. This may lead to poor flowability in the hopper during 
compression and cause bridging, arching and rat-holing.12 
 
The objective to compress the NVGLT co-crystal “as is” into a tablet could not be achieved since 
tablet defects (capping and lamination) arose during compression of the co-crystal. The co-
crystal ‘as is’ also inherently lacked the physical attributes to form a quality tablet. The tablet 
defects were ascribed to the concaved shaped punches that were used to perform compression. 
The die cavity used was also too small to accommodate all the co-crystal powder. The tablet 
processing challenges were overcome by changing the tablet punches to flat surface punches and 
increasing the die cavity diameter volume. The binding properties of the co-crystal seemed to be 
the main challenge. To overcome this challenge, excipients were included into the final 
formulation to ensure optimal and improved binding of the granules. Compression into a tablet 
and the qualifying QC test were set to hardness and disintegration as per in-house developed 
specification derived from the innovator Viramune® (figure 3.16). As few as possible excipients 
were added to the co-crystal to achieve the desired binding result without compromising the 
quality of the final dosage form. The excipients were selected from the formula of the proprietor 
brand Viramune® so as to ensure compatibility with the API, nevirapine. 
 
Even though the Carr’s index value of GLT was closer to the upper limit of the USP 
specification, a decision was made to include an excess amount of GLT, solely initially, without 
adding any other excipients to the co-crystal tablet formulation. The decision to include an 
excess amount of GLT was affirmed by the good binding properties it displayed in the 
preliminary QC tests when GLT was compressed into a disc without the addition of any other 
ingredients. The addition of the GLT had a dual purpose i.e. a binder and a bulking agent. 
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0.31340 g including 5 % excess of the co-former was compressed using direct compression. The 
compressed tablet weighed 0.3139 g of which 3.19 % was lost during the compression process. 
The tablet formed was intact. The hardness test yielded 124 Newton. This hardness result failed 
the hardness specification of between 40-60 Newton.  
 
A second tablet was compressed for disintegration purposes however, the tablet capped. A third 
tablet was produced whereby an excess amount of 0,12 mg GLT per tablet was included and the 
direct compression process definition (figure 3.16) was again followed. The resultant tablet also 
did not provide the desired binding function as capped and laminated NVGLT tablets were 
produced.  
 
This co-crystal tablet formulation thus failed to meet the qualifying tests of hardness and 
disintegration (figure 3.16). The fact that the quality control tests failed established that the 
formulation was not optimal and thus further evaluation needed to be performed in order to 
derive the best formulation. 
 
Next, the excess GLT was substituted with 10 mg of povidone (binder / glidant) per tablet. The 
povidone was added to the NVGLT co-crystal as it is an excipient in the Viramune® formulation 
and thus compatibility to NV is maintained. The ingredients were mixed and compressed to form 
a tablet. The povidone also failed to produce the desired result as the qualifying QC tests 
(hardness and disintegration) was not favourable. The povidone was then replaced with 0,3 mg 
of magnesium stearate (lubricant / glidant) per tablet. Again the tablets did not deliver the desired 
functions as both the disintegration test as well as the hardness tests failed.5 
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Figure 3.16: Direct compression process definition 
 
 
 
The rationale to pursue the utilization of as few as possible excipients yet maintaining the desired 
tablet attributes led to the inclusion of only one excipient, microcrystalline cellulose (MCC, 
AVICEL®) in the final NVGLT prototype tablet. The 150 mg of MCC provided the desired 
physical quality attributes for the tablet. The MCC has two properties i.e. binding and 
disintegration properties. These two properties are fundamental in the performance of the tablet 
as it ensures that the tablet is formed adequately when it is compressed. Secondly, MCC ensures 
that when the tablet is ingested by the patient, it is broken up effectively in order for the API to 
be liberated and absorbed into the systemic circulation. MCC also forms part for the formulation 
of the Viramune® tablet. A positive result was obtained from the QC tests performed on this 
tablet. The tablet had complied with the hardness specification and it was able to disintegrate 
within a few seconds. The final formulation consisted of 0.313 g NVGLT co-crystal and 0.1575 
g MCC which included 5 % excess.  
1. Small scale co-
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production
2. Quality Control 
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excipient  to co-
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mix
4. Quality Control 
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production
Tablet compression settings  
[Depth & Hardness] 
(d) Added AVICEL® as an excipient 
(Passed) 
(c) Added Magnesium Stearate as an 
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The total mass of one tablet was 0.4811 g. The NVGLT prototype tablet was prepared by mixing 
the NVGLT co-crystal and MCC and directly compressing the mix using a single punch and die 
apparatus.5 
 
There were challenges experienced during the compression of the tablet as the compression 
forces were not defined and manual intervention in the operation of the single punch and die 
machine was noted.5 
 
Subsequent to the successful direct compression of the co-crystal into tablets, additional quality 
control tests were performed. These tests included; uniformity of mass, resistance to crush, 
friability, durability and disintegration. The final prototype tablet quality performance was then 
compared to the proprietor brand Viramune® using the USP as a reference standard. 
 
The reference batch of tablets of Viramune® 200 mg (lot number 145057) was purchased and 
the same QC tests were applied. 
 
3.4 Quality control tests of the NVGLT prototype tablet and VIRAMUNE® tablet 
Uniformity of mass  
According to the USP2 standard the average mass of tablets should conform to the percentage 
deviations based on the average weight of the sample of tablets (table 3.7).2 The specification 
indicates that if the average mass of a tablet is 80 mg or less, the percentage deviation from the 
average is allowed to be 10 %. Should the average tablet mass be more than 80 mg however, less 
than 250 mg, the percentage deviation from the average mass is set to 7.5 %. When a tablet 
weighs 250 mg or more, the percentage deviation from the average mass is allowed to be 5 %. 
The percentage composition of the API in the final formulation of the tablet is of significant 
importance when setting uniformity of mass specifications. Therefore at times a formulator can 
deviate from pharmacopoeial specifications provided a sound scientific justification is presented.  
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Table 3.7 USP2 uniformity of mass specification 
Average weight (mass) % deviation 
80 mg or less 10 
More than 80 mg but less than 250 mg 7.5 
250 mg or more 5 
 
The uniformity of mass was determined on the NVGLT tablet and Viramune®. Twenty tablets 
were selected randomly and each tablet was weighed individually on a scale to 2 decimals. The 
average was determined and the tablets were placed into one of 3 categories according to the 
mass obtained per tablet. 
 
The NVGLT tablet average mass of 481.1 mg (table 3.8) is greater than 250 mg. Therefore 
placing it in the third category (table 3.7). The standard deviation of 0.02 % (table 3.8) met the 
USP acceptance criteria of less than 5 % deviation (table 3.7). The standard deviation of 
Viramune® was calculated to be 0.0096 % (table 3.8). This indicated that Viramune® also 
achieved the acceptance criteria of the USP standard. Based on the results the Viramune® tablet 
showed a superior uniformity of mass over the NVGLT prototype tablet. 
 
Table 3.8 Uniformity of mass of NVGLT prototype tablet and VIRAMUNE® 
 NVGLT VIRAMUNE® 
Average mass 0,4811 g 0,8133 g 
Standard deviation 0,02 % 0,0096 % 
 
Resistance to crush (Hardness) 
Ten tablets of each were used to determine the hardness of the NVGLT tablet and Viramune® 
tablet. The maximum, minimum and the mean forces were expressed in Newtons. The results 
obtained (table 3.9) showed that the force required to break the NVGLT tablet was lower than 
Viramune®. However, one cannot neglect the fact that the two tablets, the Viramune® and the 
NVGLT tablet varies in shape, size and mass (figure 3.17). On average, Viramune® has a mass 
of 0,8133 g compared to the NVGLT tablet that has a mass of 0,4811 g.  
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A greater force is required to break the Viramune® tablet. Since the NVGLT tablet weighed 
almost half of the mass of the Viramune® it can be deduced that half the force required to break 
Viramune® would be necessary to break the NVGLT tablets. 
 
Table 3.9 Force in Newtons required to break the tablet 
Tablet NVGLT tablet  VIRAMUNE® 
1 91 N 117 N 
2 58 N 128 N 
3 65 N 135 N 
4 63 N 119 N 
5 87 N 160 N 
6 67 N 130 N 
7 90 N 143 N 
8 86 N 124 N 
9 55 N 160 N 
10 66 N 141 N 
 
Figure 3.17: Example of (a) NVGLT prototype tablet and (b) VIRAMUNE® tablet. 
 
 
 
 
 
 
Friability and durability2, 5 
The friability and durability tests are quality control tests that are used to determine the impact 
handling during processing and the supply chain would have on the quality of the tablet before it 
reaches the end user. The friability test is used to measure weight loss when tablets are subjected 
to a uniform tumbling motion for a specified time. Friability percentage loss must be less than or 
equal to 1 %. The NVGLT tablet friability had been compared to Viramune® tablet. 20 tablets 
were weighed; their mass was recorded as W1X.  
(a) NVGLT tablet (b) VIRAMUNE® tablet 
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The tablets were placed in the friabilator and rotated at 100 revolutions (25/rpm for 4 min). The 
intact tablets were weighed from the 20 tablets and their mass was recorded as W2X. In addition, 
the percentage mass loss was calculated. The NVGLT tablet and Viramune® tablet both passed 
the friability test since less than 1 % mass in both instances was lost (table 3.10).  
 
The durability test is similar to the friability test however, the plexidrum is rotated for 15 minutes 
and a loss is calculated in terms of percentage. A mass of 2 % loss is acceptable as determined by 
analysis of the innovator product. The NVGLT tablet showed a mass loss of 2,08 % for the 
durability test. This result does not meet the acceptance criteria by only 0,08 % as the in-house 
specification for durability is set to less than or equal to 2 % mass loss. The NVGLT tablet had a 
mass loss of 2,08 % thus, failing the test. The Viramune® tablet showed a mass loss of 0,5512 
%, therefore passing the test for durability.  
 
Table 3.10 Friability and durability percentage mass loss 
 NVGLT tablet VIRAMUNE® tablet USP / In-house 
specification 
Friability 0,96 % 0,124 % ≤ 1 % mass loss 
Durability 2,08 % 0,5512% ≤ 2 % mass loss 
 
Disintegration2, 5 
The disintegration test measures the time taken for the tablet to break up into particles. If one or 
two tablets from a sample of six tablets fails to disintegrate completely within 30 minutes then 
the test should be repeated with another 12 tablets. The disintegration results revealed that both 
the Viramune® tablet and the NVGLT tablet disintegrated within the specified time limit (table 
3.11) 
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Table 3.11 Disintegration time of the NVGLT tablets and VIRAMUNE® 
Descriptive NVGLT tablet 
Time (sec) 
VIRAMUNE® tablet 
Time (sec) 
USP specification 
Time (sec) 
From a tablet to a fine 
particle 
900 137 < 1800 
From a tablet to a 
granule 
3 0 None 
 
According to the USP standard, if the disintegration time is too long, the tablet is too hard. If 
disintegration of the tablet is not uniform in a set of samples being analysed, it indicates batch 
inconsistency and lack of batch uniformity. There was a difference noted in the manner in which 
the NVGLT tablet and Viramune® tablet disintegrated.  
 
When the NVGLT tablet came into contact with the aqueous media (water), it firstly broke into 
fragments and thereafter, into finer particles. It took between 3-5 seconds to disintegration from 
tablet to smaller particles. The phenomena of the NVGLT tablet breaking into smaller fragments 
served as a potential advantage as fragmentation should result in an increased surface area, 
promoting a more rapid release of the drug substance.  
 
The fragmentation can be accounted for by the presence of the microcrystalline cellulose (MCC) 
which was used as an excipient. MCC exhibits very good disintegrating properties because it is 
insoluble and acts by a wicking process. During this process, capillary action and porosity play a 
major role. MCC pulls water into the pores, weakens the intermolecular bonding between 
particles, this causes a break up in the matrix, and the tablet eventually breaks into fragments. 
The Viramune® tablet was reported to not have broken up into fragments, but rather slowly 
dissolved in layers to finer particles. This observation was ascribed to one of the excipients 
contained in Viramune®, magnesium stearate. In particular, the effect observed was specifically 
attributed to the hydrophobic nature of the material and as a result, it was reported that a strong 
film layer formed, causing the aqueous medium to remain at the surface of the tablet, reducing 
penetration and wettability, causing a slower disintegration rate.2,5 
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All the pre-formulation and formulation dissolution experiments were performed in this study 
and the results achieved for these tests are presented in table 3.3(pre-formulation) and table 3.12 
(formulation). These activities form part of stage (iii), candidate selection, and stage (iv), 
exploratory development, of the product life-cycle, described in chapter 1. 
 
3.5 Comparative dissolution test performed on the formulated NVGLT prototype tablet 
and VIRAMUNE® tablet 
Comparative dissolution tests using the USP (36) as a reference standard was conducted on the 
prototype NVGLT tablet produced by Haas et al. (2013) and the proprietor brand (Viramune®) 
registered on the South African medicines market. Dissolution tests were performed in HCl 
buffer (pH 1.2), acetate buffer (pH 4.5) and phosphate buffer (pH 6.8) as per the Medicine 
Control Council of South Africa’s dissolution guidelines.13 The dissolution test aimed at 
investigating the dissolution profile equivalence or similarity of the two products in terms of 
their in vitro drug release. The buffered media would also provide a better insight into what may 
be foreseen in a simulated gastro intestinal tract environment since the previous dissolution 
medium used in the pre-formulation dissolution study excluded a buffer as the dissolution 
medium was only water. 
 
In vitro dissolution characterization is encouraged for all product formulations investigated 
including prototype formulations, particularly if in vivo absorption characteristics are being 
defined for the different product formulations. Such efforts may enable the establishment of an in 
vitro-in vivo correlation. When an in vitro-in vivo correlation or association is available the in 
vitro test can serve not only as a quality control specification for the manufacturing process, but 
also as an indicator of how the product will perform in vivo. 
 
From the results in figure 3.18, Viramune® in the acetate buffer displayed the best release profile 
compared to all the other profiles with a total drug release of 101 % after 60 minutes. The USP 
acceptance criteria states that not less than 75 % (Q) of NV should be dissolved in the media at 
the end of the dissolution run. Viramune® in the acetate buffer was the only test that met the 
USP acceptance criteria (table 3.12). Second to the acetate buffer was Viramune® in HCl buffer 
with 54 % release and then the phosphate buffer with 24 %.  
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The prototype NVGLT only managed a 22 % release in the HCl buffer. This was the greatest out 
of all the media tested for NVGLT followed by the acetate buffer with a 2 % and the phosphate 
buffer with a 1 % total dissolution. 
 
Figure 3.18: Dissolution profiles of the NVGLT prototype tablet and VIRAMUNE® tablet. 
 
 
 
Table 3.12 Total percentage drug release of the NVGLT prototype tablet and VIRAMUNE® 
tablet after 60 minutes. 
 
PRODUCT HCl BUFFER  
(pH 1.2) 
ACETATE BUFFER 
(pH 4.5) 
PHOSPHATE BUFFER 
(pH 6.8) 
NVGLT 22 % 
 
2 % 
 
1 % 
 
VIRAMUNE® 
 
54 % 
 
101 % 
 
24 % 
 
 
The solubility of NV is pH dependant and is soluble in strong acid only. The nature of NV 
according to the Biopharmaceutics Classification System is Class II, i.e. it has a low water 
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solubility and high lipid permeability. From table 3.12, it is clear that Viramune® showed 
favourable dissolution in an acidic environment i.e. pH 1.2 and pH 4.5 respectively, even though 
only the Viramune® in the acetate buffered media passed the USP 36 requirement. In contrast, 
the NVGLT dissolution in each test medium consistently performed poorly. 
 
It is important to note that even though the MCC dissolution guideline13 does allow the use of a 
surfactant such as sodium lauryl sulphate to aid dissolution, the surfactant was not employed in 
these dissolution tests. Therefore the dissolution test environment applied the most 
discriminatory and stringent specification. The favourable performance of the NVGLT co-crystal 
and physical mix during the pre-formulation dissolution tests was mainly attributed to the pKa of 
glutaric acid and its ability to dissociate. Thus, it created a conducive environment for NV to 
pass into solution (water) during the pre-formulation dissolution experiments. When the 
dissolution test parameters were changed and buffered dissolution media were introduced, the 
effect of pKa was cancelled out by the buffered media and other parameters such as solubility, 
pH, surface area and the product formula became paramount. This fact is evident by the 
dissolution results that were achieved. 
 
The dissolution process is the process by which the API passes into solution. A precursor to 
dissolution is disintegration. The disintegration process is the process whereby the tablet is 
broken up into smaller fragments when it comes into contact with the solvent medium. During 
the execution of the dissolution experiments, the Viramune® tablet formed a classic precipitate 
as it disintegrated (figure 3.19) in the dissolution media.  
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Figure 3.19: VIRAMUNE® tablet disintegrating in the dissolution media. 
 
 
 
 
 
 
 
 
 
 
 
In contrast, the NVGLT prototype tablet behaved differently during the execution of the 
dissolution tests. In each dissolution test environment the NVGLT prototype tablet laminated i.e. 
broke into two or more individual pieces of tablet when it came into contact with the dissolution 
media (figure 3.20). This observation raised concerns about the tablet formulation, tablet 
compression and the QC tests performed on the final NVGLT prototype tablet.  
 
Figure 3.20: NVGLT prototype tablet laminating in the dissolution media. 
 
 
 
 
 
 
 
 
Haas et al. (2013) reported challenges in compressing the NVGLT co-crystal into a tablet. The 
prototype tablet (figure 3.17) was compressed by weighing 0.464 g of the powder blend i.e. a 
powder mixture consisting of 0.313 g of co-crystal and 0.151 g of microcrystalline cellulose and 
manually compressing the powder blend into a tablet. This operation is in direct contrast to the 
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normal tablet compression operation where the powder blend flows via gravitational feed from 
the tableting machine hopper onto the feed-frame into the die cavity where the powder is then 
compressed with the roller. The manual method of compression employed in compression of the 
NVGLT tablet led to the introduction of interstitial air in the NVGLT tablet matrix. Therefore 
the tablet was compressed without sufficiently expelling the interstitial air.  
 
The pre-compression roller on a tablet compression machine is responsible to expel the 
interstitial air pocket prior to compression at the main or compression roller. Therefore it can be 
concluded that when the NVGLT prototype tablet came into contact with the dissolution media, 
maintained at 37 °C, the moderately warm dissolution media expelled the interstitial air that was 
entrapped in the tablet matrix and the tablet laminated into two portions.  
 
This possibly led to the poor dissolution of 22 % in HCl buffer, 2 % in acetate buffer and 1 % in 
phosphate buffer of the NVGLT tablet (table 3.12).  
 
During the execution of the dissolution experiments, it was observed that the NVGLT tablet did 
not disintegrate. In figure 3.20 it is clear that a precipitate is not present compared to what is seen 
in figure 3.19, i.e. the Viramune® tablet. As mentioned before, disintegration is an important 
precursor to dissolution and is one of the QC tests that were conducted on the NVGLT tablet and 
the Viramune® tablet after tablet formulation. 
 
A difference in the manner in which the NVGLT tablet and Viramune® tablet disintegrated was 
reported. Haas et al. indicated that when the NVGLT tablet came into contact with the aqueous 
media (water), it firstly broke into fragments and thereafter, into finer particles. It took between 
3-5 seconds for the NVGLT tablet to disintegrate from a tablet to smaller particles. The result of 
the NVGLT tablet breaking into smaller fragments was purported as an advantage as 
fragmentation would result in an increased surface area, promoting a more rapid release of the 
drug substance. The fragmentation was ascribed to the presence of the MCC in the NVGLT 
tablet. 
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Even though the disintegration test showed favourable results, it is important to note that the test 
was conducted in water. It could not have been predicted how the tablet would disintegrate in 
buffered media. The total percentage of MCC in the NVGLT tablet is 33 %. This percentage that 
was used is well above the recommended percentage range of between 20 – 25 % recommended 
by the supplier of AVICEL,® FMC.14 The inclusion of a higher dose of MCC in the prototype 
tablet is not toxic to humans. MCC is a crystalline fibrous cellulose that is made from hydrolysed 
cellulose pulp. The material safety data on MCC indicates that the lethal dose of MCC consumed 
orally is above 5 g. The maximum daily dose for a person using nevirapine to treat HIV-1 
infection is 400 mg. The NVGLT tablet contains 33 % of MCC per tablet which will amount to 
1,32 g of MCC per tablet. Therefore the maximum amount of MCC a patient would consume per 
day is 2,64 g. This amount is significantly below the 5 g lethal dose.14 
 
The MCC does have very good disintegrating properties because it is insoluble in water and acts 
by a wicking process when it comes into contact with water. The wicking process utilises 
capillary action to pull water into the tablet matrix via the pores. The intermolecular bonding 
between particles weakens and the tablet core disintegrates. Therefore, porosity plays a major 
role in the ability of MCC to act as a disintegrant. This behaviour of MCC is subjected to change 
when the material is compressed. When MCC is compressed it undergoes plastic deformation.14 
The porosity of the material deforms under compaction pressure. Therefore the higher amount of 
MCC, could have adversely impacted the disintegration process as one can deduce that a high 
MCC content would have altered the porosity of the tablet. The behaviour of MCC in water is 
well understood therefore the effect of MCC in the buffered media would be dependent on the 
percentage of water in each individual buffered media. 
 
During the dissolution experiments it was observed that the NVGLT tablet was very fragile. 
Special care was required when handling the tablets. Some tablets were found to have chipped on 
the edges pointing towards the tablet formulation and binding properties of the tablet. The 
NVGLT tablet passed the friability test but failed the durability test. Even though the durability 
test failed by only 0,08 %, this percentage was significant based on observations during the 
dissolution experiments and also the dissolution results achieved (table 3.12). Mass loss may 
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have attributed to the poor dissolution results due to formulation issues of the tablet and tablet 
processing parameters.  
 
Tablet defects were reported, such as capping and lamination with the compression of the co-
crystal into tablets and the calibration of the tablet press was challenging and wearisome. 
However, no report on the compression forces that were utilised on the compression machine 
were recorded. It is a well-known fact that compression forces can be a cause of tablet defects.12 
Therefore the robustness of the compression process needs to be addressed. The most appropriate 
pre-compression and compression forces must be identified and validated as the tablet defects 
that were reported could have been related to the compression forces used. 
 
The Viramune® tablet performed exceptionally well during the quality control analysis. All the 
QC tests were favourable. However, dissolution in the HCl and phosphate buffer (pH 1.2 and pH 
6.8) failed. The Viramune® tablet was reported to have passed the disintegration test however, 
fragmentation of the tablets were not observed during the disintegration test.5 The tablet was 
observed to dissolve slowly into layers then to finer particles. It was reported that the excipient 
responsible for this effect is magnesium stearate, a known hydrophobic compound that forms a 
strong film layer, causing the aqueous medium to remain at the surface of the tablet. It thus 
reduced the penetration of the solvent and wettability, causing a slower dissolution rate.5 This is 
a key observation in the interpretation of the comparative dissolution results of Viramune®. 
 
Based on the Noyes- Whitney equation it can be extrapolated that the surface area of the 
undissolved Viramune® particles in the diffusion layer (figure 3.19) impeded the dissolution 
process. This impediment may be due to the presence of the magnesium stearate that covers the 
particles. The layer of magnesium stearate covering the large particular precipitates acts as a 
hydrophobic barrier to the solvent media resulting in a decrease penetration of the particles. 
 
Dissolution is also pH and solubility dependent. The NV is evidently more soluble in the HCl 
buffer at a pH of 1.2 as more than double the amount of NV passed into solution here compared 
to the phosphate buffer at pH 6.8 (54 % and 24 %, respectively). Due to the poor solubility of 
NV in buffered media, the comparative dissolution results was not favourable in these two 
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buffered media since the reference standard did not dissolve, it formed a precipitate as seen in 
figure 3.19. 
 
One of the objectives was to evaluate whether the two dosage forms were equivalent in terms of 
drug release. The similarity factor (f2) was calculated to evaluate whether the two dosage forms 
were equivalent or not. The f2 is a logarithmic reciprocal square root transformation of the sum 
of squared errors, and is a measurement of the similarity in the percentage (%) dissolution 
between the two curves. Each buffered media i.e. pH 1.2, 4.5 and 6.8 with the prototype 
(NVGLT) and standard (Viramune®) curves were calculated and compared using the following 
formula: 
f2 = 50. log{[1+ (1/n)t=1 n (Rt - Tt)2]-0.5.100} 
Where n is the number of time points, Rt is the dissolution value of the reference batch at time t, 
and Tt is the dissolution value of the test batch at time t. For f2 calculations a minimum of three 
time points (excluding point zero) must be used, and only one measurement included after 85 % 
dissolution of both products had occurred. All six sampling time points were used to calculate 
the similarity factor. For the curves to be considered similar, f2 values should be close to 100. 
Generally, f2 values greater than 50 (50 to 100) ensure sameness or equivalence of the two curves 
and, thus of the performance of the test and reference products.13 
 
For the test conducted in the HCl buffer (pH 1.2) it is clear from tables 3.13, 3.14 and 3.15 that 
the two products are not equivalent neither similar. The f2 value being 25.2. 
 
Table 3.13 Percentage drug release of NVGLT HCl buffer (pH 1.2). 
 
NVGLT pH 1.2 % Released: Nevirapine 
# 
Time Vessel Number 
(min) 1 2 3 4 5 6 
1 10 8.5 8.4 46.7 12.6 20.5 14.4 
2 15 8.5 9.9 18.6 12.1 15.2 16.6 
3 20 8.4 9.5 19.7 13.1 15.7 36.4 
4 30 7.6 8.2 18.0 10.1 14.1 17.9 
5 45 7.2 8.5 16.3 9.7 13.2 16.5 
6 60 5.6 6.3 14.8 8.1 12.7 14.7 
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Table 3.14 Percentage drug release of VIRAMUNE® HCl buffer (pH 1.2). 
 
VIRAMUNE® pH 1.2 % Released: Nevirapine 
# 
Time Vessel Number 
(min) 1 2 3 4 5 6 
1 10 38.9 38.0 35.5 42.1 38.9 49.4 
2 15 32.1 35.8 35.3 43.3 42.1 53.8 
3 20 35.6 34.6 36.7 43.8 43.0 54.8 
4 30 45.3 40.8 37.1 50.3 45.5 55.5 
5 45 34.2 35.6 109.6 46.1 43.2 56.4 
6 60 38.9 38.0 35.5 42.1 38.9 49.4 
 
Table 3.15 Similarity factor between NVGLT and VIRAMUNE® in HCl buffer (pH 1.2). 
 
f2 
Profiles 
Equivalent? 
25.2 No 
 
For the test conducted in the acetate buffer (pH 4.5), tables 3.16, 3.17 and 3.118 indicates that 
the two products performed poorer with its f2 value being 15.0. This indicates that the products 
are not equivalent neither similar. 
 
Table 3.16 Percentage drug release of NVGLT acetate buffer (pH 4.5). 
 
NVGLT pH 4.5 % Released: Nevirapine 
# 
Time Vessel Number 
(min) 1 2 3 4 5 6 
1 10 0.4 0.7 0.8 2.3 1.4 1.6 
2 15 0.4 0.6 0.6 1.9 1.1 1.4 
3 20 1.0 0.8 0.8 1.2 1.4 1.6 
4 30 0.6 0.8 0.9 1.2 1.5 1.7 
5 45 0.5 0.7 0.7 0.9 1.2 1.2 
6 60 0.6 0.8 0.9 1.3 1.6 1.6 
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Table 3.17 Percentage drug release of VIRAMUNE® acetate buffer buffer (pH 4.5). 
 
VIRAMUNE® pH 4.5 % Released: Nevirapine 
# 
Time Vessel Number 
(min) 1 2 3 4 5 6 
1 10 29.7 30.6 26.5 35.7 99.8 101.2 
2 15 26.7 26.1 27.2 30.0 100.5 101.8 
3 20 21.0 27.7 25.9 26.8 100.5 101.1 
4 30 25.3 26.5 24.9 29.4 99.8 101.3 
5 45 23.3 25.7 24.4 26.2 97.8 98.8 
6 60 22.8 25.1 23.6 28.2 101.7 100.6 
 
Table 3.18 Similarity factor between NVGLT and VIRAMUNE® in acetate buffer (pH 4.5). 
 
f2 
Profiles 
Equivalent? 
15.0 No 
 
The test conducted in the phosphate buffer (pH 6.8), tables 3.19, 3.20 and 3.21 indicates that the 
two products are not equivalent neither similar. However the products are more alike in the 
phosphate buffered medium compared to the other two test media (acetate and HCl). The f2 value 
of 32.2 amplifies this fact. 
 
Table 3.19 Percentage drug release of NVGLT phosphate buffer (pH 6.8). 
 
NVGLT pH 6.8 % Released: Nevirapine 
# 
Time Vessel Number 
(min) 1 2 3 4 5 6 
1 10 0.5 0.6 0.6 0.8 1.0 1.2 
2 15 0.4 0.5 0.5 0.7 0.9 1.1 
3 20 0.5 0.6 0.6 0.8 1.1 1.3 
4 30 0.5 0.6 0.7 0.9 1.2 1.4 
5 45 0.5 0.6 0.6 0.8 1.1 1.3 
6 60 0.5 0.6 0.6 0.8 1.1 1.3 
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Table 3.20 Percentage drug release of VIRAMUNE® phosphate buffer (pH 6.8). 
 
VIRAMUNE® pH 6.8 % Released: Nevirapine 
# 
Time Vessel Number 
(min) 1 2 3 4 5 6 
1 10 21.6 23.4 23.4 24.1 24.4 24.6 
2 15 21.1 23.1 23.0 23.8 24.2 24.4 
3 20 21.1 23.1 22.9 23.6 24.0 24.2 
4 30 21.6 23.3 23.3 24.0 24.4 24.6 
5 45 20.8 22.7 22.7 23.4 23.8 24.0 
6 60 22.2 23.4 23.4 23.9 24.2 24.4 
 
Table 3.21 Similarity factor between NVGLT and VIRAMUNE® in phosphate buffer (pH 6.8). 
 
f2 
Profiles 
Equivalent? 
32.3 No 
 
(iv) Exploratory research 
3.6 Nevirapine solution stability 
A formulated drug compound does not keep its integrity indefinitely. Some medicines especially 
once made up extemporaneously can only be kept for a short time. There are many reasons why 
drug compounds break down during its shelf-life. A few general reasons why medicines do not 
keep indefinitely but for a limited time frame were identified by Rhodes in 1984.15 These causes 
include a loss of drug (such as hydrolysis), a loss of the vehicle (such as evaporation of water or 
other volatile ingredients), a loss of uniformity (such as caking of a suspension or creaming of an 
emulsion), a change in bioavailability (particularly with tablets where ageing can reduce 
available drug), a change of appearance (such as colour changes) and appearance of toxic or 
irritant products as a result of chemical change. Additional to these six causes for drug 
degradation are changes that arise from microbiological activity.15 
 
 
 
 
 
 
 
 
119 
 
The most common types of drug degradation are hydrolysis and oxidation. The drug degradation 
by hydrolysis has two mechanistic stages. During the first stage, a nucleophile such as water or 
the OH- ion adds to, for example, an acyl carbon to form an intermediate from which the leaving 
group then breaks away. The structure of the compound will affect the rate at which this reaction 
takes place and the stronger the leaving conjugate acid the faster the degradation reaction will 
occur. There are a number of factors that affects degradation by hydrolysis such as pH of the 
solution, buffer salts and ionic strength. In addition, the presence of co-solvents, complexing 
agents and surfactants can also affect this type of degradation. The solution pH is one of the main 
determinants of the stability of a compound. Hydroxyl ions are stronger nucleophiles than water, 
thus degradation reactions are usually faster in alkaline solutions than in water i.e. OH- ions 
catalyse the reaction. In solutions of low pH, H+ can also catalyse hydrolysis reactions. In this 
case catalysis by H+ and OH- is termed specific acid base catalysis. It is a fact that H+ and OH- 
ions are not the only ions that are present during an experiment or in a formulation.  
 
It is well known that buffer ions such as acetate or citrate can catalyse degradation and as a result 
effect general acid base degradation.16 Oxidation is the second most common type of drug 
degradation in solution. The redox reaction i.e. reduction or oxidation, involves the transfer of 
oxygen or hydrogen atoms of the transfer of electrons. Oxidation is promoted by the presence of 
oxygen and the reaction can be initiated by the action of heat, light or trace metal ions that 
produce organic free radicals. These radicals propagate the oxidation reaction that proceeds until 
inhibitors destroy them or by side reactions that eventually break the chain. A simple laboratory 
test for oxidation degradation can be done by bubbling oxygen air through the drug (in solution) 
or adding hydrogen peroxide to the solution then visually assessing the degradation.16 
 
There are pharmacopoeias such as the British Pharmacopoeia that includes storage of drugs as a 
heading in some drug monographs and preparations. These include phrases such as “protect from 
moisture” and “protect from light” which are described as being non-mandatory. Thus these are 
recommendations rather than pharmacopoeial requirements.  
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It is important to recognise and be aware of the potential for drug instability. At the time of the 
experiments the solution stability of NV in the buffered media was not known. The dissolution 
samples retrieved from the dissolution experiments for both the NVGLT prototype tablet and the 
Viramune® tablet was analysed for its antiviral activity against HIV-1. The samples were 
couriered overnight from Cape Town to the laboratory of the National Institute for 
Communicable Diseases in Pretoria for this analysis. As the stability of NV in the buffered 
media was not known, it became of utmost importance to conduct a stability study to evaluate 
the impact of the buffered media on the drug compound NV and also the potential impact the 
delayed antiviral testing had on the potency of the NV. 
 
A duplicate sample of the one couriered to the NICD for both the test and reference product was 
placed on stability to evaluate the solution stability of NV in the buffered dissolution media. The 
stability tests involved the exposure of the samples to 2-8 °C and 40 °C 75 % RH environmental 
conditions. The sample was exposed to these conditions for 4 weeks and was subsequently 
assayed using the same methodology as per comparative dissolution assay. 
 
The rationale behind the solution stability test was to indicate whether or not the NV degraded 
during storage prior to antiviral testing and also should degradation have occurred, what the 
significance of it was. 
 
Table 3.22 Absorbance of NV (in the HCl buffer, pH 1.2) before and after 4 weeks exposure to 
cold chain and accelerated environmental conditions. 
 
Product  Storage condition Initial absorbance  Absorbance after 4 weeks exposure 
NVGLT 
2-8 °C 
Sample 1 Sample 2 Sample 3 Sample 1 Sample 2 Sample 3 
1322413 1578890 3472244 7262318 8158188 8614233 
40 °C / 75 % RH 
Sample 1 Sample 2 Sample 3 Sample 1 Sample 2 Sample 3 
1728177 1608158 1373458 6950730 6723397 5762525 
VIRAMUNE® 
2-8 °C 
Sample 1 Sample 2 Sample 3 Sample 1 Sample 2 Sample 3 
5763774 6295995 6335705 20452512 20878645 20917417 
40 °C / 75 % RH 
Sample 1 Sample 2 Sample 3 Sample 1 Sample 2 Sample 3 
6467586 6527800 6558545 19353077 18787457 20190040 
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Both NVGLT and Viramune® indicates a higher absorbance reading for the 2-8 °C and 40 °C / 
75 % RH environmental condition after a four week exposure to these conditions (table 3.22). It 
is not possible that more than 100 percent (%) of NV was recovered after four weeks exposure at 
these environmental conditions as it is expected that any drug compound would degrade. The 
initial absorbances of NVGLT and Viramune® would be equal to 100 %. For the drug to be 
stable the absorbance reading should have been the exact amount with a variance of ± 5 %. As 
displayed in table 3.22, the absorbance readings for both the test and reference products are 
significantly higher.  
 
The higher absorbance reading can be ascribed to either degradant related NV compounds or it 
could be that small particulates of drug were in the sample and was slowly liberated over the 
course of four weeks. The latter explanation is less likely to have occurred as the samples were 
filtered twice prior to the assays. Therefore, neither NVGLT nor VIRAMUNE® is stable in HCl 
buffer media. An investigation into quantification of degradants and related compounds is 
recommended. 
 
Table 3.23 Absorbance of NV (in the Acetate buffer, pH 4.5) before and after 4 weeks exposure 
to cold chain and accelerated environmental conditions. 
 
Product  Storage condition Initial absorbance  Absorbance after 4 weeks exposure 
NVGLT 
2-8 °C 
Sample 1 Sample 2 Sample 3 Sample 1 Sample 2 Sample 3 
206510 173637 212864 768054 659975 826525 
40 °C / 75 % RH 
Sample 1 Sample 2 Sample 3 Sample 1 Sample 2 Sample 3 
212169 158454 208890 860321 670205 920969 
VIRAMUNE® 
2-8 °C 
Sample 1 Sample 2 Sample 3 Sample 1 Sample 2 Sample 3 
12765097 12806535 12796074 9900024 10920151 9283314 
40 °C / 75 % RH 
Sample 1 Sample 2 Sample 3 Sample 1 Sample 2 Sample 3 
12872482 12769443 12942099 12608747 12444449 12670075 
 
In table 3.23, NVGLT once again displays a higher absorbance reading for the 2-8 °C and 40 °C 
/ 75 % RH environmental condition after the four week exposure to these conditions. As 
explained before it is not possible that more than 100 % of NV can be recovered after four weeks 
exposure at these environmental conditions.  
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The initial absorbances of NVGLT versus absorbances after four weeks exposure are 
significantly different. The higher absorbance reading is ascribed to degradant related NV 
compounds. 
 
Table 3.23 indicates that Viramune® was stable in the acetate buffer media in both 2-8 °C and 
40 °C / 75 % RH over the course of four weeks. There is no significant change in the absorbance 
readings obtained after four weeks of exposure. Therefore it can be concluded that NVGLT is 
not stable in the acetate buffer whilst Viramune® is. 
 
Table 3.24 Absorbance of NV (in the Phosphate buffer, pH 6.8) before and after 4 weeks 
exposure to cold chain and accelerated environmental conditions. 
 
Product  Storage condition Initial absorbance  Absorbance after 4 weeks exposure 
NVGLT 
2-8 °C 
Sample 1 Sample 2 Sample 3 Sample 1 Sample 2 Sample 3 
617700 549920 629759 613877 546081 626624 
40 °C / 75 % RH 
Sample 1 Sample 2 Sample 3 Sample 1 Sample 2 Sample 3 
673396 649326 637942 675723 687335 654531 
VIRAMUNE® 
2-8 °C 
Sample 1 Sample 2 Sample 3 Sample 1 Sample 2 Sample 3 
11354484 11436348 11409001 11014027 10673450 10299260 
40 °C / 75 % RH 
Sample 1 Sample 2 Sample 3 Sample 1 Sample 2 Sample 3 
11383093 11384085 11365926 11513900 11411724 11465746 
 
From table 3.24 it is clear that both NVGLT and Viramune® were stable in the phosphate 
buffered media at 2-8 °C and 40 °C / 75 % RH environmental conditions after the four week 
exposure. There is no significant change in the initial absorbance reading and the readings 
obtained after four weeks of exposure. 
 
In summary, NVGLT and Viramune® were not stable in the HCl buffer and an investigation into 
quantification of degradants and related compounds is recommended. The NVGLT was not 
stable in the acetate buffer, however Viramune® was. Both NVGLT and Viramune® were stable 
in the phosphate buffer.  
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Therefore, even though potential drug degradation is observed in the test and reference products, 
it is unlikely that it had a significant impact on the antiviral tests as the samples couriered to 
NICD were stored at 2-8 °C and the antiviral tests were conducted immediately i.e. samples were 
not kept for longer than four weeks before the antiviral tests were conducted. 
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DISSOLUTION AND ANTIVIRAL ACTIVITY OF A NOVEL NEVIRAPINE FORMULATION 
              
CHAPTER 4 
ANTIVIRAL ACTIVITY 
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4 Introduction 
The investigation of the antiviral activity of the NV co-crystals was fundamental to complete 
stage (ii), exploratory research, of the product life-cycle process, described in chapter 1. The 
evaluation of the antiviral activity and the cytotoxic screening provided valuable information on 
the feasibility of progressing the NV co-crystals to stage (iii) candidate selection. This section of 
the work also contributed to other stages of the product life-cycle process viz. (iv) exploratory 
development and (v) full development. 
 
All the cytotoxic screening and antiviral testing was performed by the South African National 
Institute of Communicable Diseases (NICD). Chapter 4 is divided into two sections. Firstly, the 
cytotoxic screening and antiviral activity results of the five co-crystals synthesized in the pre-
formulation experiments (chapter 3) is presented and discussed. The cytotoxicity screening used 
NICD specific 293T cells and a spectrophotometric assay technique.1The antiviral activity assay 
utilized an in vitro HIV-1 single-cycle infection with a bioluminescence quantification 
technique.2The second section of chapter 4 presents the cytotoxic screening and antiviral activity 
results of the formulated NVGLT tablet and the proprietor brand Viramune®. The same 
analytical methodology was applied to evaluate the cytotoxicity and antiviral activity. 
 
The results of the antiviral activity and cytotoxicity screening of the pre-formulation co-crystals 
were used by Haas et al. (2013)3 to select the best performing co-crystal for further development 
into the co-crystal tablet, NVGLT. 
 
(ii) Exploratory research and (iii) candidate selection 
4.1 Cytotoxicity screen: Pre-formulation (co-crystals) 
Prior to the antiviral testing a toxicity screen on the 293T cells was performed to evaluate 
cytotoxicity. In many instances a substance can be very effective as an antiviral agent, however 
the concentrations at which efficacy as an antiviral is proven is at times very toxic to human 
cells.4 Therefore, it was imperative to evaluate cytotoxicity of the co-crystals before the antiviral 
activity test commenced in order to establish appropriate concentrations of the nevirapine co-
crystals. 
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Stock solutions of each co-crystal and pure NV were prepared using DMSO. The NICD was 
instructed to use purified water as a solvent, however DMSO was used instead due to challenges 
in solubilising the co-crystals. The stock solutions contained an effective NV concentration of 10 
mM. This stock solution was diluted to working concentrations in complete Dulbecco's modified 
eagle medium (DMEM). A DMSO control solution was prepared and was run in parallel. The 
working solution was titrated into complete DMEM medium by serial dilution in a 96-well 
culture plate, providing a range of concentrations for toxicity testing (table 4.1, 4.2, 4.3, 4.4 and 
4.5). A control cell was included. 
 
The cytotoxicity screening indicated that the co-crystals had no significant toxicity to the 293T 
cells, as the percentage viability of the 293T cells remained above 50 % for all co-crystals tested 
(figure 4.1). The 293T cells were viable as a colour change of the thiazolyl blue tetrazolium 
bromide compound via bioreduction to a coloured formazan product was observed in the 
cultured medium for all the co-crystals. 
 
Figure 4.1: Cytotoxic effects of the co-crystals on the viability of 293T cells in vitro1 
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The cytotoxicity screen for all the co-crystals was conducted in duplicate in order to validate the 
initial results. In tables 4.1, 4.2, 4.3, 4.4 and 4.5 the sample dilutions that were evaluated shows 
that in all instances the viability of the 293T cells was consistently being above 80 % viability 
for all the co-crystals at all the concentration levels that were tested. It is noteworthy to observe 
the trend of how the percentage viability of the 293T cells consistently was above 80 % even as 
the concentration of the co-crystals decreased. The average standard deviation reported for the 
NVSC, NVTTA and NVSLI is acceptable as it is approximately 2 %. The average standard 
deviation of the remaining two co-crystals is all above 2 %. This indicates a larger deviation in 
the percentage viability results achieved.  
 
Nevertheless, the cytotoxicity-50 (CC50), the concentration at which 50 % of the cells are viable, 
is greater than the maximum concentration tested, indicating no cytotoxic effect to the 293T 
cells. The cytotoxicity screening results suggested that these concentration ranges could be 
utilized for the screening for anti-HIV-1 activity of the co-crystals. 
 
All the co-crystals consist of the NV portion of the compound and the co-former portion of the 
compound in defined molar ratios. Even though the cytotoxicity results of all five co-crystal 
compounds were favourable, indicating that both the NV component and the co-former 
component of the co-crystal was not toxic to the 293T cells, each co-former was screened to 
validate whether the co-formers individually were toxic to the 293T cells. The results achieved 
validated that all five co-formers were not toxic to the 293T cells. These results allowed the 
experiment to progress to the antiviral activity analysis of the co-crystals versus HIV-1.  
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Table 4.1: NVSC sample dilution for 293T cell toxicity 
 
     NVSC 24.2 8.06 2.69 0.90 0.30 0.10 0.03 0.01 0.004 0.001 0.0004 µM 
Final NV  
concentration 
 
1 2 3 4 5 6 7 8 9 10 11 12 
  Raw-1 1.310 1.180 1.173 1.147 1.286 1.210 1.196 1.197 1.206 1.206 1.293 1.407 (A490nm-A650nm) 
Raw-2 1.250 1.203 1.189 1.167 1.185 1.196 1.209 1.204 1.204 1.167 1.203 1.227 (A490nm-A650nm) 
Blank (B) 0.450 0.429 0.423 0.416 0.418 0.419 0.418 0.419 0.419 0.421 0.428 0.451 
Lowest dilution 
average: 
1-Blank 0.861 0.752 0.750 0.731 0.869 0.791 0.778 0.778 0.787 0.784 0.865 0.956 0.866 
 2-Blank 0.800 0.774 0.766 0.751 0.768 0.777 0.791 0.785 0.785 0.746 0.776 0.776 
  %Viability-1 99.3% 86.8% 86.6% 84.4% 100.3% 91.3% 89.8% 89.8% 90.8% 90.6% 99.9% 
   %Viability-2 92.4% 89.3% 88.4% 86.7% 88.6% 89.7% 91.3% 90.7% 90.7% 86.1% 89.5% 
 
CC50   
Average 95.9% 88.1% 87.5% 85.5% 94.5% 90.5% 90.6% 90.2% 90.7% 88.3% 94.7% 
 
>24.2µM 
NVSC 
 Std. dev 4.93% 1.82% 1.28% 1.62% 8.25% 1.18% 1.03% 0.60% 0.13% 3.17% 7.31% 
   STD/AVE 5.1% 2.1% 1.5% 1.9% 8.7% 1.3% 1.1% 0.7% 0.1% 3.6% 7.7% 
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Table 4.2: NVTTA sample dilution for 293T cell toxicity 
 
     NVTTA 28.1 9.38 3.13 1.04 0.35 0.12 0.04 0.01 0.004 0.001 0.0005 µM 
Final sample 
concentration 
 
1 2 3 4 5 6 7 8 9 10 11 12 
  Raw-1 1.284 1.228 1.173 1.167 1.198 1.175 1.171 1.158 1.178 1.208 1.214 1.316 (A490nm-A650nm) 
Raw-2 1.281 1.145 1.194 1.231 1.210 1.177 1.175 1.192 1.210 1.179 1.246 1.437 (A490nm-A650nm) 
Blank (B) 0.460 0.426 0.415 0.413 0.415 0.414 0.409 0.414 0.417 0.418 0.420 0.449 
Lowest dilution 
average: 
1-Blank 0.824 0.802 0.757 0.754 0.783 0.760 0.762 0.744 0.761 0.790 0.794 0.866 0.927 
 2-Blank 0.822 0.719 0.778 0.818 0.795 0.763 0.766 0.778 0.793 0.761 0.826 0.988 
  %Viability-1 88.9% 86.5% 81.7% 81.4% 84.5% 82.0% 82.1% 80.2% 82.1% 85.2% 85.6% 
   %Viability-2 88.6% 77.5% 83.9% 88.2% 85.8% 82.2% 82.6% 83.9% 85.5% 82.1% 89.1% 
 
CC50   
Average 88.8% 82.0% 82.8% 84.8% 85.1% 82.1% 82.4% 82.0% 83.8% 83.7% 87.4% 
 
>28.1 µM  
NVTTA 
 Std. dev 0.21% 6.33% 1.59% 4.87% 0.89% 0.18% 0.30% 2.60% 2.43% 2.22% 2.48% 
   STD/AVE 0.2% 7.7% 1.9% 5.7% 1.0% 0.2% 0.4% 3.2% 2.9% 2.7% 2.8% 
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Table 4.3: NVMLE sample dilution for 293T cell toxicity 
 
        NVMLE 25.8 8.61 2.87 0.96 0.32 0.11 0.04 0.01 0.004 0.001 0.0004 µM 
Final sample 
concentration 
 
1 2 3 4 5 6 7 8 9 10 11 12 
  Raw-1 1.263 1.217 1.199 1.220 1.184 1.182 1.195 1.206 1.219 1.241 1.222 1.355 (A490nm-A650nm) 
Raw-2 1.359 1.269 1.163 1.276 1.176 1.235 1.207 1.283 1.275 1.267 1.237 1.348 (A490nm-A650nm) 
Blank (B) 0.463 0.420 0.425 0.420 0.422 0.417 0.414 0.419 0.419 0.421 0.428 0.402 
Lowest dilution 
average: 
1-Blank 0.799 0.798 0.774 0.800 0.762 0.766 0.781 0.788 0.801 0.820 0.794 0.953 0.949 
 2-Blank 0.896 0.849 0.738 0.856 0.754 0.819 0.794 0.865 0.856 0.846 0.808 0.946 
  %Viability-1 84.2% 84.0% 81.6% 84.3% 80.2% 80.7% 82.3% 83.0% 84.3% 86.4% 83.6% 
   %Viability-2 94.3% 89.4% 77.8% 90.2% 79.4% 86.2% 83.6% 91.1% 90.1% 89.1% 85.2% 
 
CC50   
Average 89.3% 86.7% 79.7% 87.2% 79.8% 83.5% 83.0% 87.0% 87.2% 87.7% 84.4% 
 
>25.8µM 
NVMLE 
 Std. dev 7.16% 3.84% 2.70% 4.16% 0.60% 3.93% 0.93% 5.71% 4.10% 1.96% 1.07% 
   STD/AVE 8.0% 4.4% 3.4% 4.8% 0.7% 4.7% 1.1% 6.6% 4.7% 2.2% 1.3% 
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Table 4.4: NVGLT sample dilution for 293T cell toxicity 
 
      NVGLT 26.9 8.98 2.99 1.00 0.33 0.11 0.04 0.01 0.004 0.001 0.0005 µM 
Final sample 
concentration 
 
1 2 3 4 5 6 7 8 9 10 11 12 
  Raw-1 1.236 1.126 1.208 1.184 1.193 1.179 1.179 1.183 1.186 1.188 1.185 1.282 (A490nm-A650nm) 
Raw-2 1.231 1.041 1.185 1.026 1.104 1.189 1.186 1.180 1.226 1.050 1.094 1.376 (A490nm-A650nm) 
Blank (B) 0.453 0.425 0.422 0.418 0.418 0.413 0.419 0.417 0.417 0.419 0.419 0.456 
Lowest dilution 
average: 
1-Blank 0.783 0.701 0.785 0.766 0.775 0.766 0.761 0.766 0.769 0.768 0.766 0.826 0.873 
 2-Blank 0.778 0.616 0.762 0.608 0.686 0.775 0.768 0.762 0.809 0.630 0.675 0.920 
  %Viability-1 89.7% 80.3% 90.0% 87.8% 88.8% 87.7% 87.2% 87.7% 88.0% 88.0% 87.8% 
   %Viability-2 89.2% 70.6% 87.3% 69.7% 78.6% 88.8% 88.0% 87.3% 92.7% 72.2% 77.3% 
 
CC50   
Average 89.4% 75.4% 88.7% 78.7% 83.7% 88.3% 87.6% 87.5% 90.4% 80.1% 82.6% 
 
>26.9µM 
NVGLT 
 Std. dev 0.39% 6.89% 1.86% 12.83% 7.23% 0.75% 0.57% 0.28% 3.28% 11.20% 7.39% 
   STD/AVE 0.4% 9.1% 2.1% 16.3% 8.6% 0.9% 0.6% 0.3% 3.6% 14.0% 8.9% 
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Table 4.5: NVSLI sample dilution for 293T cell toxicity 
 
      NVSLI 22.7 7.56 2.52 0.84 0.28 0.09 0.03 0.01 0.003 0.001 0.0004 µM 
Final sample 
concentration 
 
1 2 3 4 5 6 7 8 9 10 11 12 
  Raw-1 1.168 1.161 1.181 1.118 1.182 1.182 1.183 1.175 1.206 1.171 1.142 1.317 (A490nm-A650nm) 
Raw-2 1.154 1.179 1.163 1.169 1.178 1.174 1.165 1.144 1.184 1.211 1.255 1.311 (A490nm-A650nm) 
Blank (B) 0.455 0.431 0.427 0.424 0.419 0.420 0.417 0.416 0.418 0.419 0.424 0.452 
Lowest dilution 
average: 
1-Blank 0.714 0.730 0.755 0.695 0.763 0.762 0.766 0.759 0.787 0.753 0.718 0.865 0.862 
 2-Blank 0.699 0.748 0.737 0.746 0.759 0.754 0.749 0.728 0.765 0.793 0.831 0.859 
  %Viability-1 82.8% 84.7% 87.6% 80.6% 88.5% 88.4% 88.9% 88.1% 91.4% 87.4% 83.3% 
   %Viability-2 81.1% 86.8% 85.5% 86.5% 88.0% 87.5% 86.9% 84.5% 88.8% 92.0% 96.5% 
 
CC50   
Average 82.0% 85.8% 86.5% 83.6% 88.3% 87.9% 87.9% 86.3% 90.1% 89.7% 89.9% 
 
>22.7µM 
NVSLI 
 Std. dev 1.19% 1.49% 1.49% 4.19% 0.34% 0.63% 1.44% 2.51% 1.81% 3.27% 9.29% 
   STD/AVE 1.5% 1.7% 1.7% 5.0% 0.4% 0.7% 1.6% 2.9% 2.0% 3.6% 10.3% 
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(ii) Exploratory research and (iii) candidate selection 
4.2 Antiviral activity test: Pre-formulation (co-crystals versus pure NV) 
In vitro antiviral testing was performed on the co-crystals to evaluate whether the NV co-crystal 
form has comparable or improved antiviral activity against HIV-1, compared to pure NV. A 
control test was performed on the co-formers and the DMSO to evaluate whether these 
components possessed any antiviral activity against HIV-1. Neither the co-formers nor the 
DMSO solvent inhibited HIV-1. Therefore it can be accepted that the inhibitory activity 
displayed by the co-crystals (figure 4.2 and table 4.6) is directly as a result of the NV portion of 
the molecule. According to the NICD, the five co-crystals did not dissolve in water, despite 
agitation and incubation at 37 °C. For this reason DMSO was used, as NV has a solubility of 
approximately 20 mg/mL in this solvent.5  
 
NVSC and NVSLI had an average inhibitory concentration 50 (IC50) values of 0.037 mM. The 
IC50 is the concentration of the co-crystal where 50 % of the virus is inhibited. The IC50 of NVSC 
and NVSLI is significantly different from pure NV (0.083 mM), with p-values of 0.002. As 
indicated in the methodology section, the significance level was set to 5 % (0.05). Therefore, this 
result indicates that NVSC and NVSLI was significantly better at inhibiting HIV-1 compared to 
pure NV. 
 
NVMLE and NVGLT had average IC50 values of 0.055 mM and 0.054 mM respectively, which 
is significantly different from pure NV, with p-values of 0.026 and 0.019 respectively. The fact 
that the IC50  NVSC, NVSLI, NVMLE and NVGLT is all lower than pure NV implies that these 
co-crystals have better efficacy against HIV-1 compared to pure NV. The NICD has a 
specification range for the IC50 of NV in the range of 0.1002 ± 0.00273 mM.  
 
NVTTA, the only outlier, had an average IC50 value of 0.072 (with a p-value of 0.416), which 
does not differ significantly from pure NV IC50 value of 0.083 mM (figure 4.2 and table 4.6).  
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Figure 4.2: Antiviral activity of the co-crystals against HIV-1, compared to pure NV. 
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IC50 (sample) [mM] IC50 (NV equivalent) [mM] Significant difference 
  
Screen 
1 
Screen 
2 Average *S.D. 
Screen 
1 
Screen 
2 Average *S.D. **P-value compared to NV 
1 NVSC 0.045 0.052 0.049 0.005 0.034 0.039 0.037 0.004 0.002 Quite significant 
2 NVTTA 0.121 0.105 0.113 0.011 0.077 0.067 0.072 0.007 0.416 Not significant 
3 NVMLE 0.089 0.067 0.078 0.016 0.062 0.047 0.055 0.011 0.026 Significant 
4 NVGLT 0.087 0.075 0.081 0.008 0.058 0.050 0.054 0.006 0.019 Significant 
5 NVSLI 0.044 0.051 0.048 0.005 0.034 0.040 0.037 0.004 0.002 Quite significant 
6 SC >6.2 >6.2 inactive -  -  -  - 
  
 7 TTA >10.1 >10.1 inactive  -  -  -  - 
 8 MLE >7.8 >7.8 inactive  -  -  -  - 
 9 GLT >8.9 >8.9 inactive  -  -  -  - 
 10 SLI >4.7 >4.7 inactive  -  -  -  - 
 
11 
NV 
(pure) 0.096 0.070 0.083 0.018 0.096 0.070 0.083 0.018  - 
 12 DMSO  -  - inactive  -  -  -  -  - 
 
            * Standard  
Deviation 
          ** Compared to pure NV 
         
Table 4.6: Inhibitory concentration-50 (IC50) values of co-crystals, co-formers and pure NV 
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The NICD did not perform these experiments according to the molar ratio calculations provided 
to them. As NVSC and NVSLI form in a 2:1 ratio of NV to co-former respectively, the correct 
quantity of co-crystal to use when producing the stock solution would be 50 µM. This equates to 
100 µM of NV within the co-crystal.  
 
The following calculations should have been taken into account when the experiments were 
done: 
 
NVSC 2:1 molar ratio 
5 mg NVSC = 3.72 mg NV + 1.279 mg SC 
6.9µM NVSC = 13.9 µM NV : 6.9 µM SC 
Therefore:  
50 µM NVSC = 100 µM NV : 50 µM SC 
Therefore 50 µM NVSC will contain 100 µM NV 
M = C x V x Mr 
 = 0.00005 mol x 0.01 L x 715.79 g/mol 
 = 0.0003579 g 
 = 0.357 mg in 10 mL contains 100 µM NV 
 
NVSLI 2:1 molar ratio 
M = C x V x Mr 
 = 0.00005 mol x 0.01 L x 670.72 g/mol 
 = 0.000335 g 
 = 0.335 mg in 10 mL contains 100 µM NV 
 
NVTTA 1:1 molar ratio 
100 µm NVTTA = 100 µm NV : 100 µm TTA 
Therefore 100 µm NVTTA will contain 100 µm NV 
M = C x V x Mr 
 = 0.0001 mol x 0.01 L x 416.39 g/mol 
 = 0.000416 g 
 = 0.416 mg 
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NVMLE 1:1 molar ratio 
M = C x V x Mr 
 = 0.0001 mol x 0.01 L x 382.37 g/mol 
 = 0.000382 g 
 = 0.382 mg 
 
NVGLT 1:1 molar ratio 
M = C x V x Mr 
 = 0.0001 mol x 0.01 L x 398.42 g/mol 
 = 0.000398 g 
 = 0.398 mg 
 
The NICD used 134 µM of NVSC and 125 µM of NVSLI, which equals 268 µM and 250 µM of 
NV in each co-crystal respectively as per calculations above. This doubled dose could be the 
reason for NVSC and NVSLI displaying an improved antiviral activity. 
 
The expectation was that by improving the solubility of NV, a better pharmacokinetic profile 
would be obtained which would essentially improve the antiviral activity. The co-crystals 
dissociate into NV and the relevant co-former when placed into DMSO solution, therefore if the 
same molar quantities of NV in each co-crystal is used, there should not be a large difference 
between their antiviral activity compared to that of pure NV. These tests need to be repeated in 
water to determine whether improving the solubility of the co-crystals results in improved 
antiviral activity. 
 
(iv) Exploratory development 
4.3 Cytotoxicity screen: NVGLT tablet and Viramune® tablet 
In vitro antiviral testing on the comparative dissolution samples was conducted to evaluate 
whether the NVGLT prototype tablet had comparable or improved activity against HIV-1, 
compared to the Viramune® tablet and pure NV. The antiviral activity test was also intended to 
correlate the results obtained in the HPLC assay of the dissolution sample. Therefore, a decision 
was made not to supply NICD with the NV content as per dissolution results achieved. This 
deliberate decision introduced a blinded aspect where the results achieved by NICD would have 
to theoretically correlate with the dissolution results obtained. 
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The first step prior to the antiviral activity assay was to determine the cytotoxicity of the test 
samples to the 293T cells that were used in the assay. The percentage viability was determined 
through the use of MTS, a viability dye. Untreated control cells were used as a reference and had 
a viability of 100 %. A decrease in the percentage viability is indicative of toxic effects of the 
samples on the cells. Pure NV drug was used as a reference and a DMSO solvent control was 
included. The samples and controls were tested in duplicate, in two independent experiments. 
 
During the cytotoxicity screening, no coloured formazan changes were observed in the medium. 
This observation was attributed to compromised cell viability over the concentrations used 
initially. These concentrations were thus toxic to the 293T cell. In order to circumvent a 
significant compromise in cell viability the, samples were screened once more for toxicity to 
293T cells after which acceptable concentrations were established. Subsequent to this, the 
activity screening against HIV-1 was performed utilizing the sample dilutions tested for toxicity 
to 293T cells, reflected in table 4.7. 
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Table 4.7: Sample dilution for 293T cell toxicity 
  Dilution range 
Sample 1 2 3 4 5 6 7 8 9 10 11 Units 
2.6R, pH 6.8 4.0E+01 1.2E+02 3.6E+02 1.1E+03 3.2E+03 9.7E+03 2.9E+04 8.7E+04 2.6E+05 7.9E+05 2.4E+06 final dilution 
6.5R, pH 4.5 4.0E+01 1.2E+02 3.6E+02 1.1E+03 3.2E+03 9.7E+03 2.9E+04 8.7E+04 2.6E+05 7.9E+05 2.4E+06 final dilution 
5.3R, pH 1.2 4.0E+01 1.2E+02 3.6E+02 1.1E+03 3.2E+03 9.7E+03 2.9E+04 8.7E+04 2.6E+05 7.9E+05 2.4E+06 final dilution 
4.6T, pH 6.8 4.0E+01 1.2E+02 3.6E+02 1.1E+03 3.2E+03 9.7E+03 2.9E+04 8.7E+04 2.6E+05 7.9E+05 2.4E+06 final dilution 
1.4T, pH 4.5 4.0E+01 1.2E+02 3.6E+02 1.1E+03 3.2E+03 9.7E+03 2.9E+04 8.7E+04 2.6E+05 7.9E+05 2.4E+06 final dilution 
1.3T, pH 1.2 4.0E+01 1.2E+02 3.6E+02 1.1E+03 3.2E+03 9.7E+03 2.9E+04 8.7E+04 2.6E+05 7.9E+05 2.4E+06 final dilution 
Nevirapine 6.0E+00 2.0E+00 6.7E-01 2.2E-01 7.4E-02 2.5E-02 8.2E-03 2.7E-03 9.1E-04 3.0E-04 1.0E-04 µM 
DMSO 
control 6.0E-02 2.0E-02 6.7E-03 2.2E-03 7.4E-04 2.5E-04 8.2E-05 2.7E-05 9.1E-06 3.0E-06 1.0E-06 % 
 
(VIRAMUNE®) - Reference product samples - 2.6R, pH 6.8; 6.5R, pH 4.5; 5.3R, pH 1.2  
(NVGLT) - Test product samples - 4.6T, pH 6.8; 1.4T, pH 4.5; 1.3T, pH 1.2
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The NICD confirmed that neither the NVGLT sample nor Viramune® sample or the DMSO 
control and NV displayed any significant cytotoxicity to the 293T cells the second time around, 
as the percentage cell viability remained above 50 % for all test samples and the test control 
assay (figure. 4.3 and 4.4). The cytotoxicity-50 (CC50) value is greater than the maximum 
concentration tested, indicating no cytotoxic effect to the 293T cells. Since none of the samples, 
including the NV and DMSO controls, showed any considerable toxic effects to the cells over 
the dilutions tested, the same dilutions were used to test for antiviral activity to HIV-1. 
 
Figure 4.3: The in-vitro viability of 293T cells in response to different dilutions of the samples. 
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Figure 4.4: The in-vitro viability of 293T cells in response to different dilutions of the NV and 
DMSO. 
 
 
 
(iv) Exploratory development 
4.4 Antiviral activity test: Comparative dissolution samples  
(NVGLT and VIRAMUNE® tablet) 
The ability of the samples to inhibit HIV-1 was determined by performing a single-round of 
infection of 293T cells using a pseudo-HIV-1 virus in the presence of non-toxic dilutions of the 
samples (figure 4.5). This type of assay is known as a single-cycle infectivity assay in which the 
percentage viral activity was determined. An untreated virus control cell with virus in the 
medium was used as a reference for 100 % viral activity (no inhibition). The antiviral activity of 
pure NV and DMSO was also evaluated. In figure 4.6 it is clear that the DMSO had no 
significant antiviral ability whereas the pure NV was active against the viral strain. It is also 
evident from the graph that the pure NV slope follows a sigmoidal shape and that as the 
concentration of pure NV decreases the antiviral activity increases.  
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Figure 4.5: The effect of samples on the HIV-1 viral replication in-vitro. 
 
 
 
Figure 4.6: The effect of controls on the HIV-1 viral replication in-vitro. 
 
 
 
The pure NV drug, DMSO in DMEM and samples were tested in duplicate, in three independent 
experiments. The NV control inhibited viral replication at an average IC50 of 0.083 µM. This 
value falls within the expected IC50 specification range for NV with the assay (IC50 = 0.1002 ± 
0.0273 µM S.D.). The solvent, DMSO, had no effect on viral replication over the dilutions that 
were tested in the assay.  
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The dilutions that inhibited viral replication by 50 % (IC50) are shown in table 4.8. A decrease in 
percentage viral activity is indicative of viral inhibition. It is important to note the activity of the 
tested samples is provided as the dilution which inhibited 50 % of the virus activity. It was 
therefore necessary to calculate an IC50 by taking the starting concentration of the NV 
component in the sample into account. The calculation utilise the NV concentration in the 
samples as ascertained by the dissolution results (table 4.9), divided by the average dilution 
factor that gives 50 % inhibition (table 4.8). The calculated IC50 values are presented in table 
4.10. 
 
Table 4.8: Inhibitory concentration-50 (IC50) values of samples and controls supplied by NICD
2 
 
 Final dilution of samples that reduced viral activity by 50 % 
*Sample Screen 1 Screen 2 Screen 3 Average ****S.D. 
2.6R, pH 6.8 5,190 5,271 5,331 5,260 70 
6.5R, pH 4.5 4,444 6,247 7,063 5,918 1,340 
5.3R, pH 1.2 8,532 9,125 9,125 8,927 342 
4.6T, pH 6.8 108 146 146 133 22 
1.4T, pH 4.5 99 100 97 99 2 
1.3T, pH 1.2 1,163 1,480 1,478 1,374 183 
**Nevirapine 0.102 µM 0.067 µM 0.078 µM 0.083 µM 0.018 µM 
***DMSO control >0.06% >0.06% >0.06% >0.06% - 
* Values for samples indicate the final dilution of samples needed to inhibit 50 % of virus 
activity. 
**The concentration of pure NV that inhibited viral activity by 50 % is also indicated. 
***A DMSO solvent control was included for reference with the pure NV control. 
****S.D. - Standard Deviation 
Samples and controls were tested in duplicate, in three independent experiments. 
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Table 4.9: NV concentration in samples supplied to NICD 
SAMPLE  
pH 1.2 
 
% NV concentration 
 
pH 4.5 
 
% NV concentration 
 
pH 6.8 
 
% NV concentration 
VIRAMUNE®  
5.3R 
 
24 % 
 
6.5R 
 
100 % 
 
2.6R 
 
57 % 
NVGLT  
1.3T 
 
14 % 
 
1.4T 
 
2 % 
 
4.6T 
 
1 % 
 
Table 4.10: Calculated Inhibitory concentration-50 (IC50) values of samples and controls 
Sample Calculated Inhibitory concentration-50 (IC50) values (µM) 
2.6R, pH 6.8 10,0 
6.5R, pH 4.5 16,90 
5.3R, pH 1.2 2,7 
4.6T, pH 6.8 0,01 
1.4T, pH 4.5 0,02 
1.3T, pH 1.2 10,2 
 
NICD reported that antiviral activity was detected in all the samples. The report indicated that 
the most active sample of the group was 5.3R followed by 2.6R and 6.5R, which were identical. 
1.3T showed intermediate activity. The two least active were 1.4T and 4.6T.2 This conclusion 
reached by NICD does not correlate fully with the NV concentration ascertained by the 
dissolution experiments. The dissolution analysis revealed that sample 6.5R contained the 
highest concentration NV, 100 % followed by 2.6R, 57 % then 5.3R, 24 %. This was the inverse 
to what was reported by NICD. Furthermore, sample 1.3T released a 14 % of NV followed by 
1.4T with 2 % and 4.6T with 1 %. This result achieved by NICD shows a clear correlation 
between the results obtained by dissolution analysis. Further investigation is required to ascertain 
the exact reason why the antiviral activity results for the reference standard (Viramune®) does 
not correlate with the dissolution results. 
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5  Introduction 
Throughout this study various limitations were identified. However, the biggest limitation in this 
study is that stage (v) full development and stage (vi) marketing and commercialisation of this 
novel nevirapine formulation could not be completed.  
 
Chapter 5 presents all the limitations identified at each stage of the product life-cycle of the 
novel nevirapine formulation. The recommendations to optimise on the limitations that were 
identified are expounded from the author’s perspective. 
 
(i) Strategic research and (ii) exploratory research 
 
5.1 Pre-formulation dissolution and solubility study 
During the initial pre-formulation dissolution experiments Caira et al. postulated a solubility 
enhancement theory that predicted that the NVMLE co-crystal would display the greatest 
solubility, that of a five-fold increase, aqueous solubility enhancement of all the co-crystals. This 
theory was nullified by the pre-formulation dissolution results that were achieved in this study. 
In this study the NVMLE co-crystal only enhanced the aqueous solubility of NV by two-fold. 
However, there were differences in the methodology that was used in the study conducted by 
Caira et al.1 and in this study. Firstly, this study assayed the dissolution samples with HPLC 
whilst UV/VIS was used in the previous study for two of the co-crystals together with HPLC for 
the other three co-crystals. Secondly, when Caira et al. postulated the solubility enhancement 
they used dissolution results of NVSC and NVTTA and solubility analysis of NVMLE, NVGLT 
and NVSLI. The solubility analysis involved mixing an excess of the co-crystal in 20 cm3 of 
water at 37 °C over 24 hours and assaying the NV content with HPLC. This study used the 
dissolution results and HPLC to quantify the active amount of NV released in water over a three 
hour period. This method is more robust than the one used by Caira et al. and provided a more 
reliable indication of the true solubility enhancement factor of the co-formers. It is recommended 
that these dissolution experiments be repeated for validation purposes. 
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5.2 Pre-formulation antiviral activity study 
The constraints identified in the pre-formulation antiviral activity relates to the erroneous 
methodology employed by the NICD. The pre-formulation antiviral activity analysis was 
performed in DMSO as a solvent instead of water. Additionally, a human error was introduced 
when the NV stock solution concentrations were calculated as the analyst omitted to take the 
molar ratio of the NVSC and NVSLI co-crystals in to account. Nevertheless, the results of the 
analysis still provided information on the antiviral activity of the co-crystals, however the 
objective of evaluating the increase in water solubility of the NV co-crystals versus the antiviral 
activity could not be achieved.  
 
It is recommended that the antiviral activity analysis be repeated, however using water as a 
solvent and not DMSO. This will determine whether the improved water solubility of the co-
crystals results is an improved antiviral activity. 
 
(iii) Candidate selection 
Based on the limitations identified in the pre-formulation work done in stage (ii), exploratory 
development, it is recommended that when these analyses are repeated, as per recommendation, 
that the data should be reviewed to confirm and validate the selection of GLT as the most 
appropriate co-former for further development as the work done in stages (i) strategic research 
and (ii) exploratory research forms the basis of stage (iii), candidate selection. 
 
(iv) Exploratory development 
 
5.3 Tablet formulation and compression process 
There are many aspects that need to be addressed to optimise the NVGLT prototype tablet and 
produce a tablet that is of acceptable quality that can potentially be biologically equivalent to the 
proprietor brand. The areas that require optimisation of the NVGLT tablet is; (i) the tablet 
composition formulation, (ii) the tablet specifications, (iii) the tablet manufacturing method and 
(iv) the tablet compression process robustness.  
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The deficiencies observed in these parameters adversely impacted the quality attributes of the 
final tablet and the dissolution performance. Therefore, once these aspects are addressed and 
resolved, an improved tablet may be achieved. 
 
The NVGLT tablet should be reformulated by reducing the quantity of MCC to between 20-25 
% as recommended by the supplier. The inclusion of crospovidone with MCC in the formulation 
is advised to overcome the binding and disintegration challenges. The crospovidone is 
recommended instead of povidone as the former is regarded as a super disintegrant whilst the 
povidone has combination properties of a binder and disintegrant. This recommendation stems 
from the fact that the formula already has a binder in the form of MCC and including povidone 
would have a synergistic effect. This duel effect may not be desired for the tablet in terms of 
disintegration. 
 
Furthermore, a lubricant such as magnesium stearate in the appropriate amount needs to be 
included to maximize efficiency during tablet compression. A conceptual formulation (table 5.1) 
for a NVGLT tablet containing 200 mg of NV would be as follows: 
 
Table 5.1 Conceptual formula of the optimized NVGLT tablet 
Ingredients Quantity per tablet % per tablet 
NVGLT co-crystal 0,313 g  
AVICEL® MCC  20-25 % 
Crospovidone  1,2-1,5% 
Magnesium stearate  1,2 % 
 
A 200 mg ibuprofen tablet was successfully produced using the same percentage guidelines as 
seen in table 5.1.2 The drug ibuprofen has the same biopharmaceutical classification as 
nevirapine i.e. class II. The ibuprofen tablet was also produced using the direct compression 
technique. Therefore these excipients and the percentages at which they were utilised have 
proven to be at the optimal level.  
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A tighter tablet specification (quality control limits) needs to be set to ensure that a quality tablet 
is produced. Even though pharmacopoeial specifications were used as acceptance criteria, 
restricting the specification will allow for very little to no error. Therefore, being at a more 
stringent level. These tighter specification will come in handy when in-process quality tests are 
conducted. The tighter specification will provide more control over the manufacturing process.  
 
Furthermore, it is recommended that in-process quality compliance tests need to be performed 
after the production of every 50 tablets (at small scale). In-process quality compliance tests are 
the same quality compliance tests that are conducted at the end of the production run to evaluate 
the quality of the tablets produced. The rationale of introducing these tests in the production run 
is to gain a better control over the production process and the quality of the final product. It also 
allows the formulator to stop the process when the tablet fails to meet the quality parameters and 
effecting remedial actions as necessary. The introduction of these tests in the process will save 
time and resources. The results of these tests can also be trended and statistical methods can be 
applied to predict the process capability and potential issues can be predicted in advance. 
 
The direct compression method should be pursued due to its simplicity and shorter processing 
time, however dry granulation should be performed prior to compression to create granules 
instead of fine particles. The previous method was not clearly defined as per manufacturing 
method of the NVGLT tablet. The following manufacturing method for the dry granulation is 
proposed: 
 
1. Added 0,313 g NVGLT to blender 
2. Added 20-25 % MCC to blender 
3. Blended mixture for 5 minutes 
4. Passed mixture through the roller compactor to granulate 
5. Sieved the mixture through a 16 mesh sieve 
6. Added mixture to blender 
7. Added 1,2-1,5 % crospovidone to mixture 
8. Blended mixture for 5 minutes 
9. Passed mixture through the roller compactor to granulate 
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10. Sieved the mixture through a 16 mesh sieve 
11. Added mixture to the blender 
12. Added 1,2 % magnesium stearate 
13. Blended for 3 minutes 
14. Compressed the tablet with the compression machine 
 
Alternatively, the wet granulation method using the solvent (chloroform) that was used to 
produce the co-crystal is also an option. Chloroform is toxic, however does evaporate upon 
drying of the granules and is not present in the final dosage form. The wet granulation method 
uses the same conceptual formula however, without the crospovidone. The method of 
manufacture will differ as the chloroform needs to be added to the mixture of NVGLT co-crystal 
and MCC mixture. After the wet granulation of the mixture the granulate needs to dry at room 
temperature. When the granules are dry they need to be screened with a 16 mesh screen and the 
magnesium stearate should be added to the mixture before compression needs to be effected. 
 
Finally, the pre-compression and compression forces settings on the tablet press needs to be 
defined. The pre-compression force is usually set at a lower force than the compression force in 
order to prevent the occurrence of tablet defects. The correct pre-compression and compression 
forces should be derived from the hardness and uniformity of mass QC tests. Once the ideal 
compression forces are identified, these values need to be validated. 
 
5.4 Formulation dissolution 
The comparative dissolution analysis of the NVGLT tablet in the three buffered media was 
influenced by the quality defects of the tablet. The poor dissolution characteristics can be pinned 
to the quality issues identified as mentioned before. It is recommended that once the 
reformulation of the co-crystal prototype tablet has been done that prior to dissolution, a 
disintegration test be done in the three buffered media to evaluate the disintegration behaviour of 
the optimised co-crystal tablet before the dissolution is evaluated. The comparative dissolution 
needs to be repeated to evaluate bioequivalence and biosimilarity of the prototype’s dissolution 
profile versus the proprietor brand. 
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5.5 Formulation antiviral activity 
Only the highest dissolution release point in the comparative dissolution analysis of NVGLT and 
Viramune® were sampled. The vessel that released the highest percentage active NV in each 
buffered media was sampled and analysed due to budget constraints. Ideally all the dissolution 
samples should have been evaluated for their antiviral activity. This would have provided an 
indication of the antiviral activity profile and how it correlates to the dissolution profiles over 
time in the various buffered media. 
 
The antiviral activity results obtained by the NICD did not correlate fully with the NV 
concentration ascertained by the dissolution experiments. Only the NVGLT antiviral activity 
results correlated with the dissolution results. Further investigation is required to determine the 
exact reason why the antiviral activity results for the reference standard (Viramune®) did not 
correlate. 
 
Furthermore, the antiviral activity tests were not immediately performed on the comparative 
dissolution samples. The samples were couriered to Pretoria to the laboratory of the NICD. The 
solution stability tests indicated that there was potential degradation of the NV in some of the 
buffered media. 
 
These dissolution analyses should be repeated once the prototype tablet has been reformulated 
and the antiviral activity test should be performed on all the sample time points. The antiviral 
activity should also be conducted immediately on the day the dissolution is done. 
 
Finally, it was accepted that the excipients in Viramune® has no antiviral activity and thus 
antiviral tests were not performed as the excipients are regarded as inert. 
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6.1 Conclusion 
The pre-formulation dissolution of NV was enhanced in the presence of individual co-formers, 
both in co-crystal form and as a physical mixture. NVGLT was the only co-crystal that yielded 
better results than its physical mixture, but its dissolution did not comply with the BP 2005 
standard. The solubility studies indicate that the choice of co-formers for future research could 
possibly be based on pKa and melting point values. HPLC proved to be a more accurate and 
precise analytical method than UV/VIS spectrometry, producing more reliable results. 
 
The results of the pre-formulation antiviral activity studies can be considered inconclusive as the 
incorrect doses were used due to calculation errors. The studies were performed in DMSO due to 
solubility issues with the co-crystals in water. The antiviral activity of NVSC and NVSLI 
appeared to be improve compared to pure NV, however the test should be repeated in water so 
that the solubility can be correlated to the antiviral activity of the co-crystal.  
 
The prototype co-crystal tablet formulation was not optimal. Quality issues were observed with 
the final compressed tablet. These quality defects are attributed to the composition formula of the 
prototype and the robustness of the tabletting process. Once these two critical aspects are 
addressed, an optimal prototype will be produced with acceptable quality. 
 
The formulation comparative dissolution results were not successful due to the poor quality 
prototype tablet. The NVGLT prototype tablet and the Viramune® tablet both failed to meet the 
USP 36 acceptance criteria. The dissolution results did however indicate that NV is more soluble 
in acidic media. The dissolution profiles of NVGLT and Viramune® were determined to be 
neither equal nor similar, therefore implying that a biowaiver is not possible as the two products 
are not bioequivalent. 
 
The solution stability analysis provided valuable information on the stability of NV in the 
buffered media. The only buffered media that NV is likely to be stable in is the phosphate buffer. 
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Antiviral activity was detected in all the comparative dissolution samples. The NICD reported 
that the most active of the group was 5.3R followed by 2.6R and 6.5R, which were identical. 
1.3T showed intermediate activity. The two least active were 1.4T and 4.6T. The results of the 
formulation antiviral activity studies is considered to be questionable since there is 
inconsistencies between the antiviral activity results and the dissolution results.  
 
6.2 Patenting 
Co-crystals obviously meet the criterion of novelty, utility, and non-obviousness. This fact places 
the co-crystallisation process in an ideal position for the approval of a patent. The items that are 
eligible for the patent in this study are the prototype formula and the methodology for 
formulating solid-dosage form co-crystals. These features are unique and thus qualify for a 
patent. However, should the government of South Africa pursue their plans to reform patent and 
intellectual property law it may adversely impact the patenting of this novel product. 
 
However, given the liberal constitution of South Africa, this patenting law could be challenged. 
Should the courts decide to uphold the reform of the patent law, by default the authors of this 
article will present their work to the patents examination office to argue their case for this novel 
product to be patented.  
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APPENDIX A:  
FTIR IDENTIFICATION TEST RESULTS OF THE CO-CRYSTALS AND 
INDIVIDUAL COMPONENTS 
 
- SC 
- NVSC 
- NV 
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- TTA 
- NVTTA 
- NV 
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- MLE 
- NVMLE 
- NV 
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- GLT 
- NVGLT 
- NV 
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- SLI 
- NVSLI 
- NV 
 
 
 
 
 
